document incorporate reference portion proxy statement registrant annual meeting stockholder hold incorporate reference iii annual report item business general bristolmyers squibb company refer bristolmyer squibb bms company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger company division subsidiary engage discovery development licensing manufacturing marketing distribution sale pharmaceutical health care relate product acquisition divestiture january company complete sale inventory trademark patent intellectual property right relate dovonex treatment psoriasis united state warner chilcott company inc million cash addition company receive royalty base net sale dovonex end result transaction company recognize pretax gain approximately million million net tax quarter bristolmyer squibb website company internet website address wwwbmscom company make available free charge website annual quarterly current report include amendment report soon reasonably practicable company electronically file material furnish material securities exchange commission sec information relate corporate governance bristolmyer squibb include company standard business conduct ethic code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern company executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available company website wwwbmscom investorscorporate governance caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly company website information relate stockholder service include company dividend reinvestment plan direct deposit dividend available company website wwwbmscom investorsstockholder service caption company incorporate reference certain information part proxy statement annual meeting stockholder sec allow company disclose important information refer manner refer information company proxy statement annual meeting stockholder annual report available company website wwwbmscom investorssec filing caption march business segment company reportable segmentspharmaceutical nutritional health care pharmaceutical segment global pharmaceutical international consumer medicine business nutritional segment consist mead johnson nutritionals mead johnson primarily infant formula children nutritional business health care segment consist convatec medical imaging additional information segment item financial statementsnote segment information pharmaceutical segment pharmaceutical segment compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler retail pharmacy hospital government entity medical profession company manufacture product puerto rico fourteen foreign country pharmaceutical net sale account company net sale pharmaceutical net sale account total pharmaceutical net sale respectively pharmaceutical net sale europe middle east africa account total pharmaceutical net sale respectively pharmaceutical net sale japan account total pharmaceutical net sale respectively company pharmaceutical portfolio continue transition away product lose exclusivity growth driver recently launch product result company focus area significant unmet medical need product company consider growth driver include plavix clopidogrel bisulfate avaproavalide irbesartanirbesartanhydrochlorothiazide reyataz atazanavir sulfate abilify aripiprazole erbitux cetuximab recently launch product include sustiva franchise efavirenz sprycel dasatinib baraclude entecavir orencia abatacept company experience substantial revenue loss year expiration market exclusivity certain product company expect major new exclusivity loss accordingly expect reduction net sale moderate range billion billion level product lose exclusivity previous year primarily pravachol pravastatin sodium europe taxol paclitaxel europe japan compare net sale reduction billion level time amount sale reduction exclusivity loss realization particular period eventual level remain sale revenue uncertain dependent level sale time exclusivity end time degree development generic competition speed approval market entry impact factor composition matter patent plavix expire currently subject patent litigation apotex inc apotex corp apotex generic company significant jurisdiction august apotex launch generic clopidogrel bisulfate product compete plavix august court patent litigation apotex grant motion company product partner sanofi aventis sanofi enjoin sale apotexs generic clopidogrel bisulfate product order apotex recall product customer court grant preliminary injunction affirm appeal trial underlie patent litigation end february court expect rule follow posttrial briefing generic launch significant adverse impact plavix sale result operation impact generic launch apotex august estimate certainty time depend number factor include generic product apotex sell distribution channel prior grant preliminary injunction halt sale possible time reasonably assess outcome patent litigation apotex andor timing renew generic competition apotex additional generic competition generic pharmaceutical company apotex prevail patent litigation company expect renew generic competition promptly company expect generic clopidogrel bisulfate inventory market continue residual impact plavix net sale company expect plavix net sale earning growth assume absence renew additional generic competition company expect increase prescription demand plavix growth driver recently launch product compare company gross margin expect improve growth high margin product low margin erosion relate exclusivity loss improve manufacturing efficiency marketing sell administrative expense expect remain relatively unchanged efficiency saving largely offset inflationary cost increase company continue focus high value primary care specialist physician implement productivity initiative company expect continue increase investment develop additional new compound support introduction new product company subsidiary subject number significant pende lawsuit claim proceeding investigation include pende plavix litigation possible time reasonably assess final outcome investigation litigation management continue believe previously disclose aggregate impact current reserve pende plavix patent litigation litigation investigation legal matter affect company reasonably likely material company result operation cash flow material financial condition liquidity company expectation described reflect potential impact pende plavix patent litigation litigation investigation impact legal matter companys result operation current reserve ongoing matter information matter product competition research development item management discussion analysis financial condition result operationsplavix outlook item financial statementsnote legal proceeding contingency product company pharmaceutical revenue come product follow therapeutic class cardiovascular virology include human immunodeficiency virus hiv oncology affective psychiatric disorder immunoscience pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity market exclusivity base patent right andor certain regulatory form exclusivity country patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product company business focus innovative pharmaceutical product company rely patent right form protection maintain market exclusivity product discussion patent right regulatory form exclusivity intellectual property product exclusivity discussion impact generic competition company business generic competition chart show net sale key product pharmaceutical segment year basic exclusivity loss patent right datum exclusivity occur currently estimate occur european union eu japan company sell pharmaceutical product country datum provide countrybycountry basis individual country sale significant outside eu japan instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical trial datum obtain marketing approval prior expiration datum exclusivity company estimate market exclusivity period product casebycase basis purpose business planning length market exclusivity company product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation company provide estimate business planning purpose intend indication company patent fare particular patent litigation bring potential infringer assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate past currently past currently past currently estimate estimate estimate year year year basic eu basic japanese basic pharmaceutical product exclusivity loss exclusivity loss exclusivity loss dollar million cardiovascular plavix pravachol avaproavalide coumadin b monopril virology reyataz sustiva franchise total revenue c c zerit baraclude infectious disease cefzil oncology erbitux e taxol paclitaxel sprycel affective psychiatric disorder abilify total revenue f emsam immunoscience orencia e pharmaceutical efferalgan na note currently estimate year basic exclusivity loss include statutory extension exclusivity earn speculative instance laterexpire patent cover particular form compositions drug method manufacture method drug patent result favorable market position company product product exclusivity predict assure note product file biologic license application bla year exclusivity list year patent expiration currently regulatory pathway approval followon biologic product describe detail intellectual property product exclusivity indicate brand name product register trademark own company subsidiary specific trademark ownership information find company currently market product jurisdiction indicate reference eu include follow current member state austria belgium bulgaria cyprus czech republic denmark estonia finland france germany greece hungary ireland italy latvia lithuania luxembourg malta netherlands poland portugal romania slovakia slovenia spain sweden united kingdom uk basic patent application file current member state list product instance date basic exclusivity loss different eu member states instances early late date basic exclusivity loss list eu country basic patent obtain datum protection available b eu basic exclusivity expire bms acquire product c exclusivity period relate sustiva brand pende application eu patent application file cyprus estonia latvia lithuania malta netherlands slovakia slovenia e biologic product approve bla currently regulatory approval path generic biologics f companys right commercialize aripiprazole terminate summary indication intellectual property position license arrangement thirdparty manufacturing arrangement product applicable eu japan cardiovascular plavix clopidogrel bisulfate platelet aggregation inhibitor approve protection fatal nonfatal heart attack stroke patient history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel bisulfate codevelope jointly market sanofi worldwide alliance operate framework geographic territory america australia company primary territory europe asia sanofis primary territory composition matter patent expire include statutory patent term extension currently subject patent litigation apotex generic company significant jurisdiction possible time reasonably assess outcome litigation apotex andor timing renew generic competition apotex potential additional generic competition generic pharmaceutical company apotex prevail patent litigation company expect renew generic competition promptly information litigation matter generic launch apotex item management discussion analysis financial condition result operation executive summaryplavix outlook item financial statementsnote legal proceeding contingency eu regulatory datum exclusivity extend eu member country key composition matter patent expire majority eu member country company obtain bulk requirement clopidogrel bisulfate sanofi party company sanofi finish product facility information company arrangement sanofi strategic alliance item financial statementsnote alliance investment pravachol pravastatin sodium hmg coa reductase inhibitor indicate adjunct diet exercise patient primary hypercholesterolemia lower risk heart attack people clinically evident coronary heart disease elevate cholesterol reduce risk heart attack stroke patient clinically evident coronary heart disease company license patent cover pravastatin market company pravachol sankyo company ltd sankyo japan key provision agreement expiring exclusivity expire marketbymarket basis exclusivity patent include pediatric extension expire april company enter distribution agreement watson pharmaceutical watson november authorize watson distribute generic pravastatin sodium tablet eu composition matter patent expire country italy expiration occur january company obtain bulk requirement pravastatin sankyo finish product facility avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin ii receptor antagonist indicate treatment hypertension diabetic nephropathy irbesartan codevelope jointly market sanofi worldwide alliance operate framework geographic territory america australia company primary territory europe asia sanofis primary territory september company elect terminate copromotion product sanofi ireland sweden norway finland denmark basic composition matter patent expire include pediatric extension eu data exclusivity eu expire august avapro october avalide irbesartan manufacture company sanofi company manufacture bulk requirement irbesartan finish avaproavalide facility avalide company purchase bulk requirement hydrochlorothiazide party information company arrangement sanofi strategic alliance item financial statementsnote alliance investment coumadin warfarin sodium oral anticoagulant predominantly patient atrial fibrillation deep venous thrombosispulmonary embolism market exclusivity expire basic patent protection regulatory datum protection expire company acquire coumadin company obtain bulk requirement warfarin party produce majority finish good facility monopril fosinopril sodium secondgeneration angiotensin convert enzyme inhibitor onceaday dosing indicate treatment hypertension monopril discover develop internally basic composition matter patent expire june basic composition matter patent expire denmark greece portugal spain october composition matter patent obtain finland rest eu composition matter patent expire countrybycountry basis company manufacture bulk requirement fosinopril finish product facility virology reyataz atazanavir sulfate protease inhibitor treatment hiv reyataz launch july company develop atazanavir worldwide license novartis ag novartis pay royalty base percentage net sale company entitle promote reyataz use combination ritonavir atazanavir nonexclusive license agreement abbott laboratories company date july amend pay royalty base percentage net sale market exclusivity reyataz expect expire major eu member country japan company manufacture bulk requirement atazanavir finish product facility sustiva franchise efavirenz active ingredient sustiva nonnucleoside reverse transcriptase inhibitor nnrti treatment hiv sustiva franchise include sustiva antiretroviral drug treatment hiv bulk efavirenz include combination therapy atripla sell joint venture gilead sciences inc gilead company gilead share responsibility commercialize atripla gilead record atripla revenue consolidate result joint venture operating result company record revenue bulk efavirenz component atripla sale product gilead joint venture party customer company revenue efavirenz component determine apply percentage atripla revenue approximate revenue sustiva brand information company arrangement gilead strategic alliance item financial statementsnote alliance investment right market efavirenz canada uk france germany ireland italy spain license merck co inc royalty base percentage net sale market exclusivity sustiva expect expire country eu company company market efavirenz japan company obtain bulk requirement efavirenz party produce finished good facility zerit stavudine treatment hiv company hold exclusive patent license zerit yale university yale pursuant pay royalty base product sale japan company exclusive license zerit yamasa corporation pursuant pay royalty base net sale japan use patent expire december use patent series expire eu patent application pende denmark finland japan december company manufacture bulk requirement stavudine finish product facility baraclude entecavir potent selective inhibitor hepatitis b virus approve food drug administration fda march treatment chronic hepatitis b infection baraclude discover develop internally approve market country outside include china japan eu company learn china company receive clinical trial permission entecavir company seek marketing approval formulation entecavir uncertainty china exclusivity law possible company receive marketing authorization china health authority end company composition matter patent expire application patent term extension file approve extend patent expiration composition matter patent expire eu japan company manufacture bulk requirement entecavir finish product facility infectious disease cefzil cefprozil semisynthetic broadspectrum cephalosporin antibiotic treatment mild moderately severe bacterial infection throat ear sinuse respiratory tract skin cefprozil discover develop internally basic composition matter patent protect cefprozil include patent term extension expire december spain patent expire february certain european country japan patent expire european country include austria finland italy switzerland uk composition matter patent expire include term extension company manufacture bulk requirement cefprozil finish product facility oncology erbitux erbitux cetuximab igg monoclonal antibody design exclusively target block epidermal growth factor receptor egfr express surface certain cancer cell multiple tumor type normal cell erbitux biological product approve treatment combination irinotecan patient egfrexpresse metastatic colorectal cancer fail irinotecanbase regimen monotherapy patient intolerant irinotecan march fda approve erbitux use treatment squamous cell carcinoma head neck erbitux market north america company distribution copromotion agreement imclone system incorporate imclone company imclone share distribution right erbitux merck kgaa japan erbitux market japan application submit japanese pharmaceutical medical devices agency pmda use erbitux treat patient advance colorectal cancer description company alliance imclone strategic alliance item financial statementsnote alliance investment composition matter patent specifically claim erbitux erbitux approve fda health authority monotherapy use patent use erbitux combination antineoplastic agent approve fda combination use claim grant patent expire inventorship use patent challenge researcher yeda research development company ltd yeda claim name coinventor september court grant yeda complete ownership patent imclone appeal court decision imclone file declaratory judgment action allege yeda researcher remain sole inventor patent patent invalid assurance financial consequence company result court decision information litigation item financial statementsnote legal proceeding contingency european equivalent use patent oppose information biologic patent intellectual property product exclusivity company obtain finished good requirement cetuximab imclone imclone manufacture bulk requirement cetuximab facility finish perform party imclone description company supply agreement imclone manufacture quality assurance taxol paclitaxel paclitaxel treatment refractory ovarian cancer firstline treatment ovarian cancer combination cisplatin second line treatment acquire immunodeficiency syndrome aid relate kaposis sarcoma treatment metastatic breast cancer failure combination chemotherapy adjuvant treatment node positive breast cancer treatment nonsmall cell lung carcinoma cisplatin active ingredient taxol paclitaxel patent protection eu japan regulatory protection form datum exclusivity datum exclusivity expire initial approval generic version paclitaxel grant revoke fda reinstate datum exclusivity eu expire data exclusivity taxol paclitaxel japan expire patent claim approve dose administration schedule expire japan nullity action file japanese patent office invalidate patent company appeal decision generic paclitaxel launch japan paclitaxel develop collaborative research development agreement government agreement company obtain right government taxol paclitaxel data company manufacture bulk requirement paclitaxel finish product facility sprycel dasatinib multitargete tyrosine kinase inhibitor approve fda june treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include imatinib treatment adult philadelphia chromosomepositive acute lymphoblastic leukemia resistance intolerance prior therapy dasatinib approve eu november sprycel discover develop internally basic composition matter patent protect dasatinib expire april patent term extension request grant extend patent term june eu country patent pende grant expire april exclude term extension eu patent application file cyprus estonia latvia lithuania malta netherland slovakia slovenia new chemical entity protection expire orphan drug exclusivity expire protect product generic application currently approve orphan indication company manufacture bulk requirement dasatinib finish product facility affective psychiatric disorder abilify aripiprazole atypical antipsychotic agent patient schizophrenia acute bipolar mania bipolar disorder abilify introduce november approve marketing eu switzerland application pende country aripiprazole copromote company otsuka pharmaceutical co ltd otsuka company right commercialize aripiprazole terminate otsuka sole right commercialize aripiprazole company right distribute andor copromote abilify european country uk france germany italy spain act exclusive distributor product rest eu company exclusive licensee product rest world exclude japan certain country spain germany company records alliance revenue contractual share net sale record expense relate product alliance revenue record company net sale base otsukas net sale copromotion country company recognize alliance revenue abilify ship risk reward ownership transfer otsukas customer uk france italy company currently record net sale relate cost product sell country company exclusive right sell abilify company record net sale relate cost product sell information company arrangement otsuka strategic alliance item financial statementsnote alliance investment basic composition matter patent abilify expire include grant patent term extension otsuka file patent trademark office uspto request reexamination composition matter patent patent patent cover abilify aripiprazole uspto grant request reexamination otsuka determine original patent application mistakenly identify prior art reference wrong patent number addition otsuka take opportunity bring citation attention uspto reexamination allow uspto consider patentability patent claim light correctly identify patent reference newly cite document june uspto issue ex parte reexamination certificate patent confirm patentability original claim approve additional new claim otsuka receive formal notice teva pharmaceuticals usa barr pharmaceuticals inc sandoz inc synthon laboratories inc sun pharmaceuticals ltd apotex state file abbreviate new drug application anda fda dosage form aripiprazole company otsuka comarket abilify notice states anda contain piv certification direct patent cover aripiprazole expire october addition notice purport provide otsuka respective piv certification certification contain allegation enforceability patent andor validity andor infringement claim otsuka sole right enforce patent composition matter patent force germany uk france italy netherlands romania sweden switzerland spain denmark original expiration date extend grant supplemental protection certificate country romania denmark datum exclusivity eu expire composition matter patent austria belgium finland greece ireland luxembourg portugal latvia hungary cyprus czech republic slovenia slovakia poland malta lithuania bulgaria estonia company obtain bulk requirement aripiprazole otsuka otsuka company finish product facility emsam emsam transdermal patch delivery monoamine oxidase inhibitor treatment major depressive disorder adult approve fda february commercially available april emsam develop somerset pharmaceuticals inc somerset joint venture mylan laboratories inc mylan watson company obtain exclusive distribution right commercialize emsam canada market emsam new drug formulation emsam receive year hatchwaxman datum exclusivity expire patent cover different aspect selegiline transdermal patch technology issue mylan technologies inc affiliate mylan expire datum exclusivity cover new dosage form expire quarter company record impairment charge million represent unamortized balance regulatory approval milestone pay quarter result lower expect sale emsam emsam manufacture behalf somerset mylan technologies inc party somerset obtain finished good mylan technologies inc finish product supply company somerset immunoscience orencia abatacept biological product fusion protein novel immunosuppressive activity target initially adult patient moderate severe rheumatoid arthritis inadequate response certain currently available treatment abatacept approve fda december commercially available february orencia discover develop internally company series patent cover abatacept method use late composition matter patent expire company submit request extend composition matter patent time lose regulatory review period hatchwaxman act january repligen regents university michigan file complaint company district court eastern district texas marshall division allege company anticipate sale orencia infringe patent august zymogenetics inc file complaint company district court district delaware complaint allege company manufacture sale orencia infringe patent information litigation item financial statement note legal proceeding contingency company obtain bulk abatacept party manufacturing facility company finish product facility efferalgan efferalgan formulation acetaminophen introduce distribute effervescent tablet indicate treatment fever mild moderate pain adult child market exclusively europe composition matter patent europe efferalgan addition product discuss company pharmaceutical segment include company wholly own upsa consumer medicine business europe include efferlagan describe aspirine upsa dafalgan fervex europe overseas market strategic alliance arrangement company enter strategic alliance arrangement party company right develop manufacture market andor sell pharmaceutical product right own party company enter strategic alliance arrangement party party right develop manufacture market andor sell pharmaceutical product right own company alliance arrangement form include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint venture alliance arrangement reduce risk incur research development expense lead revenuegenerate product gross margin alliance product generally low substantially gross margin company product partner profit alliance product share company alliance partner assurance new alliance form company actively pursue arrangement view alliance important complement discovery development activity companys significant current alliance arrangement company product sanofi plavix avaproavalide otsuka abilify imclone erbitux gilead atripla somerset emsam sankyo pravachol company significant alliance arrangement investigational compound development pierre fabre medicament sa pierre fabre vinflunine novel investigational anticancer agent right own pierre fabre medarex inc medarex ipilimumab monoclonal antibody investigate anticancer treatment right own medarex astrazeneca plc astrazeneca saxagliptin oral compound potential treatment diabetes dapagliflozin sodiumglucose cotransporter sglt inhibitor significant alliance arrangement discuss detail additionally company licensing arrangement yale zerit novartis reyataz helmholtz zentrum fr infektionsforschung helmholtz centre infection research ixabepilone novel microtubulestabilize agent multiple tumor type general company strategic alliance arrangement periods coextensive period market exclusivity protection countrybycountry basis base company current expectation respect expiration market exclusivity company significant market license arrangement yale zerit expect expire eu japan novartis reyataz expect expire eu japan discussion market exclusivity protection include chart show net sale key product year basic exclusivity loss occur expect occur eu japan product intellectual property product exclusivity company strategic alliance arrangement party right manufacture market andor sell pharmaceutical product contain customary early termination provision typically find agreement kind generally base party material breach bankruptcy voluntary involuntary product safety concern notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination day notice generally available involuntary bankruptcy petition file dismiss material breach party occur cure early termination product safety concern typically arise product determine create significant risk harm patient concern product efficacy level toxicity company strategic alliance arrangement typically contain provision provide party right terminate alliance short notice general party company strategic alliance arrangement continue exclusivity protection expiration termination alliance company retain right product party intellectual property loss right product market sell company pursuant strategic alliance arrangement party country territory material company result operation cash flow case plavix material financial condition liquidity customary pharmaceutical industry term company strategic alliance arrangement generally coextensive exclusivity period discuss vary countrybycountry basis discuss company strategic alliance otsuka expire november puerto rico prior expiration market exclusivity protection abilify expect expire include grant patent term extension current market product sanofi company agreement codevelopment cocommercialization avaproavalide angiotensin ii receptor antagonist indicate treatment hypertension diabetic nephropathy copromote certain country outside tradename aprovelcoaprovel comarkete certain country outside company tradename karveakarvezide plavix platelet aggregation inhibitor copromote certain country outside tradename plavix comarkete certain country outside company tradename iscover worldwide alliance operate framework geographic region cover certain european asian country define territory cover puerto rico canada australia certain latin american country define territory b region cover puerto rico canada australia certain latin american country manage separate territory agreement puerto rico avaproavalide second agreement puerto rico plavix plus canada australia mexico brazil colombia argentina product territory b territory partnership exist supply product country territory manage certain central expense market research development royalty country territory b structure company local affiliate sanofi comarket affiliate operate independently sell compete brand copromote single brand territory comarketing country include germany spain italy irbesartan greece china company sell iscover karveakarvezide sanofi sell plavix aprovelcoaprovel country china company retain right currently comarket iscover company sanofi copromote plavix aprovelcoaprovel france uk belgium netherlands switzerland portugal addition company sanofi copromote plavix austria italy ireland denmark finland norway sweden turkey taiwan korea singapore malaysia hong kong aprovelcoaprovel certain french export country sanofi act operating partner territory own majority financial control interest territory company ownership interest territory company account investment partnership entity territory equity method record share result equity net income affiliate consolidate statement earning company share net income partnership entity tax million million million territory b company sanofi copromote plavix canada puerto rico avaproavalide canada territory b countries australia mexico brazil colombia clopidogrel bisulfate argentina comarketing country company sanofi modify previous exclusive license company avaproavalide puerto rico form copromotion joint venture company contribute avaproavalide intellectual property sanofi agree pay company million million company account payment sale interest license defer amortize total million income expect useful life license approximately year date formation copromotion joint venture company act operating partner territory b uspuerto rico avaproavalide territory own majority control interest territory company consolidate partnership result territory record sanofis share result minority interest expense net taxis million million million company record sale territory b uspuerto rico avaproavalide territory comarkete country germany italy spain greece million million million september company optedout copromotion right sanofi aprovelcoaprovel ireland sweden denmark finland norway company opt comarkete copromotion arrangement number country prior company receive royalty payment sanofi base percentage sanofis net sale optout country territory partnership govern series committee enumerate function power responsibilitie territory senior committee senior committee final decision make authority respect territory enumerate function power responsibility jurisdiction agreement sanofi expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patent exclusivity right applicable territory alliance arrangement terminate company sanofi affected country territory depend circumstance event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continue day order decree approving continue unstayed effect day ii material breach obligation major alliance agreement remain uncured day follow notice breach commencement diligent prosecution cure occur day notice iii deadlock senior committee render continue commercialization product impossible give country territory case avaproavalide respect advertising promotion spending level sale force commitment iv increase combine cost good royalty exceed specify percentage net selling price product v good faith determination terminate party commercialization product terminate reason patient safety case termination right agreement include provision termination relevant alliance respect applicable product applicable country territory case termination bankruptcy insolvency material breach product applicable territory termination procedure slightly different event company lose right product applicable relevant country territory case bankruptcy insolvency material breach company default party discussion company strategic alliance sanofi item financial statementsnote alliance investment otsuka company enter worldwide commercialization agreement otsuka codevelop copromote abilify treatment schizophrenia relate psychiatric disorder japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt company begin copromote product otsuka puerto rico november june company receive marketing approval european commission product currently copromote otsuka uk germany france spain germany spain product sell otsuka affiliate distributor company records alliance revenue contractual share otsukas net sale company recognize alliance revenue abilify ship risk reward ownership transfer otsukas customer uk france italy company presently exclusive distributor product company record net sale relate cost product sell company exclusive right sell abilify number country europe americas asia countries company record net sale relate cost product sell term agreement company purchase product otsuka perform finish manufacture sale company agreement expire november puerto rico eu agreement expire june later tenth anniversary commercial sale country expiration applicable patent country early termination available base party voluntary involuntary bankruptcy failure minimum payment failure commence commercial sale month receipt necessary approval material breach notice require early termination strategic alliance immediately notice case voluntary bankruptcy ii minimum payment otsuka iii commercial sale occur month receipt necessary approval day material breach occur cure commencement cure occur day notice material breach day case involuntary bankruptcy petition file dismiss addition termination available otsuka day notice event company challenge otsuka patent right marketbymarket basis company market product direct competition abilify termination expiration alliance company retain right abilify company record total revenue abilify million million million total milestone payment otsuka million million expense acquire inprocess research development remain million capitalize intangible asset amortize cost product sell remain life agreement range year company amortize cost product sell million million unamortized capitalize payment balance million million december respectively discussion company strategic alliance otsuka item financial statementsnote alliance investments imclone company purchase million share imclone share million represent approximately imclone share outstanding prior company commencement public tender offer imclone share imclone biopharmaceutical company focus develop targeted cancer treatment include growth factor blocker cancer vaccine antiangiogenesis therapeutic equity investment imclone strategic agreement company imclone include arrangement expire september codevelop copromote cancer drug erbitux series payment originally total billion company pay imclone milestone payment million million expense acquire inprocess research development million record additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone agreement imclone revise reduce total payment million billion accordance agreement company pay imclone million million million million quarter payment approval fda bla erbitux use combination irinotecan treatment patient egfr express metastatic colorectal cancer refractory irinotecan base chemotherapy use single agent treatment patient egfr express metastatic colorectal cancer intolerant irinotecan base chemotherapy fda approve imclone chemistry manufacture control supplemental biologic license application sbla licensure bb manufacturing facility milestone payment fda approval erbitux use treatment squamous cell carcinoma head neck company codevelopment copromotion right canada japan extent product commercialize country japan company imclone share distribution right erbitux merck kgaa february company imclone submit application japanese pmda use erbitux treat patient advance colorectal cancer agreement imclone receive distribution fee base flat rate product revenue north america company purchase commercial requirement bulk erbitux imclone price equal imclone manufacturing cost plus company account million total approval milestone pay license acquisition amortize payment cost product sell term remain term agreement end company amortize cost product sell million million million respectively unamortize capitalize payment balance record intangible asset net consolidated balance sheet million million december respectively company determine equity share imclone net income loss eliminate imclone result milestone revenue imclone recognize pre approval milestone payment record company additional equity investment company record net income million net loss million net income million share imclone net incomelosse company record share result equity net income affiliate consolidate statement earning company record net sale erbitux million million million company record investment market value holding imclone common stock million approximately million december respectively million approximately million december respectively company hold million share imclone stock represent approximately imclone share outstanding december share basis carry value imclone investment closing market price imclone share december respectively compare respectively december early termination available base material breach effective day notice material breach material breach cure commencement cure occur month notice company exist significant concern regulatory patient safety issue seriously impact longterm viability product termination expiration alliance company retain right erbitux mckesson corporation mckesson company wholesaler provide warehousing packing shipping service erbitux mckesson hold erbitux inventory consignment company revenue recognition policy company recognize revenue inventory ship mckesson enduser mckesson hold inventory erbitux account divestiture oncology therapeutic network otn company discontinue consignment arrangement mckesson mckesson long hold inventory account company sell erbitux intermediary wholesaler specialty oncology distributor ship erbitux directly enduser product customer intermediary begin quarter company expand distribution model include company wholesaler hold erbitux inventory company recognize revenue shipment consistent revenue recognition policy discussion company strategic alliance imclone item financial statementsnote alliance investment sankyo company license patent cover pravastatin market company pravachol sankyo key provision agreement expiring exclusivity expire marketbymarket basis exclusivity expire market italy exclusivity expire january early termination available base party voluntary involuntary bankruptcy material breach notice require early termination strategic alliance immediately notice case voluntary involuntary bankruptcy day notice case material breach occur cure commencement cure occur termination expiration alliance company retain patent exclusivity right relation pravastatin gilead company gilead enter joint venture develop commercialize fixeddose combination company sustiva gileads truvada emtricitabine tenofovir disoproxil fumarate july fda approve treatment atripla complete highly active antiretroviral therapy treatment product hiv available fixeddose combination take daily fixeddose combination contain multiple medicine formulate help simplify hiv therapy patient provider guideline issue department health human service list combination emtricitabine tenofovir disoproxil fumarate efavirenz preferred nonnnrtibase treatment use appropriate patient take antihiv medicine company gilead share responsibility commercialize atripla provide fund fieldbased sale representative support promotional effort atripla gilead record atripla revenue consolidate result joint venture operating result company record revenue bulk efavirenz component atripla sale product gilead joint venture party customer company revenue efavirenz component determine apply percentage atripla revenue approximate revenue sustiva brand september company amend agreement commercialize atripla canada subject approval product health canada company share responsibility commercialize atripla canada gilead recording atripla revenue company recording revenue bulk efavirenz component atripla joint venture company gilead continue terminate mutual agreement party describe event material breach party nonbreache party terminate joint venture party agree desirable practicable withdraw combination product market commercialize time generic version sustiva appear market gilead right terminate joint venture acquire right combination product canada company continue year receive percentage net sale base contribution bulk efavirenz atripla retain right sustiva discussion company strategic alliance gilead item financial statementsnote alliance investment somerset company somerset joint venture mylan watson enter agreement commercialization supply distribution somerset emsam selegiline transdermal system monoamine oxidase inhibitor administer transdermal patch treatment patient major depressive disorder somerset receive approval fda emsam february use dietary restriction recommend dose mg hour emsam transdermal treatment major depressive disorder term agreement company receive exclusive distribution right commercialize emsam approve canada company expense million upfront payment december million payment follow regulatory approval quarter capitalize amortize cost product sell remain term agreement quarter company record impairment charge unamortized balance million result lower expect sale emsam charge record cost product sell company consolidate statement earning addition payment somerset receive milestone payment base achievement certain sale level reimbursement certain development cost incur term agreement somerset supply product company receive royalty company sale emsam early terminate extended accordance term agreement terminate fifth anniversary date commercial sale emsam agreement early terminate party event material breach agreement bankruptcy party addition general right termination company right terminate agreement time follow launch generic product occurrence material safety issue relate emsam date month date commercial sale emsam day prior notice somerset right terminate agreement time follow occurrence material safety issue relate emsam failure company meet specify detail requirement termination somerset retain product right emsam investigational compound development medarex company enter worldwide collaboration share purchase agreement medarex codevelop copromote ipilimumab fully human antibody currently phase iii development treatment metastatic melanoma agreement effective january company receive certain governmental clearance approval receipt consent public health service sublicense company medarexs right mdx gp vaccine develop combination ipilimumab fda grant fast track status ipilimumab combination mdx treatment patient late stage unresectable metastatic melanoma fail intolerant line therapy january term agreement company cash payment million medarex expense research development additional million equity investment medarex milestone payment expect successful achievement regulatory sale relate stage company medarex share future development commercialization cost medarex receive million regulatory milestone meet million salesrelated milestone medarex option copromote receive profit company company receive exclusive license outside pay royalty medarex agreement medarex expire follow event occur company voluntarily terminate agreement entirety countrybycountry basis provide medarex month prior write notice company voluntarily terminate agreement productbyproduct basis second product glp toxicology study later countrybycountry basis provide medarex month prior write notice depend circumstance company terminate medarexs co promotion option right day write notice end second calendar year event medarex provide percent certain performance obligation consecutive calendar year termination right exercise respect indication medarex fail meet performance obligation termination company scenario medarex long right share profit loss product terminate indication instead company pay medarex royalty net sale product medarex terminate agreement respect product day write notice company provide percent certain performance obligation consecutive calendar year generally termination company assign right product medarex receive royalty intellectual property license company medarex medarex elect copromote product indication event receive royalty sale product indication material breach manufacturing party party shall limit termination party manufacturing right pierre fabre company pierre fabre enter relate agreement patent knowhow license agreement trademark license agreement supply agreement develop commercialize vinflunine novel investigational anticancer agent vinflunine phase iii clinical trial metastatic bladder cancer phase iii trial lung breast cancer term agreement company receive exclusive license vinflunine canada japan korea select southeast asian market pierre fabre responsible development marketing vinflunine country include europe supply company requirement product term agreement company expensed upfront milestone payment million million million potential additional million milestone payment time patent knowhow license agreement company license right market vinflunine expire countrybycountry product formbyproduct form basis date expiration applicable patent datum exclusivity give product form country ii tenth anniversary commercial sale product form country time company exercise royaltyfree nonexclusive right market product agreement terminate soon follow party terminate agreement voluntary involuntary bankruptcy insolvency party dismiss certain period time party terminate material breach cure specify period termination shall relate country product form relate material breach product form iv form case form terminate breach pertain case country terminate pierre fabre pierre fabre terminate supply agreement material breach company party day notice justifiable demonstrable safety efficacy technical regulatory reason preclude development iv form indication determine joint steering committee pierre fabre company fail file process registrational filing require file agreement justifiable demonstrable safety efficacy technical regulatory reason b company launch iv product form country time period require agreement generally ninety day follow receipt regulatory applicable pricing approval c company challenge contest pierre fabre patent right company make improper contract assignment e company fail meet certain minimum sale level agreement company cause countrybycountry basis give pierre fabre ninety day prior write notice notice give prior regulatory approval approve indication ii eighty day prior write notice regulatory approval approve indication generally termination pierre fabre termination company cause company shall retain right product right shall revert pierre fabre astrazeneca january company enter worldwide japan codevelopment cocommercialization agreement astrazeneca codevelopment cocommercialization saxagliptin dppiv inhibitor phase iii clinical trial saxagliptin agreement codevelopment cocommercialization dapagliflozin sglt inhibitor phase iib clinical trial sglt agreement compound study treatment diabete discover company term agreement company receive upfront payment million january capitalize amortized life agreement income milestone payment expect receive company successful achievement regulatory sale relate stage agreement company astrazeneca share future development commercialization cost saxagliptin agreement company receive million regulatory milestone meet additional million salesbased milestone meet sglt agreement company receive million regulatory milestone meet additional million salesbased milestone meet majority development cost initial development plan pay astrazeneca additional development cost generally share equally agreement company share commercialization expense profitslosse equally global basis exclude japan company manufacture product certain limited exception record net sale agreement additional compound dppiv sglt class develop party propose inclusion collaboration predesignate trigger point end phase ii iii lead compound fail party actively conduct clinical development compound class accept party inclusion collaboration upfront payment regulatory sale base milestone pay nondevelope party additional compound timing depend nature trigger event additional compound replace develop addition lead compound event astrazeneca party develop compound control intellectual property right astrazeneca assume right obligation company collaboration respect compound company right astrazeneca respect compound certain limited exception company party develop compound control intellectual property right respect initial compound agreement expire productbyproduct countrycountry basis late expiration lasttoexpire patent control party cover product country expiration statutory exclusivity product country permanent cessation sale product country agreement soon terminate entirety productbyproduct regionbyregion countrybycountry basis case mutual write agreement party accordance term agreement follow astrazeneca cause regionby region productbyproduct basis month notice give soon finalization clinical database database lock complete pivotal phase iii clinical trial later date company elect opt sale force effort obligation ii astrazeneca cause regionbyregion productbyproduct basis month notice termination effective early year launch product region iii party respect agreement entirety write notice give follow permanent cessation development product long product develop commercialize iv party day notice party materially breach agreement engage gross negligence willful misconduct willful misrepresentation fundamentally frustrate transaction contemplate agreement v party event insolvency bankruptcy party vi party give product country party fails provide require sale force effort consecutive year vii party party incapable consecutive month perform material obligation force majeure viii party productbyproduct basis event material safety issue ix party development commercialization give compound enjoin sglt agreement astrazeneca exercise termination right lead compound meet specify end phase ii success criterion event termination astrazeneca company event development commercialization collaboration compound enjoin party offer collaboration compound actively conduct clinical development accept party inclusion collaboration upfront payment regulatory salesbased milestone pay nondevelope party additional compound event astrazeneca party develop compound control intellectual property right astrazeneca assume right obligation company collaboration respect compound company right astrazeneca respect compound certain limited exception additional compound offer additional compound offer accept collaboration agreement terminate event change control party result merger consolidation sale substantially asset similar transaction agreement assign assumed successor company agreement terminate astrazeneca describe clause iv v vi precede paragraph prior change control company company retain right product pay astrazeneca royalty net sale agreement terminate astrazeneca describe clause iv v vi precede paragraph follow change control company astrazeneca elect receive royalty net sale elect product right assign pay company royalty net sale agreement terminate company describe clause iv v vi precede paragraph company retain right product pay astrazeneca royalty net sale information alliance relate product development drug discovery research development health care group health care group consist segment nutritional health care health care segment currently consist convatec medical imaging prior include consumer medicine health care group sale account company sale company sale company sale health care group sale account total health care group sale respectively international health care group sale account total health care group sale respectively nutritional segment nutritional segment mead johnson manufacture market distribute sell infant formula nutritional product include entire line enfamil product enfamil lipil product infant formula contain nutrients docosahexaenoic acid dha arachidonic acid ara naturally find breast milk dha ara believe support infant brain eye development company obtain nutrients sole provider pursuant nonexclusive worldwide license supply agreement supply agreement force provide firm guaranty supply pricing subject change pursuant pricing formula license expire begin countrybycountry basis year company commence sale country company nutritional product generally sell wholesaler retailer promote primarily health care professional company promote nutritional product directly consumer worldwide advertising company manufacture product foreign country nutritional sale account company sale company sale company sale nutritional sale account total nutritional sale respectively international nutritional sale account total nutritional sale respectively approximately onehalf gross sale infant formula subject rebate issue woman infant child wic program sale subject wic rebate low margin nonwic program sale net sale select product product category nutritional segment follow dollar million infant formula enfamil toddlerchildren nutritional enfagrow february company complete divestiture adult nutritional business novartis million include million payment contingent achievement contractual requirement satisfy million upfront payment tenyear supply agreement health care segment health care segment currently consist convatec medical imaging prior include consumer medicine health care sale account company sale respectively health care sale account total health care sale respectively international health care sale account total health care sale respectively convatec convatec manufacture distribute sell ostomy modern wound skin care product principal brand convatec include natura surfit esteem aquacel duoderm flexiseal product market worldwide primarily hospital medical profession medical supplier company mainly rely internal sale force sale distributor world company manufacture product uk dominican republic convatec sale account approximately company sale company sale convatec sale account total convatec sale respectively international convatec sale account total convatec sale respectively medical imaging medical imaging manufacture distribute sell medical imaging product principal brand include cardiolite kit preparation technetium tcm sestamibi injection cardiac perfusion image agent definity vial perflutren lipid microsphere injectable suspension ultrasound contrast agent product manufacture company puerto rico party market internal sale force cardiolite radiopharmaceutical product primarily sell distribute thirdparty radiopharmacie endcustomer eg healthcare provider definity distribute directly endus customer definity call luminity eu approve eu company currently supplier technetium tcm generator widely radioisotope require compound unitdose cardiolite injection company rely single source supply key ingredient molybdenum connection company international business medical imaging own certain radiopharmacie outside cardiolite cover series patent claim component patent coverage differ somewhat countrybycountry basis cardiolite patent exclusivity expire january cardiolite entitle sixmonth extension exclusivity july company submit fda january certain pediatric clinical datum accordance write request issue fda guarantee company able fulfill requirement write request eu patent expiry timeline span december japan patent expiry timeline span august medical imaging sale account approximately company sale approximately company sale medical imaging sale account total medical imaging sale international medical imaging sale account total medical imaging sale company maintain license supply agreement radiopharmacie include cardinal health nuclear pharmacy service independent radiopharmacie provide right sell cardiolite source availability raw material general company purchase raw material medical device supply require production company product open market product company purchase raw material medical device supply single source certain circumstance specify company product registration require company obtain raw material supply particular source company attempt possible mitigate raw material supply risk company inventory management alternative source strategy discussion source manufacture quality assurance discussion particular product manufacture quality assurance company seek design operate manufacturing facility manage thirdparty manufacturer maintain inventory way allow meet expect product demand maintain flexibility reallocate manufacturing capacity improve efficiency respond change supply demand pharmaceutical production process complex highly regulate vary widely product product shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval discussion regulatory impact company manufacturing government regulation price constraint pharmaceutical manufacturing facility require significant ongoing capital investment maintenance compliance increase regulatory requirement addition company add product line realign focus year company expect modify exist manufacturing network devote substantial resource excess historical level meet heighten processing standard require sterile newly introduce product include biologic biologic manufacturing involve complex process traditional pharmaceutical operation company capacity manufacture biologic clinical trial commercial launch capacity manufacture large commercial volume limited biologic important company product portfolio company continue arrangement thirdparty manufacturer addition expect substantial investment increase internal capacity produce biologic commercial scale board director approve capital expenditure approximately million bulk biologic manufacturing facility february company complete land purchase acre site locate large scale multiproduct bulk biologic manufacturing facility deven massachusetts construction facility expect begin early facility project operationally complete company expect submit site regulatory approval commercial production biologic compound anticipate begin company rely party manufacture supply active ingredient necessary manufacture certain product include plavix abilify erbitux sustiva franchise orencia pravachol coumadin taxol paclitaxel maintain stable supply product company take variety action design provide reasonable level ingredient hold thirdparty supplier company company manufacture operation interrupt additional protection case company take step maintain approve backup source available company receive approval fda manufacture orencia company syracuse ny manufacturing facility give company current limited capacity commercial volume biologics product company receive approval fda manufacture orencia lonza biologic plcs lonza manufacturing facility expect rely celltrion inc celltrion exist facility celltrion new largescale facility provide additional capacity orencia commercial scale production pende submission approval sbla fda company rely initially party manufacturer manufacture belatacept ipilimumab commercial scale product commercialize belatacept ipilimumab investigational biologic compound late stage development company filing fda seek approval celltrion manufacture orencia ii lonza celltrion manufacture belatacept ipilimumab company seek approval fda market sell belatacept ipilimumab assurance regulatory approval product obtain regulatory approval manufacturing facility obtain company enter agreement lonza celltrion thing reserve portion respective biologic manufacturing capacity company future requirement orencia ii contain certain right negotiate lonza celltrion additional biologic manufacturing capacity biologic product company commence certain discussion thirdparty manufacturer relate biologic manufacturing capacity belatacept ipilimumab regulatory approval obtain information orencia product additional information belatacept ipilimumab research development company thirdparty manufacturer company rely exist future product unable maintain stable supply product operate sufficient capacity meet order requirement comply government regulation manufacturing pharmaceutical meet heighten processing requirement biologic company business performance prospect negatively impact additionally company thirdparty supplier experience extend plant shutdown substantial unplanned increase demand suspension manufacture regulatory reason company experience interruption supply certain product product shortage production resume expand connection divestiture license arrangement distribution agreement certain company product certain circumstance company enter agreement company agree supply product party addition liability arise company failure supply product agreement arrangement require company invest facility production non strategic product result additional regulatory filing obligation cause interruption manufacturing product company success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part company operation include research development purchasing facility planning manufacturing distribution company maintain qualityassurance procedure relate quality integrity scientific information production process control production process involve rigid specification ingredient equipment facility manufacturing method process packaging material label company perform test stage production process final product assure product meet regulatory requirement company standard test involve chemical physical chemical analyse microbiological testing combination analyse quality control provide business unitsite quality assurance group monitor exist manufacturing procedure system company subsidiary thirdparty supplier intellectual property product exclusivity company own license number patent foreign country primarily cover pharmaceutical product company develop brand name trademark product area company consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity country market exclusivity expire generic version product approve market substantial rapid decline product sale rate decline vary country therapeutic category discussion generic version product impact product sale generic competition product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory intellectual property right develop country provide certain nonpatent incentive development medicine example eu japan provide minimum period time approval new drug regulatory agency rely innovators data approve competitor generic copy regulatory intellectual property right available certain market incentives research new indication orphan drug medicine useful treat pediatric patient regulatory intellectual property right independent patent right company possess particularly important drug lack broad patent protection regulatory form exclusivity prevent competitor gain regulatory approval prior expiration regulatory data exclusivity basis competitor safety efficacy datum drug drug identical market innovator company estimate likely market exclusivity period product casebycase basis possible predict length market exclusivity company product certainty complex interaction patent regulatory form exclusivity inherent uncertainty concern patent litigation assurance particular product enjoy market exclusivity period time company currently estimate exclusivity limited estimate discussion market exclusivity pharmaceutical segment addition patent regulatory form exclusivity company hold intellectual property form trademark product enfamil trademark effect market exclusivity product consider marketing value worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely specific aspect law govern market exclusivity pharmaceutical vary country country follow summarize key exclusivity rule market represent significant company sale united states company seek market innovative pharmaceutical file complete set safety efficacy datum fda type application file depend drug chemical small molecule biological product large molecule innovative pharmaceutical chemical company file new drug application nda medicine biological product bla file type application file affect regulatory exclusivity right competitor seek launch generic substitute chemical innovative drug file anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical know new chemical entity entitle year regulatory data protection anda file fda innovators patent challenge describe generic manufacturer file anda fourth year fiveyear datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation new indication basis new clinical trial receive year datum protection finally nda designate orphan drug drug gain indication treatment condition occur rarely receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use significant portion patent life lose time take obtain regulatory approval innovator extend patent compensate innovator lose patent term specifically innovator identify patent claim product approve method use depend number factor extend expiration date patent limit extension maximum term patent extend year second extension cause patent effect year date nda approval company earn month additional exclusivity drug specific clinical trial conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity sixmonth period extend form exclusivity patent regulatory list fda time study complete submit fda product finally approve currently generic version biological product approve law law change future absence new legislation fda take step allow generic version certain biologic competitor seek approval biological product file safety efficacy datum address challenge biologic manufacturing involve complex process costly traditional pharmaceutical operation innovative drug cover patent hold nda sponsor minimum period regulatory exclusivity provide law innovator company required list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph iv certification innovator decide file patent infringement suit generic manufacturer ndaliste patent successfully challenge innovator chooses sue filer paragraph iv certification filer generic qualifie entitle day period market exclusivity generic manufacturer time time anda include paragraph iv certification file respect certain company product company evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right increase likelihood generic challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product discussion litigation relate patent challenge generic company item financial statementsnote legal proceeding contingenciesplavix litigation intellectual property litigation second statutory regulatory provision limit ability innovator company prevent generic drug approve launch patent litigation ongoing fda actively consider way expand use regulatory mechanism allow regulatory approval drug similar generic copy innovative drug basis extensive datum require nda result development possible predict length market exclusivity particular company product certainty base solely expiration relevant patent current form regulatory exclusivity information new legislation government regulation price constraint european union eu innovative pharmaceutical entitle year regulatory data protection marketing approval obtain centralized procedure product receive approval centralized procedure automatically receive approval member state eu company obtain pricing reimbursement pharmaceutical product typically subject member state law pricing reimbursement procedure month year obtain consequently regardless innovative medicine cover patent generic copy rely innovator datum usually approve minimum year approval additional year protection available certain circumstance innovator drug receive substantial new indication approval innovative pharmaceutical gain marketing approval noncentralized mutual recognition procedure period year depend individual eu member state regardless regulatory exclusivity competitor obtain approval identical product basis safety efficacy datum time recent pharmaceutical legislation eu impact procedure authorization pharmaceutical product eu centralize mutual recognition procedure particular legislation contain new data protection provision product regardless approve centralized mutual recognition procedure subject regime year innovator receive community authorization medicinal product generic company file marketing authorization application product health authority generic company commercialize product year elapse initial marketing authorization grant innovator possible year extension available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment transitional provision new datum protection requirement provision apply new marketing authorization application submit new legislation patent pharmaceutical product generally enforceable eu contrast patent list regulatory authority generic copy approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant patent eu extended compensate patent term lose regulatory review process extension grant countrybycountry basis general eu law treat chemically synthesize drug biologically derive drug respect intellectual property market exclusivity european medicine evaluation agency emea issue guideline outline additional information provide biosimilar product know generic biologic order emea review application marketing approval japan japan medicines new chemical entity nce generally afford year datum exclusivity approve indication dosage japans ministry health expect extend pharmaceutical datum exclusivity period nce year patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemically synthesize biologically derive drug respect intellectual property market exclusivity rest world country outside eu japan wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar eg canada eu eg switzerland develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply world trade organization wto commitment take step implement law meaningful way enforcement wto obligation long process assurance outcome assess likely future market exclusivity company innovative drug develop country company take account formal legal right political factor marketing distribution customer company promote product medical journal directly health care provider doctor nurse practitioner physician assistant pharmacist technologist hospital pharmacy benefit manager pbms manage care organization mcos government agency company market directly consumer directtoconsumer print radio television advertising addition company sponsor general advertising educate public innovative medical research discussion regulation promotion marketing pharmaceutical government regulation price constraint company sale marketing organization company explain approve use advantage product medical professional company work gain access health authority pbm mco formulary list recommend approve medicine product include medicare plan reimbursement list demonstrate quality treatment benefit product marketing prescription pharmaceutical limit approve use particular product company continue develop information product provide information response unsolicite inquiry doctor medical professional drug complete clinical trial require regulatory authority safe effective treat medical problem manufacturer choose undertake additional study include comparative clinical trial competitive product demonstrate additional advantage compound study costly year complete result uncertain balancing consideration make difficult decide undertake additional study successful study major impact approve marketing claim strategy company operation include pharmaceutical marketing sale organization organization market distinct group product support sale force typically base particular therapeutic area physician group sale force focus sell new product introduce promotion physician increasingly target specialist high value primary care physician company prescription pharmaceutical product sell principally wholesaler company sell directly retailer hospital clinic government agency pharmacie sale pharmaceutical wholesaler mckesson cardinal health inc cardinal amerisourcebergen corporation amerisourcebergen account approximately respectively company total net sale sale mckesson cardinal amerisourcebergen account approximately respectively company total net sale sale mckesson cardinal amerisourcebergen account approximately respectively company total net sale sale wholesaler concentrated pharmaceutical segment company pharmaceutical business inventory management agreement ima arrangement substantially direct wholesaler customer allow company monitor wholesaler inventory level require wholesaler maintain inventory level month demand agreement twoyear term december subject certain termination provision mckesson company wholesaler provide warehousing packing shipping service erbitux mckesson hold erbitux inventory consignment company revenue recognition policy company recognize revenue inventory ship mckesson enduser mckesson hold inventory erbitux account divestiture otn company discontinue consignment arrangement mckesson mckesson long hold inventory account company sell erbitux intermediary wholesaler specialty oncology distributor ship erbitux directly enduser product customer intermediary begin quarter company expand distribution model include company wholesaler hold erbitux inventory company recognize revenue shipment consistent revenue recognition policy information sale marketing nutritional health care product nutritional segment health care segment competition market company compete generally broadbase highly competitive principal mean competition vary product category business group company pharmaceutical segment compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate cost effectiveness marketing effectiveness product label service research development new product process sale company product impact new study indicate competitor product great efficacy treat disease particular form disease company product company sale impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage companys product subject progressive price reduction decrease volume sale successfully compete business manage care pharmacy benefit management organization company demonstrate product offer medical benefit cost advantage compare form care new product company introduce compete product market product later develop competitor manufacturer generic pharmaceutical typically invest far research development researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product certain country outside patent protection weak nonexistent company compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation discussion generic launch clopidogrel bisulfate product compete plavix item financial statementsnote legal proceeding contingenciesplavix litigation company large small manufacture sell product similar market company nutritional health care segment source competitive advantage include product quality efficacy brand identity advertising promotion product innovation broad distribution capability customer satisfaction price significant expenditure advertising promotion marketing generally require achieve consumer trade acceptance product company believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment assurance company research development effort result commercially successful product product process outmoded time time result product process develop competitor manage care organization growth mco major factor competitive makeup health care marketplace half population participate version manage care size patient population cover mcos marketing prescription drug pbms serve organization important company business mco include medical insurance company medical plan administrator healthmaintenance organization medicare formulary alliance hospital physicians physician organization organization consolidate few large entity enhance purchasing strength importance company major objective mco contain possible reduce health care expenditure typically use formulary volume purchase longterm contract negotiate discount pharmaceutical provider mcos pbms typically develop formulary reduce cost medication formulary base price therapeutic benefit available product generally low cost generic medicine favor breadth product cover formulary vary considerably mco formulary include alternative competitive product treatment particular medical problem mcos use variety mean encourage patient use product list formulary exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price company generally universally successful major product include mco formulary generic competition big competitive challenge company face less extent internationally generic pharmaceutical manufacturer expiration loss market exclusivity product company lose major portion sale product short period time fda approval process exempt generic costly timeconsuming clinical trial demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product generic competitor operate company large research development expense cost convey medical information product medical community information market exclusivity intellectual property product exclusivity rate sale decline product expiration exclusivity vary country general decline market rapid develop country decline develop country tend rapid develop country rate sale decline expiration exclusivity historically influence product characteristic example drug large patient population eg prescribe primary care physician tend experience rapid decline drug specialized area medicine eg oncology drug complex manufacture eg sterile injectable product usually experience slow decline simple manufacture note mco focus primarily immediate cost drug favor generic brandname drug government encourage use generic alternative brandname drugs health care program law generally allow case require pharmacist substitute generic drug rate government procedure therapeutically equivalent brandname drug substitution prescribe physician expressly forbid law policy provide add incentive generic manufacturer seek marketing approval automatic substitution remove need generic manufacturer incur sale marketing cost innovator incur research development company invest heavily research development believe critical longterm competitiveness pharmaceutical research development carry bristolmyers squibb pharmaceutical research institute major facilities princeton hopewell new brunswick nj wallingford ct pharmaceutical research development carry facility belgium canada uk management continue emphasize leadership innovation productivity quality strategy success pharmaceutical research institute company spend million million million company sponsor research development activity company sponsor pharmaceutical research development spending include certain payment thirdparty collaboration contract end company employ approximately people research development company include pharmaceutical research institute include substantial number physician scientist hold graduate postgraduate degree higher skilled technical personnel company concentrate pharmaceutical research development effort follow disease area significant unmet medical need affective psychiatric disorder alzheimersdementia atherosclerosisthrombosis diabete hepatitis hivaid obesity oncology rheumatoid arthritis relate disease solid organ transplant company continue analyze selectively pursue promising lead area addition discover develop new molecular entity company look way expand value exist product new use formulation provide additional benefit patient supplement company internal effort company collaborate independent research organization include educational institution researchbase pharmaceutical biotechnology company contract performance research facility company drug discovery program include alliance collaborative agreement agreement bring new product pipeline help company remain cut edge technology search novel medicine drug development company engage service physician hospital medical school research organization worldwide conduct clinical trial establish safety effectiveness new product drug development timeconsume expensive risky development human health product industry practice government regulation foreign country provide determination effectiveness safety new molecular entity preclinical test control clinical evaluation new drug marketed record datum preclinical clinical experience include nda bla fda require approval development certain product subject government regulation cover safety efficacy foreign country assurance compound develop result program obtain regulatory approval necessary market particular disease indication average thousand chemical compound discover pharmaceutical industry researcher prove medically effective safe approve medicine process discovery regulatory approval typically take year long drug candidate fail stage process latestage product candidate fail receive regulatory approval company believe investment research internally collaboration reward number new pharmaceutical compound indication stage development list investigational compound company later stage development compound phase iii clinical trial investigational compound ultimately company market product depend result preclinical clinical study competitive landscape potential product market manufacturing process necessary produce potential product commercial scale factor note assurance company seek regulatory approval compound approval sought obtain stage development company determine intellectual property issue patent protection available investigational compound patent coverage highlight include potential patent term extension apixaban apixaban oral factor xa inhibitor develop internally recently enter phase iii clinical trial prevention thromboembolic disorder company owns issue patent covering composition matter method use apixaban expire september extend february patent term adjustment saxagliptin saxagliptin oral compound potential treatment diabete discover internally currently phase iii clinical trial january company enter worldwide japan agreement astrazeneca codevelopment cocommercialization saxagliptin patent application cover composition matter issue expire ixabepilone ixabepilone epothilone b analog novel microtubulestabilize agent multiple tumor type phase iii clinical trial treatment metastatic breast cancer phase ii clinical trial treatment prostate cancer company composition matter patent expire company acquire right develop ixabepilone compound class epothilone analogs helmholtz centre infection research ipilimumab ipilimumab codevelope medarex currently phase iii clinical trial monoclonal antibody investigate anticancer treatment novel class agent intend potentiate element immunologic response company own composition matter patent expire right method use patent own medarex expire company right medarex composition matter patent expires extend patent term adjustment pende medarex patent application cover composition matter method use ipilimumab belatacept belatacept biological product develop internally phase iii clinical trial fusion protein novel immunosuppressive activity target prevention solid organ transplant rejection company composition matter patent expire vinflunine vinflunine codevelope pierre fabre currently phase iii clinical trial metastatic bladder cancer novel investigational anticancer agent pierre fabre composition matter patent expire company enter agreement respect investigational compound order share cost risk development case facilitate commercialization agreement form include codevelopment comarketing copromotion andor joint venture arrangement company competitor devote substantial fund resource research development addition consolidation occur pharmaceutical industry create company substantial research development resource extent company competitor successful research result erosion sale product unanticipate product obsolescence government regulation price constraint pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act fdc act federal statute regulation state statute regulation law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion company product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition company operation subject complex federal state local foreign environmental occupational safety law regulation company anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment particular importance fda jurisdiction virtually company business impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance company pharmaceutical product fda regulate company nutritional health care product case fda requirement increase time money necessary develop new product bring market company pharmaceutical product medical device product sell convatec business subject premarket approval requirement new drug approve subject fdc act relate regulation biological drug subject fdc act public health service act phs act relate regulation biological drug license phs act medical device subject fdc act include medical device amendment nutritional product regulate fda primarily infant formula act amendment fda mandate drug manufacture package label conformity current good manufacturing practice cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production record keep quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject manufacturer possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy product occur follow approval federal government extensive enforcement power activitie pharmaceutical medical device manufacturer include authority withdraw product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market company materially adversely affect business financial condition result operation cash flow federal government similar power respect manufacturing operation nutritional business marketing authorization company product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject prescription drug marketing act pdma fdc act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel record keep packaging quantity label product handle facility storage security requirement intend prevent sale pharmaceutical product sample diversion discussion recent settlement certain investigation drug pricing sale marketing activity item financial statementsnote legal proceeding contingency marketing practice pharmaceutical manufacturer subject federal state health care law protect integrity government health care program office inspector general department health human service oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal anti kickback statute criminalize offer value induce recommendation order purchase product service reimburse government health care program oig issue series guidances segment health care industry include compliance program guidance pharmaceutical manufacturer oig guidance include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice company subscribe phrma code implement compliance program address requirement set forth oig guidance company compliance health care law failure comply health care law subject company administrative legal proceeding include action state federal government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect company business financial condition result operation cash flow company subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service company license drug enforcement agency procure produce control substance company subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy federal state agency regulatory authority manufacture storage transportation disposal medical imaging product radioactive nature company activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing company product regulatory requirement vary country country eu way company obtain marketing authorization pharmaceutical product route centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product second route obtain marketing authorization eu mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state set forth pricing reimbursement product continue subject member state law fda approval approval emea obtain product approval product comparable regulatory authority country outside eu case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country market outside company operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut method cost control european country provide market price new medicine uk germany pricing freedom limited uk operation profit control plan germany operation reference price system company face significant delay mainly france spain italy belgium market access new product year elapse new medicine available national market additionally member states eu regularly impose new additional cost containment measure pharmaceutical recent year italy example impose mandatory price decrease existence price differential europe different national pricing reimbursement law lead significant parallel trade flow recent year congress state legislature consider number proposal enact law effect major change health care system nationally state level drive budget concern medicaid access reimbursement restriction implement state propose similar cost containment issue exist foreign country company business federal state government pursue direct method reduce cost drug pay company participate state governmentmanage medicaid program certain qualify federal state government program discount rebate provide participate state local government entity rebate medicaid relate state program reduce revenue million million million decrease compare primarily exclusivity loss pravachol low plavix sale shift patient enrollment medicaid medicare medicare result decrease medicaid rebate partially offset corresponding increase company manage health care rebate company participate prime vendor program government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase prime vendor program company participate provide discount outpatient medicine purchase certain public health service entity hospital meet certain criterion company record discount relate prime vendor program million million million governmental cost containment effort extend federally fund special supplemental nutrition program wic state participate wic program sought obtain rebate manufacturer infant formula product program state conduct competitive bidding infant formula contract require use specific infant formula product state wic program physician request noncontract formula wic customer state participate wic program require engage competitive bidding use cost containment measure yield saving equal great saving generate competitive bidding system mead johnson participate program approximately half gross sale subject rebate wic program rebate wic program reduce revenue million million million discussion rebate program item management discussion analysis financial condition result operation result operation environmental regulation company facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require company operation permit subject modification renewal revocation issue authority environment health safety group company monitor operation world provide company overview regulatory requirement oversee implementation company standard compliance company incur operate capital cost matter ongoing basis company expend approximately million million million capital environmental project undertake specifically meet environmental requirement respectively expect spend approximately million company believe substantial compliance applicable environmental health safety requirement permit require operation company incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law company current facility operation year time company operator facility generate store dispose substance waste consider hazardous federal state foreign environmental law include comprehensive environmental response compensation liability act cercla result soil groundwater certain facility contaminated company require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently company involve investigation remediation approximately current company facility company identify potentially responsible party prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing company face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site company bear remediation responsibility pursuant contract obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter item financial statementsnote legal proceeding contingency employee company employ approximately people december foreign operation company significant operation outside conduct company subsidiary distributor involve business segment company operation pharmaceutical nutritional health care revenue operation outside billion account company total revenue revenue exceed million france japan canada spain italy mexico revenue exceed million france japan spain canada italy germany revenues exceed million france japan germany spain italy canada uk single country outside contribute company total revenue geographic breakdown net sale table caption geographic item financial statementsnote segment information discussion company sale geographic area item management discussion analysis financial condition result operationsgeographic area international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit limitation foreign participation local enterprise restrictive governmental action company international business subject governmentimpose constraint include law price reimbursement use product depend direction change relative dollar foreign currency value increase reduce report dollar value company net asset result operation change foreign exchange rate net favorable impact growth rate revenue company predict certainty future change foreign exchange rate effect company attempt mitigate impact operational mean financial instrument discussion item quantitative qualitative disclosure market risk item financial statementsnote financial instrument item risk factor factor describe significantly negatively affect business prospect financial condition operating result credit rating cause trading price common stock decline additional risk uncertainty presently know company risk company currently consider immaterial impair company operation patent infringement lawsuit apotex involve plavix ongoing risk generic competition apotex generic pharmaceutical company company large product rank net sale plavix clopidogrel bisulfate net sales united state billion billion billion composition matter patent plavix expire currently subject patent litigation apotex inc apotex corp apotex generic company significant jurisdiction august apotex launch generic clopidogrel bisulfate product compete plavix august district court southern district new york court patent litigation apotex grant motion company product partner sanofiaventis sanofi enjoin sale apotexs generic clopidogrel bisulfate product order apotex recall product customer court grant preliminary injunction affirm appeal trial underlie patent litigation end february court expect rule follow posttrial briefing atrisk launch generic clopidogrel bisulfate significant adverse effect net sale plavix company estimate range billion billion particular launch significant adverse effect net sale quarter company estimate range million million fourth quarter company estimate range million million second fourth quarter net sale plavix million million million million respectively estimate total prescription demand clopidogrel bisulfate brand generic increase compare estimate total prescription demand brand plavix decrease period company expect generic clopidogrel bisulfate sell distribution channel follow apotex atrisk launch august residual impact plavix net sale company overall financial result impact apotexs launch generic clopidogrel bisulfate product company reasonably estimate time depend number factor include generic product sell apotex company sanofi company prevail underlie patent litigation company prevail pende patent case extent launch apotex permanently adversely impact pricing prescription demand plavix damage seek andor recover company apotexs ability pay damage loss market exclusivity plavix andor sustain generic competition material company sale plavix result operation cash flow material company financial condition liquidity company territory partnership alliance sanofi plaintiff additional pende patent infringement lawsuit dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt relate patent trial date action dr reddys set patent infringement action teva cobalt stay pende resolution apotex litigation party action agree bind outcome litigation apotex teva cobalt appeal outcome litigation dr reddys teva file abbreviate new drug application food drug administration fda exclusivity periods statutory stay periods hatchwaxman act expire exception month stay applie teva expire february accordingly final approval fda provide company authorization distribute generic clopidogrel bisulfate product subject legal remedy company apply include injunctive relief damage company continue believe plavix patent valid infringe sanofi vigorously pursue enforcement patent right plavix possible time reasonably assess ultimate outcome ongoing patent litigation apotex plavix patent litigation timing renew generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical company apotex prevail trial company expect face renew generic competition plavix apotex promptly previously disclose prior generic launch apotex company enter propose settlement apotex pende plavix patent litigation fail receive require antitrust clearance antitrust division department justice conduct criminal investigation propose settlement plavix patent litigation apotex company cooperate fully investigation possible time reasonably assess outcome investigation impact company possible time reasonably assess impact investigation company compliance defer prosecution agreement attorney office district new jersey company record defer tax asset relate foreign tax credit research tax credit carryforward expire vary amount begin realization foreign tax credit research tax credit carryforward dependent generate sufficient domestic taxable income prior expiration realization assure management believe likely defer tax asset realize foreign tax credit research tax credit carryforward consider realizable reduce near term plavix subject renew additional generic competition event occur company need record significant valuation allowance federal defer tax asset additional information pende plavix patent litigation relate legal matter include item management discussion analysis executive summaryplavix outlook sec consent order defer prosecution agreement item financial statementsnote legal proceeding contingency company face competition pharmaceutical manufacturer include lowerpriced generic product competition manufacturer compete product include lowerpriced generic version company product major challenge internationally competition include new product develop competitor low price superior performance feature competitive company current product ii technological advance patent attain competitor iii result clinical study relate company product competitor product iv problem licensor supplier distributor v business combination company competitor major customer manufacturer generic product increasingly seek challenge patent expire case launch generic product expiration applicable patent andor final resolution relate patent litigation company experience difficulty delay manufacture sale product company experience difficulty delay inherent manufacturing sale seizure recall pharmaceutical product force closing manufacture plant ii failure obtain imposition limitation use loss patent intellectual property right iii failure company vendor supplier comply current good manufacturing practice application regulation quality assurance guideline lead temporary manufacturing shutdown product shortage delay product manufacture iv construction delay relate construction new facility expansion exist facility include intended support future demand company biologic product v manufacture distribution problem include change manufacture production site limit manufacturing capacity regulatory requirement change type product produce biologic physical limitation impact continuous supply company experience difficulty delay development commercialization new product company experience difficulty delay development commercialization new product include inherent risk uncertainty associate product development compound product appear promise development fail reach market expect optimal timeframe fail reach market approve additional indication number reason include efficacy safety concern delay denial necessary regulatory approval difficulty excessive cost manufacture ii failure enter successfully implement optimal alliance appropriate discovery andor commercialization product maintain consistent scope variety promise latestage product iii failure company product achieve maintain commercial viability legal matter adverse outcome negatively affect company business company continue obligation defer prosecution agreement dpa securities exchange commission sec consent order relate wholesaler inventory accounting matter pursuant company agree implement certain remedial measure include recommendation monitor dpa undertake corporate reform include additional disclosure periodic report file sec annual report shareholder company currently involve lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition include intellectual property dispute ii sale marketing practice internationally iii adverse decision litigation include product liability commercial case iv recall withdrawal pharmaceutical product force closing manufacture plant v failure fulfill obligation supply contract government customer result liability vi product pricing promotion matter vii lawsuit claim assert violation security antitrust federal state pricing law viii environmental health safety matter ix failure comply antibribery law foreign corrupt practice act x tax liability assurance increase scope matter additional lawsuit claim proceeding investigation future assurance matter material adverse impact company foreign regulation negatively affect company sale profit margin company subject new government law regulation health care reform initiative state federal level country ii change fda foreign regulatory approval process cause delay approve prevent approval new product iii tax change phase tax benefit heretofore available certain foreign country iv new law regulation judicial decision affect pricing marketing jurisdiction v change intellectual property law vi matter compulsory license alter protection afford product company face increase pricing pressure abroad manage care organization institutional purchaser government agency program negatively affect company sale profit margin pharmaceutical product subject increase price pressure restriction worldwide include rule practice manage care group institutional governmental purchasers ii judicial decision governmental law regulation relate medicare medicaid healthcare reform include medicare prescription drug improvement modernization act iii potential impact importation restriction legislative andor regulatory change pharmaceutical reimbursement medicare formularie product pricing general iv development technology andor industry practice directly indirectly impact reimbursement policy practice thirdparty payer company rely party meet contractual regulatory obligation company rely vendor partner include alliance pharmaceutical company development commercialization product party meet contractual regulatory obligation relation arrangement company failure party meet obligation andor development significant disagreement factor materially disrupt ongoing commercial relationship prevent optimal alignment partner activity material adverse impact company company adversely impact economic factor control company significant operation outside revenue operation outside account company revenue company expose change fluctuation foreign currency exchange rate information company foreign currency exchange exposure item quantitative qualitative disclosure market risk company significant borrowing expose change interest rate december company shortterm borrowing longterm debt billion information company interest rate exposure item quantitative qualitative disclosure market risk company expose economic factor company control failure execute company business strategy adversely impact growth profitability company able fully execute strategic transformation business attain new period sustainable revenue earning growth company continue invest growth driver pipeline focus address area significant unmet medical need failure realize additional cost saving achieve maintain competitive cost base successfully transition product portfolio materially adversely affect company result operation addition company failure hire retain personnel right expertise experience operation critical business function adversely impact execution business strategy change company structure operation revenue cost efficiency result acquisition divestiture merger alliance restructuring strategic initiative result great expect cost difficulty include need regulatory approval appropriate company increasingly dependent information technology company increasingly dependent information technology system significant breakdown invasion destruction interruption system negatively impact operation company believe prudent plan assumption assurance give goal plan set forth forward look statement achieve reader caution place undue reliance statement speak date company undertake obligation release publicly revision forwardlooke statement result new information future event item b unresolved staff comment item property company world headquarter locate park avenue new york ny lease approximately square foot floor space approximately square foot sublet company manufacture product major worldwide location aggregate floor space approximately million square foot facility own company follow table illustrate geographic location company significant manufacturing facility business segment total company pharmaceutical nutritional health care united states europe middle east africa western hemisphere pacific total portion facility facility own lease company research administration storage distribution information company facility item businessmanufacture quality assurance item legal proceeding information pertain legal proceeding find item financial statementsnote legal proceeding contingency incorporate reference item submission matter vote security holder matter submit vote security holder fourth quarter year end december ia executive officer registrant list information executive officer company february executive officer elect board director initial term continue board meeting follow annual meeting stockholder elect oneyear term successor elect executive officer serve pleasure board director current position age employment history past year lamberto andreotti president europe worldwide medicine group division executive vice president president company worldwide pharmaceutical senior vice president president international member management council worldwide medicine group division company executive committee present executive vice president president worldwide pharmaceutical division company stephen e bear present senior vice president human resource corporate staff senior vice president human resource company corporate staff member management council executive committee andrew r j bonfield executive director finance bg group plc executive vice president chief financial officer present chief financial officer corporate staff company corporate staff member management council executive committee joseph c caldarella vice president finance pharmaceutical research institute vice president corporate controller division company corporate staff present vice president corporate controller corporate staff company john e celentano vice president general manager northern europe president health care group international medicine division company member management council senior vice president operation plan worldwide executive committee medicine group division company president canada mexico puerto rico worldwide medicine group division company president latin america canada worldwide medicine group division company present president health care group division company james cornelius chief executive officer chairman board guidant interim chief executive officer corporation member management council interim chief executive officer chairman board executive committee guidant corporation present interim chief executive officer director company sandra leung corporate secretary corporate staff company senior vice president general counsel vice president corporate secretary corporate staff corporate staff company member management council vice president corporate secretary act general executive committee counsel corporate staff company present senior vice president general counsel corporate staff company elliott sigal md phd senior vice president drug discovery exploratory executive vice president chief scientific officer development pharmaceutical research institute division company president pharmaceutical research institute senior vice president global clinical pharmaceutical member management council development pharmaceutical research institute division company executive committee present chief scientific officer president pharmaceutical research institute division company ii item market registrant common stock stockholder matter market price bristolmyer squibb common preferred stock trade new york stock exchange nyse trade nyse arca inc pacific exchange inc symbol bmy bmypr december company voluntarily withdraw security list nyse arca inc quarterly summary high low market price present common high low high low quarter second quarter quarter fourth quarter prefer high low high low quarter second quarter quarter fourth quarter second quarter second quarter trade company prefer stock prefer stock pay quarterly dividend share holder common stock number record holder common stock december number record holder base actual number holder register book company date include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company vote security principal holder reference proxy statement file march respect vote security principal holder incorporate reference hereof response information require item dividend dividend declare share common prefer quarter second quarter quarter fourth quarter december board director company declare quarterly dividend share common stock company pay february shareholders record january unregistere sale equity security use proceed follow table summarize surrender company equity security connection stock option restrict stock program twelvemonth period end december total number approximate dollar total number share purchase value share average price publicly share pay announce plan purchase period purchaseda sharea programsb plan programsb dollar million share datum january february march month end march april june month end june july august september month end september october november december month end december month end december reflect follow transaction month end december surrender company share common stock pay exercise price satisfy tax withholding obligation connection exercise employee stock option ii surrender company share common stock satisfy tax withholding obligation connection vest restricted stock issue employee b june company announce board director authorize purchase billion company common stock month end december share repurchase pursuant program purchase share program expect performance graph follow performance graph compare performance bristolmyer squibb period indicate performance standard poor stock index sp average performance group consist peer corporation lineofbusiness basis corporation make peer company group abbott laboratories astrazeneca plc eli lilly company glaxosmithkline plc johnson johnson merck co inc novartis ag pfizer inc sanofiaventis include performance aventis prior merger sanofi scheringplough corporation wyeth total return index reflect reinveste dividend weight beginningperiod market capitalization report time period measure performance group proxy statement comparison year cumulative total return bristolmyer squibb sp index peer group assume invest bristolmyer squibb common stock sp index peer company group index value december specify year assume dividend reinveste item select financial datum fiveyear financial summary amount million share datum income statement datum net sale earning continue operation minority interest income taxis earning continue operation earning continue operation common share basic diluted average common share outstanding basic dilute dividend pay common prefer stock dividend declare common share financial position datum december total asset cash cash equivalent marketable security longterm debt stockholder equity company record item affect comparability result discussion item year item management discussion analysis financial condition result operationsexpense item financial statementsnote alliance investment note restructure note acquisition divestiture note discontinued operation note shortterm borrowing longterm debt note legal proceeding contingency exclude discontinue operation oncology therapeutic network year clairol zimmer million weightedaverage share issuable million interest expense net tax assume conversion convertible debt include diluted earning share calculation dilutive include impact adoption statement financial accounting standard sfas employer account define benefit pension postretirement plansan amendment fasb statement r discussion sfas item financial statementsnote pension postretirement benefit item management discussion analysis financial condition result operation executive summary company bristolmyer squibb company bms company bristolmyer squibb worldwide pharmaceutical relate health care product company mission extend enhance human life provide high quality pharmaceutical relate health care product company engage discovery development licensing manufacturing marketing distribution sale pharmaceutical relate health care product company reportable segmentspharmaceutical nutritional health care pharmaceutical segment comprise global pharmaceutical international consumer medicine business account approximately company net sale nutritional segment consist mead johnson nutritionals mead johnson primarily infant formula children nutritional business account approximately company net sale health care segment consist convatec medical imaging business account approximately company net sale financial highlight company progress longrange strategy despite significant challenge occur year include atrisk launch generic clopidogrel bisulfate product adversely impact plavix sale loss exclusivity pravachol united state certain european market increase litigation reserve company launch important product include orencia sprycel gilead sciences inc gilead atripla orencia sprycel continue gain market share double digit sale growth abilify reyataz erbitux sustiva franchise baraclude key component strong product line longterm growth company continue invest late stage compound development new product grow importance biologics february company complete land purchase major new biologic facility deven massachusetts expansion exist facility syracuse new york manati puerto rico construction deven facility schedule begin early worldwide net sale continue operation decrease billion compare worldwide net sale product company view growth driver increase compare period exclude plavix worldwide net sale growth driver increase compare period product company consider growth driver plavix avaproavalide abilify reyataz erbitux net income billion compare billion result include million increase reserve price sale litigation settlement million early debt retirement cost result include million gain sale consumer medicine business plavix company large product rank net sale plavix clopidogrel bisulfate sale billion billion billion composition matter patent plavix expire currently subject patent litigation apotex inc apotex corp apotex generic company significant jurisdiction company previously disclose certain development pende plavix litigation apotex include atrisk launch generic product apotex august note apotex launch generic clopidogrel bisulfate product compete plavix august august district court southern district new york court grant motion company product partner sanofiaventis sanofi enjoin sale apotexs generic clopidogrel bisulfate product order apotex recall product customer court grant preliminary injunction affirm appeal trial underlie patent litigation end february court expect rule follow posttrial briefing atrisk launch generic clopidogrel bisulfate significant adverse effect net sale plavix company estimate range billion billion particular launch significant adverse effect sale quarter company estimate range million million fourth quarter company estimate range million million second fourth quarter net sale plavix million million million million respectively estimate total prescription demand clopidogrel bisulfate brand generic increase compare estimate total prescription demand brand plavix decrease period company expect generic clopidogrel bisulfate sell distribution channel follow apotex atrisk launch august residual impact plavix net sale company overall financial result impact apotexs launch generic clopidogrel bisulfate product company reasonably estimate time depend number factor include generic product sell apotex company sanofi company prevail underlie patent litigation company prevail pende patent case extent launch apotex permanently adversely impact pricing prescription demand plavix damage seek andor recover company apotexs ability pay damage loss market exclusivity plavix andor sustain generic competition material company sale plavix result operation cash flow material company financial condition liquidity company territory partnership alliance sanofi plaintiff additional pende patent infringement lawsuit dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt relate patent patent trial date action dr reddys set patent infringement action teva cobalt stay pende resolution apotex litigation party action agree bind outcome litigation apotex teva cobalt appeal outcome litigation dr reddys teva file abbreviate new drug application anda food drug administration fda exclusivity periods statutory stay periods hatchwaxman act expire exception month stay applie teva expire february accordingly final approval fda provide company authorization distribute generic clopidogrel bisulfate product subject legal remedy company apply include injunctive relief damage company continue believe plavix patent valid infringe sanofi vigorously pursue enforcement patent right plavix possible time reasonably assess ultimate outcome ongoing patent litigation apotex plavix patent litigation timing renew generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical company apotex prevail trial company expect face renew generic competition plavix apotex promptly previously disclose antitrust division department justice conduct criminal investigation propose settlement pende patent plavix litigation apotex company cooperate fully investigation possible time reasonably assess outcome investigation impact company possible time reasonably assess impact investigation company compliance defer prosecution agreement dpa attorney office district new jersey usao previously disclose usao initiate investigation conduct monitor dpa monitor usao corporate governance issue relate company negotiation propose settlement apotex include review violation federal security law connection propose settlement apotex term previously disclose consent order company enter securities exchange commission august consent sec consent monitor complete investigation submit report investigation usao monitor report find violation consent federal security law connection propose settlement monitor conclude company violate certain paragraph dpa related governance matter violation cite monitor report relate thing communication failure include insufficient communication company chief executive officer ceo general counsel board director board member senior management failure comply certain internal company policy procedure monitor finding respect company knowingly materially breach dpa recommendation usao advise company believe matter cite monitor report fully remediate accordingly intend action dpa respect monitor report additional discussion legal matter include plavix patent litigation antitrust division investigation relate propose settlement apotex term dpa sec consent item financial statementsnote legal proceeding contingency outlook sec consent order defer prosecution agreement business environment company conduct business primarily pharmaceutical industry highly competitive subject numerous government regulation competitive factor significantly affect company sale product include product efficacy safety price costeffectiveness marketing effectiveness product label quality control quality assurance manufacturing operation research development new product successfully compete business health care industry company demonstrate product offer medical benefit cost advantage currently company new product introduction compete product market therapeutic category addition potential future competition new product competitor introduce future company manufacture brand product price high generic product generic competition company lead challenge globally pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product lose exclusivity long protect patent subject new compete product form generic brand exclusivity loss company lose major portion product sale short period time internationally health care industry subject governmentimposed regulation authorize price price control continue impact company sale congress state legislature consider number proposal enact law effect major change health care system nationally state level drive budget concern medicaid access reimbursement restriction implement state propose addition january medicare prescription drug improvement modernization act effective provide outpatient prescription drug coverage senior citizen company assess impact legislation business include potential negative impact pharmaceutical business legislative andor regulatory change result additional pricing pressure control market outside company operate environment governmentmandate costcontainment program regulatory body group exert downward pressure pricing pricing freedom limited united kingdom uk instance operation profit control plan germany operation reference price system company face significant delay market access new product year elapse drug approval new medicine available national market growth manage care organization mcos play large role competition surround health care industry mco seek reduce health care expenditure participant make volume purchase enter longterm contract negotiate discount pharmaceutical provider market potential create large pool participant marketing prescription drug mcos important company strategy company compete inclusion mco formulary company generally successful major product include company believe development manage care industry include continued consolidation continue generally downward pressure price pharmaceutical production process complex highly regulate vary widely product product shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval biologic manufacturing involve complex process traditional pharmaceutical operation biologic important company product portfolio company continue arrangement thirdparty manufacturer substantial investment increase internal capacity produce biologic commercial scale include build new stateoftheart manufacturing facility production biologic devens massachusetts construction commence early company maintain competitive position market strive uphold position dependent success discover develop innovative costeffective product serve unmet medical need company subsidiary subject number significant pende lawsuit claim proceeding investigation possible time reasonably assess final outcome investigation litigation management continue believe previously disclose year aggregate impact current reserve legal matter affect company reasonably likely material company result operation cash flow material financial condition liquidity additional discussion legal matter item financial statementsnote legal proceeding contingency strategy company continue execute strategy longterm growth currently track strategic transition strategy consist increase investment growth brand new specialty product focus company research development program product pharmaceutical pipeline disease area address significant unmet medical need align sale marketing emphasis specialist high value primary care prescriber implement initiative design achieve maintain efficient cost base company pharmaceutical portfolio continue transition away product lose exclusivity growth driver recently launch product include plavix clopidogrel bisulfate abilify aripiprazole avaproavalide irbesartanirbesartan hydrochlorothiazide reyataz atazanavir sulfate sustiva efavirenz franchise erbitux cetuximab orencia abatacept baraclude entecavir sprycel dasatinib net sale product account company pharmaceutical net sale compare worldwide net sale product account company worldwide pharmaceutical net sale compare company experience series major anticipate exclusivity loss market exclusivity expiration pravachol certain market europe expect significant new exclusivity loss year order support production specialty product pharmaceutical portfolio include biologics board director approve capital expenditure approximately million bulk biologic manufacturing facility february company complete land purchase acre site locate new largescale expandable multiproduct bulk biologic manufacturing facility deven massachusetts construction expect begin early facility project operationally complete company expect submit site regulatory approval commercial production biologic compound anticipate begin addition company expand manati puerto rico facility target start expansion add new space renovate exist space fill finishing company sterile product biologic compound include orencia investigational compound give company current limited capacity commercial volume biologics product company receive approval fda permit party manufacture orencia additional facility facility party facility pende submission approval fda support increase production capacity necessary meet expect longterm demand orencia initial requirement biologic product commercialize keeping strategy company invest billion research development represent growth rate research development dedicated pharmaceutical product include milestone payment inlicense development program billion compare billion strategy company reexamine operating cost achieve maintain efficient cost base end company launch initiative identify realize productivity saving initiative company reexamine operating model focus resource high value priority simplify streamline business process improve governance decision make build capability sustain cost reduction long term company plan achieve goal realize minimum million productivity saving incremental million make company productive efficient effective new product pipeline development january company astrazeneca plc astrazeneca announce collaboration develop commercialize investigational compound saxagliptin dapagliflozin study treatment type diabetes company discover compound collaboration compound worldwide japan separately company announce collaboration otsuka pharmaceutical co ltd otsuka develop saxagliptin japan november fda grant fast track designation ipilimumab combination chemotherapy dacarbazine previously untreated metastatic melanoma patient fda grant fast track designation ipilimumab monotherapy previously treat metastatic melanoma patient october company move investigational antithrombosis compound apixaban phase iii development apixaban oral direct factor xa inhibitor october company receive fda approval new oncedaily mg single capsule formulation reyataz treatment human immunodeficiency virus hiv infection adult combination therapy replace reyataz mg capsule appropriate patient company onepill oncedaily hiv medicine option available drug class combination therapy company otsuka receive approval fda september european medicine evaluation agency emea october abilify injection readytouse singledose vial atypical antipsychotic control agitation adult schizophrenia bipolar mania august company sanofi receive approval fda emea additional indication plavix reduce rate death cause rate combine endpoint reinfarction stroke death patient acute stsegment elevation myocardial infarction july atripla firstever oncedaily single tablet threedrug regimen hiv intend standalone therapy combination antiretroviral receive approval fda product combine sustiva efavirenz manufacture company truvada emtricitabine tenofovir disoproxil fumarate manufacture gilead company gilead merck co inc submit marketing authorization approval atripla emea october addition company gilead submit atripla regulatory approval canada september june company receive approval sprycel dasatinib fda treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia philadelphia chromosomepositive acute lymphoblastic leukemia phall resistance intolerance prior therapy include gleevec imatinib mesylate sprycel launch july november company receive approval sprycel committee medicinal product human use emea product launch austria germany france finland sweden uk february company receive approval sprycel phall indication switzerland april company launch emsam selegiline transdermal system emsam transdermal patch delivery monoamine oxidase inhibitor treatment major depressive disorder adult emsam develop somerset pharmaceuticals inc joint venture mylan laboratories inc mylan watson pharmaceuticals inc watson company obtain exclusive distribution right commercialize emsam canada market emsam exist neuroscience sale force march fda approve erbitux copromote company imclone system incorporate imclone use treatment squamous cell carcinoma head neck erbitux previously indicate treatment metastatic colorectal cancer february company launch baraclude treatment hepatitis b china company launch baraclude new market quarter include germany france uk japan baraclude approve country worldwide february company launch orencia treatment sign symptom rheumatoid arthritis receive approval fda december june company receive approval orencia canada launch product august outlook company expect reduction net sale product lose exclusivity previous year range billion billion compare billion billion company expect generic clopidogrel bisulfate inventory market continue residual impact plavix net sale company expect plavix net sale earning growth assume absence renew additional generic competition company expect increase prescription demand plavix key brand newly launch product compare gross margin expect improve growth high margin product low margin erosion relate exclusivity loss improve manufacturing efficiency marketing sell administrative expense expect remain relatively unchanged efficiency saving largely offset inflationary cost increase company continue focus high value primary care specialist physician implement productivity initiative company expect continue increase investment develop additional new compound support introduction new product company subsidiary subject number significant pende lawsuit claim proceeding investigation include pende plavix litigation describe assurance increase scope matter future lawsuit claim proceeding material company addition increase trend foreign government scrutinize sale marketing activity pharmaceutical company assurance investigation investigation material possible time reasonably assess final outcome investigation litigation management continue believe previously disclose year aggregate impact current reserve pende plavix patent litigation litigation investigation legal matter affect company reasonably likely material company result operation cash flow material financial condition liquidity company expectation year describe reflect potential impact litigation company result operation previously disclose composition matter patent plavix expire subject litigation apotex trial underlie patent litigation end february court expect rule follow posttrial briefing apotex prevail trial patent litigation company expect face renew generic competition plavix promptly pende plavix patent litigation significant market product company territory partnership alliance sanofi plaintiff additional pende patent infringement lawsuit dr reddys teva cobalt relate patent dr reddys teva file anda fda exclusivity period statutory stay periods hatchwaxman act expire exception month stay applie teva expire february accordingly final approval fda provide company authorization distribute generic clopidogrel bisulfate product launch point time risk adverse damage award company prevail underlie patent litigation company continue believe plavix patent valid infringe sanofi vigorously pursue case possible time reasonably assess ultimate outcome patent litigation apotex plavix patent litigation timing renew generic competition plavix apotex additional generic competition plavix generic pharmaceutical company loss market exclusivity plavix andor development sustain generic competition material company sale plavix result operation cash flow material company financial condition liquidity plavix company large product net sale net sale plavix billion billion billion respectively previously disclose antitrust division department justice conduct criminal investigation propose settlement pende plavix patent litigation apotex company cooperate fully investigation possible time reasonably assess outcome investigation impact company possible time reasonably assess impact investigation company compliance dpa usao previously disclose usao initiate investigation conduct monitor dpa usao company negotiation propose settlement apotex include review corporate governance issue violation federal security law connection propose settlement apotex term previously disclose consent company enter securities exchange commission sec monitor complete investigation submit report investigation usao monitor report find violation consent federal security law connection propose settlement monitor conclude company violate certain paragraph dpa related governance matter violation cite monitor report relate thing communication failure include insufficient communication company ceo general counsel board member senior management failure comply certain internal company policy procedure monitor finding respect company knowingly materially breach dpa recommendation usao advise company believe matter cite monitor report fully remediate accordingly intend action dpa respect monitor report additional discussion legal matter include plavix patent litigation antitrust division investigation relate propose settlement apotex term dpa sec consent executive summaryplavix sec consent order defer prosecution agreement item financial statement note legal proceeding contingency result operation follow discussion company result continue operation exclude result relate oncology therapeutic network otn business previously present separate segment prior divestiture segregate continue operation reflect discontinued operation period present discontinued operation change dollar million vs vs net sale earning continue operation minority interest income taxis net sale provision income taxis effective tax rate earning continue operation net sale net sale net sale continue operation decrease billion compare net sale decrease billion compare international net sale decrease billion compare include favorable foreign exchange impact net sale continue operation decrease billion compare net sale decrease billion compare international net sale billion remain relatively constant compare include favorable foreign exchange impact composition change net sale follow analysis change total change volume price foreign exchange vs vs general company business seasonal information pharmaceutical prescriber demand reference table business segment pharmaceutical section set forth comparison change net sale estimate total prescription growth retail mail order customer certain company pharmaceutical product product company view current future growth driver sell company operate reportable segmentspharmaceutical nutritional health care company complete sale otn previously present separate segment result operation otn present company result discontinue operation accordance statement financial standard sfas accounting impairment disposal longlive asset accordingly otn result operation prior period reclassify discontinued operation conform current year presentation company net sale segment follow net sale change dollar million vs vs pharmaceutical net sale nutritional net sale health care net sale health care group total company recognize revenue net sale adjustment arrive net sale report consolidated statement earning adjustment refer grosstonet sale adjustment describe critical accounting policy follow table set forth reconciliation company gross sale net sale significant category grosstonet sale adjustment year end december dollar millions gross sale grosstonet sale adjustment prime vendor chargeback woman infant child wic rebate manage health care rebate contract discount medicaid rebate cash discount sale return adjustment total grosstonet sale adjustment net sale decrease grosstonet sale adjustment compare affect number factor include change customer mix portfolio shift case product require low rebate change contract status decrease prime vendor chargeback primarily result low plavix net sale volume erosion highly rebated paraplatin carboplatin taxol paclitaxel generic competition impact discontinue commercialization tequin gatifloxacin manage health care rebate contract discount decrease primarily result reversal reserve relate tricare retail pharmacy refund program exclusivity loss pravachol reduce medicaid rebate addition low plavix net sale shift patient enrollment medicaid medicare medicare result decrease medicaid rebate partially offset corresponding increase manage health care rebate decrease cash discount primarily exclusivity loss pravachol low plavix sale volume increase sale return primarily high return trend nonexclusive brand discontinue commercialization tequin decrease prime vendor chargeback manage health care rebate primarily low relative sale volume segment product mix decrease sale return primarily low return certain product include tequin pravachol sustiva decrease adjustment low sale discount government rebate international business follow table set forth activity end balance significant category grosstonet sale adjustment manage health care woman rebate infant prime vendor child contract medicaid cash dollar million chargeback wic rebate discount rebate discount sale return adjustment total balance january provision relate sale current period provision relate sale prior period return payment impact foreign currency translation balance december provision relate sale current period provision relate sale prior period return payment impact foreign currency translation balance december company record grosstonet sale adjustment relate sale prior period significant item include charge sale return million primarily relate high expect return trend certain nonexclusive product discontinued commercialization tequin credit contract discount million primarily reversal reserve relate tricare retail pharmacy refund program significant item include charge million medicaid rebate primarily result higher expect medicaid utilization product credit million adjustment primarily result lower expect rebate foreign government credit million sale return result low return certain product include tequin avaproavalide plavix significant revision estimate grosstonet sale adjustment pharmaceutical composition change pharmaceutical sale follow analysis change foreign total change volume price exchange vs vs worldwide pharmaceutical sale decrease million pharmaceuticals sale decrease million million primarily low sale plavix result atrisk launch generic clopidogrel bisulfate august loss exclusivity pravachol offset continue growth abilify erbitux reyataz sustiva franchise avaproavalide sale new product include orencia baraclude sprycel aggregate estimate wholesaler inventory level company key pharmaceutical product sell pharmaceutical business end approximately half week international pharmaceutical sale decrease million million primarily decline pravachol taxol paclitaxel sale result increase generic competition europe partially offset increase sale new product include reyataz abilify baraclude worldwide pharmaceutical sale decrease million pharmaceuticals sale decrease million compare million primarily continued impact exclusivity loss paraplatin glucophage franchise increase competition pravachol partially offset increase sale growth driver include plavix abilify erbitux reyataz aggregate estimate wholesaler inventory level company key pharmaceutical product sell pharmaceutical business end end approximately threetenth month approximately half week decline inventory level negatively impact sale performance certain product international pharmaceutical sale decrease include favorable foreign exchange impact million primarily increase generic competition pravachol taxol paclitaxel partially offset increase sale new product include reyataz abilify growth plavix key pharmaceutical product sale represent total pharmaceutical sale respectively follow change dollar million vs vs cardiovascular plavix pravachol avaproavalide coumadin monopril virology reyataz sustiva franchise total revenue zerit baraclude infectious disease cefzil oncology erbitux taxol paclitaxel sprycel affective psychiatric disorder abilify total revenue emsam immunoscience orencia pharmaceutical efferalgan excess sale plavix platelet aggregation inhibitor company alliance sanofi decrease million sale plavix decrease million primarily result launch generic clopidogrel bisulfate product august market exclusivity plavix expect expire major european market composition matter patent plavix subject litigation include litigation apotex note trial underlie patent litigation end february court rule follow posttrial briefing apotex prevail trial underlie patent litigation additional competition plavix thirdparty generic pharmaceutical company plavix face renew generic competition sale increase include favorable foreign exchange impact million million sale increase million million primarily increase demand additional information plavix litigation generic launch apotex executive summaryplavix item financial statementsnote legal proceeding contingency sale pravachol hmg coa reductase inhibitor decrease include unfavorable foreign exchange impact million market exclusivity expiration april result generic competition strength generic competition key european market estimate total prescription demand decrease approximately compare sale pravachol decrease million million primarily low demand result increase competition relate reduction wholesaler inventory level partially offset lower manage health care rebate market exclusivity european union eu end exception sweden expiration occur march italy expiration occur january france generic competition authorize company commence july previously disclose company authorize watson distribute pravastatin sodium tablet sale avaproavalide angiotensin ii receptor blocker treatment hypertension sanofi alliance increase include favorable foreign exchange impact million sale increase million compare primarily high average net selling price high volume estimate total prescription demand increase approximately compare international sale increase include favorable foreign exchange impact million compare sale increase include favorable foreign exchange impact million million sale increase million compare million international sale increase include favorable foreign exchange impact million million primarily increase sale canada france germany market exclusivity avaproavalide know eu aprovelkarvea expect expire include pediatric extension country eu avaproavalide currently market japan sale coumadin warfarin sodium oral anticoagulant predominantly patient atrial fibrillation deep venous thrombosispulmonary embolism increase million compare primarily high average net selling price partially offset low demand drive continued competition estimate total prescription demand decrease approximately compare sale decrease million million continued competition market exclusivity coumadin expire sale monopril second generation angiotensin convert enzyme inhibitor treatment hypertension sell exclusively non market decrease million sale million decrease include favorable foreign exchange impact million sale decline year product supply issue key european market market exclusivity protection monopril expire expire expect expire country eu monopril currently market japan sale reyataz protease inhibitor treatment hiv increase include favorable foreign exchange impact million primarily increase demand europe latin america estimate total prescription demand increase approximately compare sale increase million million primarily high demand high average net selling price international sale increase include favorable foreign exchange impact million compare sale million compare million primarily increase demand europe reyataz launch second quarter market exclusivity reyataz expected expire country eu japan total revenue sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv increase include favorable foreign exchange impact million high demand launch atripla quarter estimate total prescription demand sustiva franchise increase approximately compare july company gilead launch atripla oncedaily single tablet threedrug regimen hiv intend standalone therapy combination antiretroviral total revenue sustiva franchise include sale sustiva revenue bulk efavirenz include combination therapy atripla company record revenue bulk efavirenz component atripla sale atripla gilead joint venture thirdparty customer sustiva sale increase million million primarily increase demand high average selling price low sale return market exclusivity sustiva expect expire country eu company market sustiva japan additional information revenue recognition sustiva franchise item financial statementsnote alliance investment sale zerit stavudine antiretroviral agent treatment hiv decrease million primarily result low demand europe estimate total prescription demand decrease approximately compare zerit sale decrease include favorable foreign exchange impact million million primarily result decrease demand market exclusivity protection zerit expect expire country eu japan sales baraclude oral antiviral agent treatment chronic hepatitis b increase million compare million baraclude launch april china february uk germany july france japan september company composition matter patent expire germany france uk sale cefzil antibiotic treatment mild moderately severe bacterial infection decrease million primarily generic competition estimate total prescription demand decrease approximately compare cefzil sale decrease include favorable foreign exchange impact million million primarily low demand market exclusivity expire december expect expire eu sales erbitux sell company exclusively increase million million drive continue growth relate usage treatment colorectal cancer treatment head neck cancer approve fda march sale increase million million erbitux market company distribution copromotion agreement imclone use patent relate combination therapy cytotoxic treatment expire patent covering monotherapy currently generic version biological product approve law law change future absence new legislation fda take step allow generic version certain biologic competitor seek approval biological product file safety efficacy datum address challenge biologic manufacturing involve complex process costly traditional pharmaceutical operation company right market erbitux north america japan agreement imclone expire september company market erbitux country eu previously disclose imclone yeda research development company ltd yeda litigation ownership use patent combination therapy cytotoxic treatment relate erbitux september court grant yeda complete ownership patent imclone appeal court decision information pertain legal proceeding involve erbitux item financial statementsnote legal proceeding contingency note alliance investment sale taxol paclitaxel anticancer agent sell exclusively nonus market million compare million sale taxol paclitaxel decrease include unfavorable foreign exchange impact primarily increase generic competition europe generic entry japan quarter taxol paclitaxel sale decrease include unfavorable foreign exchange impact million million primarily result increase generic competition europe market exclusivity protection taxol paclitaxel expire country eu generic paclitaxel product receive regulatory approval japan generic product enter market sprycel oral inhibitor multiple tyrosine kinase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate launch july certain european market fourth quarter sale million market exclusivity sprycel expect expire total revenue abilify antipsychotic agent treatment schizophrenia acute bipolar mania bipolar disorder increase million sale increase million million primarily high demand high average net selling price estimate total prescription demand increase approximately compare total revenue abilify million compare million primarily demand growth continued growth europe achieve sale million total revenue abilify primarily consist alliance revenue represent company share net sale country copromote otsuka product sell otsuka affiliate distributor otsukas market exclusivity protection abilify expect expire include grant patent term extension otsuka receive formal notice generic pharmaceutical company state file anda fda dosage form aripiprazole company otsuka comarket abilify notice states anda contain piv certification direct patent patent cover aripiprazole expire october addition notice purport provide otsuka respective piv certification certification contain allegation enforceability patent andor validity andor infringement claim otsuka sole right enforce patent additional information item business business segment pharmaceutical segment company right copromote abilify european country uk france germany spain act exclusive distributor product rest eu composition matter patent force germany uk france italy netherlands romania sweden switzerland spain denmark original expiration date extend grant supplemental protection certificate country romania denmark datum exclusivity eu expire company contractual right market abilify expire november puerto rico country eu company exclusive right market abilify june additional information revenue recognition abilify item financial statementsnote alliance investment emsam transdermal patch delivery monoamine oxidase inhibitor treatment major depressive disorder adult launch april sale million quarter result lower expect sale emsam company record million impairment charge emsam relate asset emsam develop somerset joint venture mylan watson company obtain exclusive distribution right commercialize emsam canada market emsam exist neuroscience sale force new drug formulation emsam receive year hatchwaxman datum exclusivity expire orencia fusion protein indicate adult patient moderate severe rheumatoid arthritis inadequate response currently available treatment methotrexate antitumor necrosis factor therapy launch february sale million substantially company composition matter patent expire patent eligible patent term restoration possibly extend term note generic version biological product approve law law change future sale efferalgan paracetamol formulation acetaminophen pain relief sell principally europe decrease million primarily change government reimbursement sale increase include favorable foreign exchange impact million million primarily increase sale italy spain result strong flu season estimate prescription change datum provide include information retail mail order channel reflect information channel hospital institution longterm care estimate prescription prescription change datum base national prescription audit npa datum provide ims health im supplier market research pharmaceutical industry describe instance basic exclusivity loss date indicate expiration date patent claim active ingredient drug method drug approve indication instance basic exclusivity loss date indicate expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval prior expiration datum exclusivity period submit clinical trial datum obtain marketing approval company assess market exclusivity period product case bycase basis length market exclusivity company product difficult predict certainty complex interaction patent regulatory form exclusivity factor assurance particular product enjoy market exclusivity period time company currently anticipate estimate market exclusivitie report business planning purpose intend reflect company legal opinion strength weakness particular patent legal position estimate endus demand pharmaceutical follow table set forth company pharmaceutical product base annual net sale product company view current future growth driver sell pharmaceutical business year end december change report net sale period b estimate total prescription growth retail mail order channel calculate company base npa datum nextgeneration prescription service ngps version datum provide im month end december estimate therapeutic category share applicable product calculate company base npa datum ngps datum provide ims year end december month end december estimate trx change change total prescription therapeutic category share net sale npa datum b ngps datum c npa datum b ngps datum c abilify total revenue avaproavalide baraclude e cefzili coumadin erbitux f na na na na glucophage franchise kenalog g na na na na orencia h na na na na paraplatin f na na na na plavix pravachol reyatazi sprycel j sustiva franchise k total revenue tequin videxvidex ec zerit year end december month end december estimate trx change change total prescription therapeutic category share net sale npa datum b ngps datum c npa datum b ngps datum c abilify total revenue avaproavalide baraclude e cefzil coumadin erbitux f na na na na glucophage franchise kenalog g na na na na orencia h na na na na paraplatin f na na na na plavix pravachol reyatazi sprycelj sustiva tequin videxvidex ec zerit year end december month end december estimate trx change change total prescription therapeutic category share net sale npa datum b ngps datum c npa datum b ngps datum c abilify total revenue avaproavalide baraclude e cefzil coumadin erbitux f na na na na glucophage franchise kenalog g na na na na orencia h na na na na paraplatin f na na na na plavix pravachol reyataz sprycelj sustiva tequin videxvidex ec zerit reflect percentage change net sale dollar term include change average selling price wholesaler buy pattern b base simple average estimate number prescription retail mail order channel provide ims c base weightedaverage estimate number prescription unit tablet milliliter retail mail order channel base datum provide ims therapeutic category determine company product consider direct competition company product product list compete follow therapeutic category abilify antipsychotic avaproavalide angiotensin receptor blocker baraclude oral antiviral agent cefzil brand oral solid liquid antibiotic coumadin warfarin erbitux oncology glucophage franchise oral antidiabetic kenalog intraarticularintramuscular steroid orencia fusion protein paraplatin carboplatin plavix antiplatelet agent pravachol hmg coa reductase inhibitor reyataz protease inhibitor exclude norvir sprycel tkis leukemia sustiva franchise antiretroviralsthird agent exclude norvir trizivir tequin brand oral solid antibiotic videxvidex ec zerit nucleoside reverse transcriptase inhibitor e baraclude launch april f erbitux paraplatin specifically parenterally administer oncology product general prescriptionlevel datum physician write prescription product company believe therapeutic category share information provide party product reliable accordingly present g company prescription level datum kenalog product dispense retail pharmacy company believe therapeutic category share information provide party product reliable accordingly present h orencia launch february company prescription level datum product dispense retail pharmacy prior year estimate trx therapeutic category share percentage recalculate conform current year presentation follow cefzil recalculate percentage share base combined oral liquidsuspension market reyataz recalculate percentage share protease inhibitor exclude norvir sustiva franchise recalculate percentage share agent exclude norvir trizivir j sprycel launch july k begin quarter sustiva franchise total revenue include sale sustiva revenue bulk efavirenz include combination therapy atripla therapeutic category share information change total prescription growth sustiva franchise antiretroviral agent exclude norvir trizivir include brand sustiva atripla prescription unit excess company historically report estimate total prescription change estimate therapeutic category share base npa datum ims make available public subscription basis simple average estimate number prescription retail mail order channel quarter company begin disclose estimate total prescription change estimate therapeutic category share base npa ngps version datum ngps version datum collect ims new revise methodology release ims limited basis pilot program im announce ngps version datum available public subscription basis start january legacy npa ngps version discontinue company believe ngps datum provide im provide superior estimate prescription data company product retail mail order channel company calculate estimate total prescription change estimate therapeutic category share base ngps datum weightedaverage basis reflect fact mail order prescription include great volume product supply compare retail prescription company believe calculation estimate total prescription change estimate therapeutic category share base ngps datum weightedaverage approach respect retail mail order channel provide superior estimate total prescription demand company use methodology internal demand forecast estimate prescription change datum estimate therapeutic category share report annual report include information retail mail order channel reflect information channel hospital institution longterm care datum provide im product im recordkeeping process estimate base sampling procedure subject inherent limitation estimate base sampling addition ngps version datum pilot program replace im incorporate ngps version release january company continuously seeks improve quality estimate prescription change amount therapeutic category share percentage ultimate patientconsumer demand review methodology process calculation estimate review analysis party datum calculation company expect continue review refine methodology process calculation estimate continue review analyze party datum calculation international pharmaceutical nutritional health care follow table set forth company key pharmaceutical product growth driver sell company international pharmaceutical business include pharmaceutical product sell company major nonus country base net sale key product sell report segment list percentage change company estimate ultimate patientconsumer demand month december september compare period prior year company commence collect estimate ultimate patientconsumer demand report segment march period company believe yeartoyear comparison provide meaningful comparison change sale quarter quartertoprior quarter comparison previously provide change demand constant dollar basis december september vs december vs september international pharmaceutical abilify total revenue avaproavalide baraclude bufferin capoten dafalgan efferalgan maxipime monopril paraplatin perfalgan plavix pravachol reyataz sustiva franchise total revenue taxol paclitaxel videxvidex ec nutritional enfamilenfagrow nutramigen health care convatec ostomy wound therapeutic medical imaging cardiolite excess estimate inventory month hand distribution channel pharmaceutical follow table set forth company pharmaceutical product base annual net sale product company view current future growth driver sell company pharmaceutical business pharmaceutical net sale estimate number month hand applicable product wholesaler distribution channel quarter end december september company believe estimate number month hand quarter end december september precede year provide meaningful comparison estimate endus demand pharmaceutical disclose company practice provide recent quarter december december december month month month dollar million net sale hand net sale hand net sale hand abilify total revenue avaproavalide baraclude cefzil coumadin erbitux glucophage franchise kenalog orencia paraplatin plavix pravachol reyataz sprycel sustiva franchise total revenue tequin videxvidex ec zerit september september september month month month dollar million net sale hand net sale hand net sale hand abilify total revenue avaproavalide baraclude cefzil coumadin erbitux glucophage franchise kenalog orencia paraplatin plavix pravachol reyataz sprycel sustiva franchise total revenue tequin videxvidex ec zerit begin quarter sustiva franchise include sale sustiva revenue bulk efavirenz include combination therapy atripla estimate month hand product wholesale distribution channel include brand sustiva inventory baraclude launch april anticipation launch company wholesaler build inventory product meet expect demand september baraclude inventory wholesaler distribution channel exceed month hand estimate value baraclude inventory wholesaler distribution channel work month hand subsequent quarter december september estimate value cefzil inventory wholesaler distribution channel exceed month hand approximately million million respectively demand cefzil decrease significantly reduce wholesaler outmovement generic competition begin december december estimate value cefzil inventory exceed month hand approximately million company build high inventory product meet expect high demand typically experience winter month company continue monitor cefzil sale objective work wholesaler inventory level month hand december estimate value glucophage franchise product inventory glucophage xr glucophage ir glucovance metaglip wholesaler distribution channel exceed month hand approximately million product month hand estimate glucophage franchise product average month hand stockkeepe unit skus product group increase month hand glucophage franchise product end fourth quarter month hand result primarily purchase wholesaler certain sku give effect purchase increase month hand skus month hand increase month hand sku average skus glucophage franchise product aggregate estimate month hand exceed month march estimate value glucophage franchise product inventory wholesaler distribution channel work approximately month hand work remain month hand subsequent quarter december september estimate value kenalog inventory wholesaler distribution channel exceed month hand approximately million million respectively high level goodsintransit cause shipping delay subsequent quarter estimate value kenalog inventory wholesaler distribution channel work month hand october pediatric exclusivity period paraplatin expire result entry multiple generic competitor paraplatin lead significant decrease demand paraplatin turn lead month hand product wholesaler distribution channel exceed month hand december september september december september estimate value paraplatin inventory wholesaler distribution channel month hand approximately million december million september million september million december million september company long produce paraplatin market continue monitor paraplatin wholesaler inventory level deplete september estimate value plavix inventory wholesaler distribution channel exceed month hand approximately million atrisk launch generic clopidogrel bisulfate august demand plavix decrease precipitously follow atrisk launch generic clopidogrel bisulfate december plavix inventory wholesaler distribution channel work month hand sprycel launch july consistent customary practice time new product launch company wholesaler build inventory product meet expect demand december september estimate value sprycel inventory wholesaler distribution channel exceed month hand approximately million million respectively company continue monitor sprycel inventory sale objective work wholesaler inventory level month hand quarter company decision discontinue commercialization tequin commercial reason company stop ship product wholesalers june establish accrual estimate return tequin inventory july company notify wholesaler retail distribution channel allow return product regardless expiry date estimate value tequin inventory wholesaler distribution channel exceed month hand de minimis september december company aware significant amount tequin inventory remain wholesaler distribution channel company expect tequin inventory channel reduce nominal level quarter estimate value videxvidex ec didanosine inventory wholesaler distribution channel exceed month hand de minimis december approximately million september result generic competition commence fourth quarter demand videxvidex ec decrease significantly product erbitux orencia company determine month hand estimate divide estimate product wholesaler distribution channel estimate outmovement product wholesaler distribution channel period day calculate describe factor influence company estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum represent recordkeeping process reflect estimate company maintain inventory management agreement imas pharmaceuticals wholesaler account nearly total gross sale pharmaceutical product current term ima company large wholesaler customer provide company weekly information respect inventory level product hand outmovement product wholesaler account approximately total gross sale pharmaceutical product inventory information receive wholesaler exclude inventory hold intermediary sell retailer hospital exclude good transit wholesaler company use information provide wholesaler friday close quarter end calculate inventory hand wholesaler applicable quarter end increase company estimate good transit wholesaler applicable friday reflect weekly datum provide wholesaler company revenue recognition policy sale record substantially risk reward ownership transfer pharmaceutical business generally product ship case good transit wholesaler own applicable wholesaler accordingly reflect calculation inventory wholesaler distribution channel company estimate good transit information provide wholesaler respect open order applicable friday company record sale wholesaler respect open order company determine outmovement product wholesaler period day recent week outmovement product provide wholesaler extrapolate day basis company estimate inventory level hand outmovement pharmaceutical business wholesaler customer large wholesaler product base assumption amount bear relationship large wholesaler inventory level movement product percentage aggregate sale product wholesaler applicable quarter bear aggregate sale product company large wholesaler quarter finally company consider adjustment necessary extrapolate amount base factor historical sale individual product wholesaler thirdparty market research datum relate prescription trend patient demand addition company receive inventory information wholesaler selective basis certain key product company pharmaceutical business ima discuss arrangement substantially direct wholesaler customer require wholesaler maintain inventory level month demand response atrisk launch generic clopidogrel bisulfate august company offer certain mcos incremental rebate wholesaler list price plavix certain condition march small number mcos accept offer offer reject qualify terminate prior time issuance preliminary injunction august offer company provide temporary price reduction federal supply schedule plavix veterans administration limited period august september primarily result limited participation rebate offer company estimate impact program plavix net sale fourth quarter de minimis orencia launch february launch second quarter company distribute orencia exclusive distribution arrangement single distributor follow approval supplemental biologic license application sbla allow party manufacture orencia additional site exclusive distribution arrangement terminate july company expand distribution network orencia multiple distributor estimate month hand calculate dividing inventory orencia hold distributor end quarter outmovement product day period report distributor inventory hand outmovement report distributor product distributor recordkeeping process mckesson corporation mckesson company wholesaler provide warehousing packing shipping service erbitux mckesson hold erbitux inventory consignment company revenue recognition policy company recognize revenue inventory ship mckesson enduser mckesson hold inventory erbitux account divestiture otn company discontinue consignment arrangement mckesson mckesson long hold inventory account company sell erbitux intermediary wholesaler specialty oncology distributor ship erbitux directly end user product customer intermediary begin quarter company expand distribution model include company wholesaler hold erbitux inventory company recognize revenue shipment consistent revenue recognition policy estimate month hand calculate dividing inventory erbitux hold wholesaler account report wholesaler end quarter outmovement product report wholesaler day period inventory level report wholesaler product wholesaler recordkeeping process previously disclose company pharmaceutical business outside nutritional health care business unit world company significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly company rely variety method estimate direct customer product level inventory calculate month hand business unit estimate inventory month hand distribution channel follow table set forth company key product sell business list net sale applicable product quarter end december september december september estimate number month hand applicable product direct customer distribution channel business end quarter company believe estimate number month hand quarter end december september precede year provide meaningful comparison estimate endus demand international pharmaceutical nutritional health care disclose company practice provide recent quarter estimate month hand key product describe international pharmaceutical business base datum collect company significant business unit outside describe information nonkey product inventory hand direct customer approximately month impact de minimis nonpharmaceutical report segment estimate base datum collect significant business unit outside december september month month dollar million net sale hand net sale hand international pharmaceutical abilify total revenue avaproavalide baraclude bufferin capoten dafalgan efferalgan maxipime monopril paraplatin perfalgan plavix pravachol reyataz sustiva franchise total revenue taxol paclitaxel videxvidex ec nutritional enfamilenfagrow nutramigen health care convatec ostomy wound therapeutic medical imaging cardiolite begin quarter sustiva franchise include sale sustiva revenue bulk efavirenz include combination therapy atripla estimate month hand product distribution channel include brand sustiva inventory december september month month dollar million net sale hand net sale hand international pharmaceutical abilify total revenue avaproavalide baraclude bufferin capoten dafalgan efferalgan maxipime monopril paraplatin perfalgan plavix pravachol reyataz sustiva taxol paclitaxel videxvidex ec nutritional enfamilenfagrow nutramigen health care convatec ostomy wound therapeutic medical imaging cardiolite month hand information represent company estimate aggregate product level inventory hand direct customer divide expect demand applicable product expect demand estimate ultimate patientconsumer demand calculate base estimate endus consumption direct customer outmovement datum recent day period reasonable period factor affect company estimate include generic competition seasonality product direct customer purchase light price increase new product product presentation launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation company rely variety method calculate month hand business report segment available company rely information provide party determine estimate aggregate product level inventory hand direct customer expect demand business report segment list company limited information direct customer product level inventory endus consumption direct customer outmovement datum quality thirdparty information available vary widely circumstance case new product seasonal product historical endus consumption outmovement information available applicable case company use estimate prospective demand case direct customer product level inventory ultimate patientconsumer demand outmovement datum exist available company develop variety methodology calculate estimate datum include factor historical sale direct customer thirdparty market research datum relate prescription trend endus demand september company enter exclusive distributorship arrangement certain product eastern central european market september december september dafalgan analgesic product sell principally europe approximately month inventory hand respectively direct customer level inventory hand primarily private pharmacist purchase dafalgan approximately week seasonality product september efferalgan analgesic product sell principally europe approximately month inventory hand direct customer level inventory hand primarily private pharmacist purchase efferalgan approximately week seasonality product september reyataz antiviral product approximately month inventory hand direct customer increase level inventory hand primarily government purchasing pattern brazil december september videxvidex ec antiviral product approximately month inventory hand direct customer increase level inventory hand primarily government purchasing pattern brazil company contractually obligate provide videxvidex ec brazilian government placement order product government term contract company control inventory level relate order company expect inventory level videxvidex ec work december september nutramigen infant nutritional product sell principally approximately month inventory hand direct customer level inventory hand end quarter end december primarily holiday stocking retailer quarter end september primarily impact retailer hold high level inventory response hurricane katrina company continuously seeks improve quality estimate month hand inventory hold direct customer include thorough review methodology process calculation estimate thorough review analysis party datum calculation company expect continue review refine methodology process calculation estimate continue review analyze party data calculation company continue step expedite receipt processing datum nonus pharmaceutical business health care group combined revenues health care group increase million compare period despite unfavorable impact divestiture canadian consumer medicine consumer medicine business quarter combine revenues health care group increase million compare period nutritional composition change nutritional sale follow analysis change total change volume price foreign exchange vs vs key nutritional product line sale represent total nutritional sale respectively follow change dollar million vs vs infant formula enfamil toddlerchildren nutritional enfagrow worldwide nutritional sale increase include favorable foreign exchange impact million worldwide nutritional sale million increase include favorable foreign exchange impact despite unfavorable impact divestiture adult nutritional business million quarter company divest adult nutritional business international sale increase include favorable foreign exchange impact million primarily increase sale children nutritional product international sale increase include favorable foreign exchange impact despite unfavorable impact divestiture adult nutritional business million million primarily increase sale enfamil enfagrow sale increase million primarily increase sale enfamil sale increase despite unfavorable impact divestiture adult nutritional business million million primarily increase sale enfamil health care health care segment include convatec medical imaging business consumer medicine business quarter company sell consumer medicine business relate asset composition change health care segment sale follow analysis change total change volume price foreign exchange vs vs health care sale decrease million compare period include unfavorable impact divestiture consumer medicine business health care sale decrease million compare period include unfavorable impact divestiture consumer medicine business health care sale business key product year end december follow change dollar million vs vs convatec ostomy wound therapeutic medical imaging cardiolite consumer medicine worldwide convatec sale increase include favorable foreign exchange impact million ostomy sale increase million include favorable foreign exchange impact sale wound therapeutic product increase include favorable foreign exchange impact million million primarily continued growth aquacel franchise worldwide convatec sale increase include favorable foreign exchange impact million million primarily increase worldwide sale wound therapeutic product worldwide medical imaging sale increase million growth primarily increase technelite technetium tcm generator sale result competitor market absence quarter increase definity sale competitor continue absence market cardiolite sale decrease million million primarily decrease price medical imaging sale increase million million primarily increase demand cardiolite geographic area general company product available country world large market france japan canada spain italy mexico germany company sale geographic area follow change dollar million vs vs united states total europe middle east africa total western hemisphere total pacific total total sale decrease primarily result low sale plavix loss exclusivity pravachol april decrease sale partially offset growth remain pharmaceutical growth driver recently launch product sale decrease result low sale paraplatin glucophage franchise continue impact early exclusivity loss pravachol low demand result increase competition decrease sale offset increase sale growth driver include plavix abilify erbitux reyataz strong sale growth enfamil sale europe middle east africa decrease result sale decline pravachol taxol paclitaxel result increase generic competition decrease sale partially offset increase sale major european market reyataz avaproavalide sale decrease include favorable foreign exchange impact result sale decline taxol paclitaxel increase generic competition pravachol exclusivity loss select market include uk netherlands decrease sale partially offset increase sale major european market reyataz abilify launch europe second quarter sale western hemisphere country increase include favorable foreign exchange impact primarily increase sale avaproavalide canada key nutritional product partially offset decrease sale tequin pharmaceutical product sale increase include favorable foreign exchange impact primarily increase sale plavix canada mexico reyataz brazil canada avaproavalide canada sales pacific region remain consistent compare sale increase result increase sale taxol paclitaxel japan enfagrow enfamil china expense change vs vs dollar million cost product sell net sale marketing sell administrative net sale advertising product promotion net sale research development net sale acquire inprocess research development net sale provision restructure net net sale litigation charge net net sale gain sale business net sale equity net income affiliate net sale expense net net sale total expense net net sale excess cost product sell percentage sale increase compare company include million percentage sale certain cost cost product sell reported marketing sell administrative expense prior year result addition reclassification increase primarily unfavorable impact pharmaceutical net sale mix include low sale plavix impairment charge tequin emsam relate asset manufacture facility cost product sell percentage sale unfavorable impact gross margin result change pharmaceutical sale mix offset tequin impairment charge million net litigation charge record marketing sell administrative expense decrease million compare include decrease result mention reclassification addition reclassification decrease primarily low sale force expense result previously announce restructure primary care sale organization effective march low expense pravachol partially offset impact adoption stock option expense marketing sell administrative expense increase million million primarily high legal cost high pension expense reflect increase amortization unrecognize net loss change actuarial assumption partially offset low sale force expense result focus specialist high value primary care physicians marketing sell administrative expense percentage sale include decrease reclassification compare respectively advertising product promotion expenditure decrease million compare primarily drive divestiture consumer medicine business low spending mature brand partially offset increase investment new product include orencia sprycel advertising product promotion expenditure increase million compare million primarily increase investment directtoconsumer marketing campaign plavix abilify increase cost associate pre launch activity orencia launch baraclude partially offset low spending mature product company investment research development million increase investment research development million represent increase million increase reflect company strategy continue investment latestage compound develop pipeline disease area address significant unmet medical need research development cost include charge consist primarily upfront milestone payment million primarily exelixis pharmaceuticals inc solvay global solvay million primarily medarex pierre fabre medicament sa pierre fabre million primarily pierre fabre solvay percentage sale research development expense compare percentage sale impact low plavix sale acquire inprocess research development million relate purchase acordis ukbased company additional information acquisition item financial statementsnote acquisition divestiture restructure program implement realign streamline operation order increase productivity reduce operating expense rationalize company manufacture network research facility sale marketing organization action restructure program expect substantially complete action restructure program substantially complete december result action company expect future annual benefit earning continue operation minority interest income taxis approximately million million million program respectively additional information restructuring item financial statementsnote restructuring litigation charge net settlement income insurance recovery million million million million net charge consist increase reserve million settlement principle certain pricing sale investigation partially offset insurance recovery million unrelated matter million income settlement litigation matter million net charge consist increase reserve million liability primarily relate private litigation governmental investigation partially offset insurance recovery million million charge consist million relate private litigation governmental investigation relate wholesaler inventory issue accounting matter million related platinol litigation settlement million relate pharmaceutical pricing sale practice additional information litigation item financial statementsnote legal proceeding contingency gain sale business million million net tax relate sale inventory trademark patent intellectual property right relate dovonex gain sale business million million net tax relate sale consumer medicine business relate asset gain sale business million million net tax relate sale adult nutritional business additional information transaction item financial statementsnote acquisition divestiture equity net income affiliate million compare million million respectively equity net income affiliate principally relate company joint venture sanofi investment imclone million increase equity net income affiliate primarily increase net income joint venture sanofi income equity investment imclone compare loss million increase equity net income affiliate primarily reflect increase net income sanofi joint venture partially offset net loss investment imclone additional information equity net income affiliate item financial statementsnote alliance investment expense net million million million respectively expense net include net interest expense foreign exchange gain loss income thirdparty contract manufacture royalty income expense debt retirement cost gain loss disposal property plant equipment gain loss sale marketable security certain litigation matter million increase expense net primarily high debt retirement cost connection repurchase billion note compare repurchase billion note million nonrecurring income result termination muraglitazar collaborative agreement partially offset low net foreign exchange loss million decrease expense net primarily deferred income recognize termination collaborative agreement muraglitazar partially offset debt retirement cost connection repurchase billion note high net foreign exchange loss additional information item financial statementsnote expense net stockbase compensation expense recognize statement financial accounting standard sfas revise sharebased payment sfas r year end december million charge record cost product sell marketing sell administrative expense research development expense stockbase compensation expense recognize accounting principle board apb year end december million million respectively expense record marketing sell administrative expense year end december company record expenseincome item affect comparability result period present set forth follow table discussion item item financial statementsnote alliance investment note restructure item note acquisition divestiture note income taxis note intangible asset note shortterm borrowing longterm debt note legal proceeding contingency marketing litigation research selling provision settlement year end december cost restructure expense expense gain sale dollar million product sell development admin net income income net product asset total litigation matter pharmaceutical pricing sale litigation product liability claim damage commercial litigation insurance recovery debt retirement cost accelerate depreciation asset impairment contract termination upfront milestone payment streamline worldwide operation gain sale product asset income taxis item change estimate taxis prior year item reduction net earning continue operation litigation research provision gain settlement year end december cost sale expense expense dollar million product sell development restructure business income income net total litigation matter private litigation governmental investigation erisa liability matter pharmaceutical pricing sale litigation insurance recovery accelerate depreciation asset impairment debt retirement cost streamline worldwide operation upfront milestone payment loss sale fix asset gain sale equity investment termination muraglitazar agreement gain sale consumer medicine business income taxis item adjustment taxis repatriation foreign earning increase net earning continue operation acquire litigation expense cost research inprocess gain provision settlement year end december product research sale restructure expense income dollar million sell development development business net income net total litigation matter private litigation governmental investigation product liability antitrust litigation pharmaceutical pricing sale litigation commercial litigation product liability insurance recovery accelerate depreciation streamline worldwide operation acordis iprd writeoff upfront milestone payment gain sale adult nutritional business income taxis item defer taxis anticipation repatriation foreign earning tax adjustment reduction net earning continue operation earning minority interest income taxis earning continue operation minority interest income taxis change dollar million vs vs pharmaceutical nutritional health care health care group total segment corporateother total excess earning continue operation minority interest income taxis decrease million million decrease primarily drive net impact item affect comparability result discuss low net sale pharmaceutical product result low plavix net sale loss exclusivity pravachol increase spending research development partially offset increase equity net income affiliate low advertising promotion expense earning continue operation minority interest income taxis increase million million increase primarily result growth nutritional segment net impact item affect comparability result discuss partially offset low sale gross margin pharmaceutical product primarily exclusivity loss increase spending research development primarily latestage pharmaceutical compound pharmaceutical earning minority interest income tax million decrease primarily low net sale result low plavix sale loss exclusivity pravachol investment research development continue investment key growth driver new product earning minority interest income taxis million decrease million primarily low net sale gross margin primarily relate exclusivity loss high advertising product promotion investment growth driver increase spending research development health care group nutritional earning minority interest income tax million increase primarily sale growth children nutritional product partially offset increase investment advertising expense research development program earning minority interest income taxis million increase million primarily increase worldwide sale infant formula product international sale toddler children nutritional product partially offset increase investment advertising product promotion research development program health care earning minority interest income tax million increase primarily drive increase sale convatec medical imaging business earning minority interest income taxis million decrease million primarily sale consumer medicine business quarter high spending research development partially offset sale growth convatec medical imaging business corporateother loss minority interest income tax million increase primarily high debt retirement cost compare low gain sale product asset compare consumer medicine business million income result termination muraglitazar collaborative agreement low insurance recovery compare partially offset low litigation charge compare loss minority interest income taxis million decrease million primarily increase gain sale businessesproduct line defer income recognize termination collaborative agreement muraglitazar reduction litigation charge net income taxis effective income tax rate earning continue operation minority interest income taxis compare increase effective tax rate compare result elimination tax benefit section internal revenue code treatment provision portion certain litigation reserve nondeductible tax benefit associate settlement internal revenue service irs examination favorable adjustment taxis special dividend american job creation act ajca partially offset favorable tax legislation enact related tax treatment certain intercompany transaction company foreign subsidiary implementation tax planning strategy relate utilization certain charitable contribution decrease effective tax rate primarily charge approximately million taxis special dividend ajca charge relate establishment valuation allowance certain charitable contribution tax benefit discuss partially offset lower estimate foreign tax credit company record significant defer tax asset relate foreign tax credit carryforward approximately million research tax credit carryforward approximately million expire vary amount begin realization foreign tax credit research tax credit carryforward dependent generate sufficient domestic taxable income prior expiration realization assure management believe likely defer tax asset realize company anticipate increase level domestic profitability time undertaking action increase biologic manufacturing capacity implement tax planning strategy increase domestic profitability likely cause company effective tax rate increase enhance company ability utilize foreign tax credit research tax credit carryforward foreign tax credit research tax credit carryforward consider realizable reduce near term plavix subject renew additional generic competition event occur company need record significant valuation allowance federal defer tax asset discussion plavix relate matter item financial statementsnote legal proceeding contingency companys federal income tax return currently examination irs irs propose significant disallowance certain litigation settlement expense significant reduction foreign tax credit claim follow company previously disclose international restructuring irs position matter affect foreign tax credit claim company year currently examination company believe strong position respect issue intends contest irs position possible predict outcome issue company establish tax contingency reserve reflect good estimate probable tax liability matter company prevail final nonappealable determination matter loss excess establish reserve material adverse effect company result operation company believe determination material adverse effect cash flow minority interest minority interest net taxis decrease million million primarily low earning company partnership sanofi territory cover america result impact august atrisk launch generic clopidogrel bisulfate discontinued operation company complete sale otn equity partner llc cash proceed million include impact preliminary work capital adjustment company record pretax gain million million net tax present gain sale discontinue operation consolidated statement earning otn previously present separate segment discussion otn item financial statementsnote discontinue operation follow amount related otn business segregate continue operation reflect discontinue operation period present year end december dollar million net sale loss income taxis loss net taxis financial position liquidity capital resource cash cash equivalent marketable security approximately billion december compare billion december company continue maintain sufficient level work capital approximately billion december decrease billion december note recent development pende patent litigation involve plavix include generic launch apotex august currently subject preliminary injunction halt sale apotex trial underlie patent litigation end february court expect rule follow posttrial briefing apotex prevail trial company expect plavix face renew generic competition promptly subject risk company currently believe absence renew additional generic competition plavix generic pharmaceutical company future period cash generate operation exist cash borrowing capital market sufficient cover cash need work capital capital expenditure company expect include substantial investment facility increase maintain company capacity provide biologic commercial scale milestone payment dividend pay cash cash equivalent marketable security conversion workingcapital item borrowing expect fund nearterm operation circumstance renew additional generic competition plavix material company sale plavix result operation cash flow material company financial condition liquidity additional information pende plavix patent litigation recent adverse development include item financial statementsnote legal proceeding contingenciesintellectual property plavix litigation executive summaryplavix fourth quarter company disclose anticipate repatriate approximately billion special dividend record million provision defer income taxis pursuant ajca enact pende matter company repatriate approximately billion foreign subsidiary quarter repatriate remain balance approximately billion fourth quarter company expect continue use special dividend accordance requirement establish ajca treasury department second quarter treasury department issue ajca related guidance clarify grossup foreign taxis associate special dividend qualify tax rate establish ajca result guidance company reduce million provision recording benefit approximately million tax provision earning associate special dividend discuss income taxis provide balance unremitte earning nonus subsidiary company invest expect invest earning permanently offshore december company approximately billion undistributed earning foreign subsidiary taxis provide company invest expect invest undistributed earning permanently offshore future earning repatriate company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide cash cash equivalent december primarily consist dollar denominate bank deposit original maturity month marketable security december primarily consist dollar denominate float rate instrument aaaaaa credit rating nature instrument company consider reasonable expect fair market value significantly impact change interest rate liquidate cash short notice average interest yield invest cash cash equivalent december respectively interest yield marketable security average respectively september company sanofi post million million bond court collateral support preliminary injunction company pledge issuer bond collateral million bond consist shortterm high quality security collateral report marketable security company consolidate balance sheet december term pledge agreement company entitle receive income generate marketable security certain investment strategy decision restrict million pledge security purpose time bond cancel december company complete sale leaseback administrative facility new jersey million result pretax gain transaction million defer reduce future lease rental cost lease period range year shortterm borrowing end million million respectively company maintain cash balance shortterm investment excess shortterm borrowing longterm debt billion december compare billion december fourth quarter company restructure longterm debt retire outstanding billion principal note cash tender offer subsequent redemption issue million aggregate principal note million aggregate principal note billion aggregate principal note company incur aggregate pretax expense approximately million connection early redemption note termination relate interest rate swap include writeoff relate unamortized discount issuance cost defer loss interest rate lock longterm debt december include japanese yen debt billion yen december company replace prior billion revolve credit facility new billion year revolve credit facility syndicate lender extendable anniversary date consent lender facility contain customary term condition substantially similar prior facility include financial covenant ratio consolidated debt consolidated capital exceed end quarter company compliance covenant inception new facility borrowing outstanding revolve credit facility december august whollyowne subsidiary company enter new billion term loan facility syndicate lender borrowing facility guarantee company subsidiary borrower certain european subsidiary company facility contain fiveyear tranche billion twoyear tranche million fully draw december fourth quarter company repay entire million twoyear tranche million fiveyear tranche company subject substantially covenant include december revolve credit facility company subject restriction include certain financial covenant prior borrowing proceed facility company obtain waiver lender covenant default facility onetime intercompany distribution december company compliance covenant second quarter company repurchase outstanding billion aggregate principal note incur aggregate pretax loss approximately million connection early redemption note termination relate interest rate swap majority company debt fix rate company enter fixed float interest rate swap billion longterm debt include billion euro interest expense net interest swap gain million million million respectively increase interest expense primarily high interest rate moodys investor service moodys longterm shortterm credit rating company currently prime respectively follow downgrade longterm credit rating quarter moodys longterm credit rating amend negative outlook stable outlook quarter standard poor sp longterm shortterm credit rating company currently respectively sps longterm credit rating remain negative outlook fitch rating fitch longterm shortterm credit rating company currently f respectively fitch place company rating watch negative follow discussion work capital december dollar million work capital decrease work capital million december december impact decrease cash marketable security primarily repayment longtem debt low receivable primarily low plavix sale loss exclusivity pravachol offset high receivable alliance partner increase inventory support growth driver recently launch product offset reduction pravachol inventory result loss exclusivity reduction defer tax asset primarily litigation settlement payment low account payable low purchase pravachol raw material increase deferred income result high defer alliance revenue lower accrue rebate return primarily exclusivity loss pravachol volume erosion highly rebated paraplatin taxol paclitaxel lower plavix volume partially offset high sale return follow discussion cash flow activity year end december dollar million cash flow provide byused operating activity invest activity financing activity net cash provide operating activity billion billion million increase compare mainly attributable significant change adjustment net earning million net change operate asset liability million offset low net earning million significant positive change adjustment net earning compare million mainly include million positive cash flow variance defer income tax expensebenefit low level increase defer tax benefit compare increase defer tax benefit associate research development foreign tax credit increase litigation reserve increase defer tax benefit associate reversal tax liability relate repatriation special dividend ajca million positive cash flow variance low gain sale product asset compare sale business million positive cash flow variance deferred income recognize related termination muraglitazar collaborative agreement net positive change operate asset liability compare million mainly include million negative cash flow variance receivables increase cash flow drive increase receivable alliance partner partially offset low trade receivable volume increase cash flow drive collection foreign withholding taxis alliance partner million positive cash flow variance inventory primarily increase inventory result growth new product anticipation new product launch reduction inventory result pravachol exclusivity loss million negative cash flow variance litigation primarily settlement payment million dpa vanlev litigation partially offset unrelated insurance recovery million million positive cash flow variance income taxis payable primarily relate payment settlement examination irs year repatriation special dividend ajca net cash provide investing activity million compare net cash provide million million negative cash flow variance primarily attributable million negative cash flow variance mainly sale marketable security million negative cash flow variance low proceed sale product asset compare sale consumer medicine otn business million negative cash flow variance milestone payment primarily relate imclone million positive cash flow variance proceed disposal property connection sale lease transaction net cash financing activity million compare million million positive cash flow variance mainly attributable million positive cash flow variance repayment shortterm borrowing negative cash flow variance retirement longterm debt company repay debt million retire note million company retire note million net cash provide operating activity billion billion million decrease compare mainly attributable significant change adjustment net earning million net change operate asset liability million offset high net earning million significant negative change adjustment net earning compare million mainly include million negative cash flow variance primarily reversal million ajca defer tax provision record million negative cash flow variance low litigation settlement expense million negative cash flow variance high gain sale business compare net change operate asset liability compare million mainly include million positive cash flow variance receivables increase cash flow receivables drive low sale volume increase foreign withholding taxis receivable million positive cash flow variance primarily low litigation settlement payment insurance recovery million negative cash flow variance account payable accrue expense primarily vendor payment prior sale otn business low accrue rebate return compare million negative cash flow variance income taxis payable primarily relate payment settlement examination irs year repatriation special dividend ajca net cash provide investing activity million compare net cash million million positive cash flow variance primarily attributable million positive cash flow variance mainly sale marketable security compare purchase million positive cash flow variance high proceed sale consumer medicine otn business compare sale adult nutritional business million positive cash flow variance milestone payment imclone million positive cash flow variance purchase acordis specialty fibre net cash financing activity million compare million million negative cash flow variance mainly attributable million negative cash flow variance retirement commercial paper compare purchase million negative cash flow variance repurchase billion note million positive cash flow variance proceed borrowing new term loan facility cash provide operation borrowing primarily past year pay dividend approximately billion company invest approximately billion past year capital expansion improve plant efficiency maintain superior research facility past year company repurchase common stock total share acquire share repurchase program inception million share share repurchase program authorize company purchase common stock time time open market private transaction market condition permit program intend reduce increase share outstanding option exercise obtain share general corporate purpose dividend declare common share december company declare quarterly dividend common share indicate dividend year share dividend decision quarterly basis company board director companys financial condition liquidity affect obligation milestone onetime payment outcome pende litigation investigation include challenge plavix patent andor potential renew additional generic competition plavix information item financial statementsnote alliance investment note legal proceeding contingency contractual obligation payment period company contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt operating lease purchase obligation standby letter creditperformance guarantee pension liability total current portion longterm debt obligation include shortterm borrowing company consolidated balance sheet december balance approximate outstanding nominal longterm debt value contractual obligation table exclude interest payment obligation company convertible debenture include payment contain feature addition company commit potential future milestone payment thirdpartie inlicense development program payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record company consolidate balance sheet discussion contractual obligation item financial statementsnote shortterm borrowing longterm debt note financial instrument note lease note pension postretirement benefit plan sec consent order defer prosecution agreement previously disclose august company enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit company quarterly report form q period end september term consent company agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice company agree consent certain measure implement include establish formal review certification process annual quarterly report file sec b establish business risk disclosure group c retain outside consultant comprehensively study help reengineer company account financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand e ensure company budget process give appropriate weight input come come adequately document process company agree consent retain independent advisor date company year end file sec independent advisor continue serve monitor dpa discuss previously disclose june company enter dpa usao district new jersey resolve investigation usao company relate wholesaler inventory accounting matter cover company settlement sec pursuant dpa usao file criminal complaint company allege conspiracy commit security fraud defer prosecution company dismiss complaint year company satisfie requirement dpa copy dpa file exhibit form k file company june incorporate reference hereto exhibit w fiscal year end december dpa thing company agree include form q k file sec annual report shareholder follow information estimate wholesalerdirect customer inventory level product sell pharmaceutical business b major nonus country estimate aggregate wholesalerdirectcustomer inventory level pharmaceutical product sell country take measure aggregate annual sale country c arrangement policy concern wholesalerdirect customer distributor product include effort company control monitor wholesalerdistributor inventory level datum concern prescription measure endus demand product pursuant dpa company agree include filing report information acquisition divestiture restructuring reserve policy activity rebate accrual policy activity company agree implement remedial measure undertake mandate consent settlement derivative litigation federal security class action relate wholesaler inventory accounting matter addition company agree undertake additional remedial action corporate reform action include appoint additional nonexecutive director acceptable usao b establish maintain training education program topic include corporate citizenship financial reporting obligation c make additional million payment shareholder compensation fund establish connection consent engage attempt engage criminal conduct term define dpa e continue cooperate usao include respect ongoing investigation individual current employee company f retain monitor dpa board separate role chairman chief executive officer ceo company june elect nonexecutive chairman note dpa company agree engage attempt engage criminal conduct criminal conduct define dpa crime relate company business activity commit executive officer directors b security fraud accounting fraud financial fraud business fraud materially affect book record publicly file report company c obstruction justice usao discretion prosecute company federal crime usao knowledge include matter subject criminal complaint reference usao determine company commit criminal conduct monitor define power responsibility dpa include responsibility april oversee company compliance term dpa consent settlement derivative action federal security class action monitor authority require company step believe necessary comply term dpa company require adopt recommendation monitor company object recommendation usao agree adoption recommendation require addition monitor report usao quarterly basis company compliance dpa implementation effectiveness internal control financial reporting disclosure process relate compliance function company september board announce company current ceo general counsel leave respective position effective immediately announcement take place board receive consider report company outside counsel issue relate plavix patent litigation apotex preliminary recommendation monitor terminate employment individual monitor recommendation follow investigation initiate usao conduct monitor usao corporate governance issue relate company negotiation propose settlement apotex company advise monitor usao investigation involve matter subject ongoing investigation antitrust division department justice plavix settlement agreement time monitor preliminary recommendation monitor usao advise company find violation dpa unlawful conduct company employee investigation include review violation federal security law connection propose settlement apotex term sec consent monitor complete investigation submit report investigation usao monitor report find violation consent federal security law connection propose settlement monitor conclude company violate certain paragraph dpa related governance matter violation cite monitor report relate thing communication failure include insufficient communication company ceo general counsel board member senior management failure comply certain internal company policy procedure monitor finding respect company knowingly materially breach dpa recommendation usao advise company believe matter cite monitor report fully remediate accordingly intend action dpa respect monitor report additional information pende plavix patent litigation antitrust division investigation item financial statement note legal proceeding contingency company establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis company maintain imas pharmaceutical wholesaler account nearly total gross sale pharmaceutical product current term ima company large wholesaler customer provide company weekly information respect month hand product level inventory outmovement product wholesaler currently account total gross sale pharmaceutical product inventory information receive wholesaler company internal information estimate month hand product level inventory wholesaler company estimate month hand product inventory level pharmaceutical businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler company consider adjustment necessary extrapolate amount base factor historical sale individual product wholesaler thirdparty market research datum relate prescription trend patient demand contrast company pharmaceutical business outside nutritional health care business unit world company significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly company rely variety method estimate month hand product level inventory business unit company disclose pharmaceutical product base net sale pharmaceutical product company view current future growth driver sell pharmaceutical business net sale estimate number month hand wholesaler distribution channel end immediately precede quarter end applicable quarter correspond information prior year quarterly annual report form q k company disclose correspond information pharmaceutical product pharmaceutical product company view current future growth driver sell major nonus country describe business unit company disclose quarterly basis key product level inventory information require estimate month hand product level inventory direct customer distribution nonus pharmaceutical business available prior file quarterly report form q applicable quarter accordingly company disclose information website approximately day end applicable quarter furnish form k company form q follow quarter addition forego quarterly disclosure company include forego information business unit immediately precede quarter applicable quarter correspond information prior year annual report product describe inventory direct customer exceed approximately month hand company disclose estimate month hand product impact company de minimis company enhance continue seek enhance method estimate month hand product inventory level pharmaceutical business nonus pharmaceutical business world take account complexity describe company take continue step expedite receipt processing datum nonus pharmaceutical business company believe abovedescribe procedure provide reasonable basis ensure compliance consent dpa provide sufficient information comply disclosure requirement recently issue accounting standard company adopt sfas r sharedbase payment require measurement recognition compensation expense stock base payment award employee director base estimate fair value sfas r supersede company previous accounting apb accounting stock issue employee period begin january march sec issue staff accounting bulletin sab sharebase payment relate sfas r company apply provision sab adoption sfas r company adopt sfas r modify prospective transition method require application accounting standard january elect alternative method provide fasb staff position fsp r transition election relate accounting tax effect share base payment award determine company pool excess tax benefit company consolidate financial statement year end december reflect impact sfas r accordance modify prospective transition method company consolidate financial statement prior period restate reflect include impact sfas r stockbase compensation expense recognize sfas r year end december million million net tax share corresponding record additional paidin capital stockholder equity additionally million relate performance award reclassify liability stockholder equity connection adoption sfas r february financial accounting standard board fasb issue sfas fair value option financial asset financial liability permit entity measure certain financial asset financial liability fair value objective sfas improve financial reporting allow entity mitigate volatility report earning cause measurement relate asset liability different attribute apply complex hedge accounting provision sfas entity elect fair value option instrument report unrealize gain loss earning subsequent reporting date fair value option election irrevocable new election date occur sfas establishe presentation disclosure requirement help financial statement user understand effect entitys election earning eliminate disclosure requirement accounting standard asset liability measure fair value display face balance sheet statement effective fiscal year begin november company evaluate pronouncement september fasb issue sfas employer account define benefit pension postretirement plansan amendment fasb statement r pronouncement require employer recognize overfunde underfunded status define benefit postretirement plan multiemployer plan asset liability statement financial position recognize change fund status year change occur comprehensive income business entity pronouncement require employer measure fund status plan date yearend statement financial position limited exception pronouncement require prior period restate reflect impact sfas company adopt sfas fiscal year end december adoption accounting pronouncement result million reduction accumulate comprehensive income stockholder equity million reduction total asset million increase total liability adoption sfas impact company result operation cash flow september fasb issue sfas fair value measurement pronouncement define fair value establishe framework measure fair value expand disclosure fair value measurement statement effective fiscal year begin november adoption accounting pronouncement expect material effect company consolidate financial statement september sec issue staff accounting bulletin sab consider effect prior year misstatement quantify misstatement current year financial statement express staff view process quantify financial statement misstatement bulletin effective interim period fiscal year end november sab require company utilize dual approach assess quantitative effect financial statement misstatement dual approach include income statement focus balance sheet focus assessment adoption bulletin effect company consolidate financial statement july fasb issue fasb interpretation fin accounting uncertainty income taxesan interpretation fasb statement case company effective january fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas accounting income taxis fin require tax position evaluate recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return difference tax position take tax return amount recognize financial statement record adjustment income taxis payable receivable adjustment defer taxis fin require expand disclosure end annual reporting period include tabular reconciliation unrecognized tax benefit accordance fin company report difference net asset liability recognize statement financial position prior application fin cumulative effect adjustment opening balance retain earning adoption account pronouncement expect material effect company consolidate financial statement march fasb issue sfas accounting servicing financial assetsan amendment fasb statement pronouncement relate account separately recognize service asset servicing liability statement effective fiscal year begin september adoption accounting pronouncement expect material effect company consolidate financial statement february fasb issue sfas account certain hybrid financial instrument amendment fasb statement pronouncement primarily resolve certain issue address implementation sfas accounting derivative instrument hedge activity concern beneficial interest securitize financial asset statement effective financial instrument acquire issue subject remeasurement event occur begin fiscal year adoption accounting pronouncement expect material effect company consolidate financial statement fasb issue sfas accounting change error correction replace apb opinion accounting change sfas report accounting change interim financial statement pronouncement apply voluntary change account principle revise requirement accounting reporting change accounting principle sfas require retrospective application prior period financial statement voluntary change accounting principle impracticable pronouncement require change method depreciation amortization depletion longlive nonfinancial asset account change accounting estimate affect change accounting principle sfas effective accounting change correction error fiscal year begin december statement change transition provision exist accounting pronouncement include transition phase effective date sfas adoption account pronouncement material effect company consolidate financial statement march fasb issue fin accounting conditional asset retirement obligation fin clarifie entity record liability conditional asset retirement obligation fair value obligation reasonably estimate asset retirement obligation cover fin entity legal obligation perform asset retirement activity time method settling obligation conditional future event control entity fin clarifie entity sufficient information reasonably estimate fair value asset retirement obligation adoption account pronouncement material effect company consolidate financial statement december fasb issue fsp application sfas accounting income taxis tax deduction qualified production activity provide american job creation act fsp provide deduction qualified production activity treat special deduction describe sfas accounting income taxis accordingly tax effect deduction report component company tax provision effect defer tax asset liability irs issue final tax regulation ftr respect deduction qualified production activity section internal revenue code final regulation effective taxable year begin june adoption ftr fsp material impact company consolidate financial statement december fasb issue sfas exchange nonmonetary asset provision statement effective nonmonetary asset exchange occur fiscal period begin june provision statement apply prospectively eliminate exception fair value measurement nonmonetary exchange similar productive asset paragraph b apb accounting nonmonetary transaction replace exception exchange commercial substance adoption account pronouncement material effect company consolidate financial statement november fasb issue sfas inventory costsan amendment arb chapter pronouncement require abnormal amount idle facility relate expense recognize current period charge require allocation fix production overhead cost conversion base normal capacity production facility sfas effective inventory cost incur fiscal year begin june adoption accounting pronouncement material effect company consolidate financial statement critical accounting policy company prepare financial statement conformity accounting principle generally accept preparation financial statement conformity generally accept accounting principle gaap require use estimate assumption affect report amount asset liability include disclosure contingent asset contingent liability date financial statement report amount revenue expense report period company critical accounting policy important company financial condition result operation require difficult subjective complex judgment management application result need estimate effect matter inherently uncertain uncertainty factor surround estimate judgment preparation consolidated financial statement actual result vary estimate company believe follow discussion represent critical accounting policy management discuss company critical accounting policy audit committee board director revenue recognition company recognize revenue accordance sab revenue recognition financial statement amend sab revenue recognition company accounting policy revenue recognition substantial impact report result rely certain estimate require difficult subjective complex judgment management company recognize revenue substantially risk reward ownership transfer customer generally occur date shipment exception describe previous year certain transaction companys pharmaceutical wholesaler account consignment model case sale wholesaler result incentive excess wholesaler ordinary course business inventory level time understand agreement course deal consistent business practice company extend incentive base level excess inventory connection future purchase time incentive cover substantially vary directly wholesaler cost carry inventory excess wholesaler ordinary course business inventory level substantially risk reward ownership transfer shipment accordingly sale account consignment model determination sale wholesaler meet forego criterion involve evaluation variety factor number complex judgment consignment model company recognize revenue shipment product shipment product company invoice wholesaler record defer revenue gross invoice sale price classifie inventory hold wholesaler consignment inventory company cost inventory company recognize revenue net gross net sale adjustment discuss involve significant estimate judgment consignment inventory long subject incentive arrangement later inventory sell wholesaler customer firstin firstout basis fifo case new product product introduction extension exist line product company determine product similar therapeutic category company determine new product dissimilar characteristic exist product company reliably estimate expect return new product company defer recognition revenue right return long exist company develop sufficient historical experience estimate sale return discussion revenue recognition item financial statementsnote accounting policiesrevenue recognition sale rebate return accrual grosstonet sale adjustment company follow significant category grosstonet sale adjustment prime vendor chargeback wic rebate manage health care rebate contract discount medicaid rebate cash discount sale return adjustment involve significant estimate judgment require company use information external source company account grosstonet sale adjustment accordance emerge issue task force issue account consideration give vendor customer include reseller vendor product sfas revenue recognition right return exist applicable net sale section reconciliation company gross sale net sale significant category grosstonet sale adjustment prime vendor chargeback company business participate prime vendor program government entity significant department defense department veteran affair party pricing product extend wholesaler list price participate entity entity purchase product wholesaler low prime vendor price wholesaler charge difference acquisition cost low prime vendor price company company account prime vendor chargeback reduce account receivable equal company estimate chargeback claim attributable sale company determines estimate prime vendor chargeback primarily base historical experience prime vendor chargeback current contract price prime vendor program company consider prime vendor payment level inventory distribution channel company claim processing time lag adjust reduction account receivable periodically quarter reflect actual experience wic rebate company nutritional business participate competitive bidding basis nutrition program sponsor state tribal government commonwealth puerto rico territory wic program company reimburse entity difference wholesaler list price contract price eligible product company account wic rebate establish accrual equal company estimate wic rebate claim attributable sale company determines estimate wic rebate accrual primarily base historical experience wic rebate current contract price wic program company consider level inventory distribution channel new wic contract terminate wic contract change exist wic contract wic participation adjust accrual periodically quarter reflect actual experience manage health care rebate contract discount company offer rebate discount manage health care organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit addition commercial plan globally contract counterpartie hospital group purchasing organization company account manage health care rebate contract discount establish accrual equal company estimate manage health care rebate contract discount attributable sale company determine estimate manage health care rebate contract discount accrual primarily base historical experience rebate discount current contract price company consider sale performance product subject manage health care rebate contract discount level inventory distribution channel adjust accrual periodically quarter reflect actual experience medicaid rebate company business participate state governmentmanage medicaid program certain qualify federal state government program discount rebate provide participate state local government entity discount rebate provide program include company medicaid rebate accrual consider medicaid rebate purpose discussion company account medicaid rebate establish accrual equal company estimate medicaid rebate claim attributable sale company determines estimate medicaid rebate accrual primarily base historical experience medicaid rebate expansion prospective basis participation nonmandatory aspect qualify federal state government program legal interpretation applicable law relate medicaid qualify federal state government program new information change medicaid program regulation guideline impact rebate company consider outstanding medicaid claims medicaid payment level inventory distribution channel adjust accrual periodically quarter reflect actual experience cash discount certain country company offer cash discount approximate sale price incentive prompt payment company account cash discount reduce account receivable discount company consider payment performance adjust accrual reflect actual experience sale return company account sale return accordance sfas revenue recognition right return exist establish accrual equal company estimate sale record related product expect return provision sale return million million million respectively gross sale year return establish product company determine estimate sale return accrual primarily base historical experience sale return consider factor impact sale return factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product company consider factor adjust accrual periodically quarter reflect actual experience company consider level inventory distribution channel determine believe adjustment sale return accrual appropriate company adjust sale return accrual base historical experience company return good policy shelf life company product life cycle product level inventory distribution channel company consider introduction generic product factor impact sale return calculation base historical experience company return good policy event product recall product discontinuance company consider reason impact action adjust sale return accrual appropriate taking account historical experience estimate level inventory distribution channel product discontinuance estimate continue demand sale return accrual new product estimate primarily base historical sale return experience similar product line product similar therapeutic category limit circumstance new product extension exist line product company historical experience product similar therapeutic category company reliably estimate expect return new product company defer recognition revenue right return long exist company develop sufficient historical experience estimate sale return company consider shelf life new product determine believe adjustment sale return accrual appropriate shelf life connection new product tend short shelf life establish product company develop optimal manufacturing process new product lengthen shelf life addition high launch quantity manufacture advance launch date ensure sufficient supply exist satisfy market demand case company assess reduce shelf life estimate level inventory distribution channel project demand determine believe adjustment sale return accrual appropriate adjustment addition grosstonet sale adjustment describe company make grosstonet sale adjustment example company offer sale discount significantly nonus business offer consumer coupon rebate significantly nutritional pharmaceutical business addition number country outside include major european country company provide rebate government entity company generally account grosstonet adjustment establish accrual equal company estimate adjustment attributable sale company generally determine estimate accrual grosstonet sale adjustment primarily base historical experience performance commitment government entity relevant factor include estimate level inventory distribution channel adjust accrual periodically quarter reflect actual experience use information external source company use information external source estimate grosstonet sale adjustment company estimate inventory wholesaler defer revenue consign inventory base project prescription demandbase sale product historical inventory experience company analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum companys internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital company receive information im supplier market research pharmaceutical industry use project prescription demandbase sale pharmaceutical product company historically report estimate total prescription growth estimate therapeutic category share base npa datum im available public subscription basis simple average estimate number prescription retail mail order channel quarter company begin disclose estimate total prescription growth estimate therapeutic category share base npa ngps version datum ngps version datum collect ims new revise methodology release ims limited basis pilot program im announce ngps version datum available public subscription basis start january legacy npa ngps version discontinue company believe ngps datum provide im provide superior estimate prescription data company product retail mail order channel company calculate estimate total prescription growth estimate therapeutic category share base ngps datum weight average basis reflect fact mail order prescription include great volume product supply compare retail prescription company believe calculation estimate total prescription growth estimate therapeutic category share base ngps datum weight average approach respect retail mail order channel provide superior estimate total prescription demand company use methodology internal demand forecast company use information external source identify prescription trend patient demand average selling price company estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date company receive thirdparty information retirement benefit company pension plan postretirement benefit plan account actuarial valuation require sfas employer account pension sfas employer account postretirement benefit pension company consider accounting retirement plan critical management require significant subjective judgment number actuarial assumption include discount rate salary growth longterm return plan asset retirement turnover health care cost trend rate mortality rate depend assumption estimate pension postretirement benefit expense vary range outcome material effect report earning addition assumption materially affect project benefit obligation future cash funding company adopt sfas employer account define benefit pension postretirement plansan amendment fasb statement r fiscal year end december adoption accounting pronouncement result million reduction accumulate comprehensive income stockholder equity million reduction total asset million increase total liability adoption sfas impact company result operation cash flow plan description company certain subsidiary define benefit pension plan define contribution plan termination indemnity plan regular time employee principal define benefit pension plan bristolmyers squibb retirement income plan principal define contribution plan bristolmyer squibb saving investment program approximately total company define benefit pension plan asset liability hold plan asset plan hold single trust common asset allocation specify reference section total company plan ie plan international plan benefit company define benefit pension plan base primarily year credit service participant compensation asset company define benefit plan consist primarily equity fixedincome security december fair market value plan asset company define benefit plan increase million million december plan asset allocate equity security compare end fix income security compare end private equity investment compare end bristolmyer squibb common stock represent asset plan end company provide comprehensive medical group life benefit substantially retiree elect participate company comprehensive medical group life plan asset allocation postretirement plan identical asset allocation describe define benefit pension plan accrual account significant assumption consistent requirement sfas company account pension benefit accrual method recognize pension expense payment benefit retiree accrual method accounting pension benefit necessarily require actuarial assumption concern future event determine timing benefit payment company key assumption calculate cost pension benefit discount rate rate compensation increase expect longterm rate return plan asset company consultation actuary evaluate key actuarial assumption assumption calculate cost pension benefit retirement turnover mortality rate base expectation actual experience appropriate determine assumption december year calculate liability information date pension expense follow year depend assumption pension expense vary range outcome material effect report earning addition assumption materially affect project benefit obligation future cash fund actual result give year differ estimate economic factor determine discount rate company use yield high quality corporate bond coincide cash flow plan estimate payout citigroup median yield curve determine discount rate plan assume rate compensation increase company determine future pension obligation reflect estimate change actual future compensation level general price level productivity seniority factor net pension expense company define benefit pension plan include earning minority interest income taxis million compare million plan pension expense determine assumed discount rate assume rate compensation increase present value benefit obligation december plan determine assumed discount rate assume rate compensation increase assume discount rate determine plan pension expense reduce expense increase approximately million assumed rate compensation increase determine plan pension expense reduce expense decrease approximately million assumed discount rate determine accumulate benefit obligation december reduce accumulate benefit obligation increase million plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million actual rate return earn plan asset year follow year return year return december company increase assumed discount rate plan maintain assume rate compensation increase compensation assume increase scale different rate different age rate disclose december single rate age produce present value benefit obligation company maintain expect rate return plan asset company expect net pension expense define benefit pension plan include earning minority interest income taxis approximately million low million reflect primarily positive delay impact favorable investment return company assume discount rate expect longterm rate return plan asset calculate cost pension benefit cost postretirement benefit plan case discount rate december rate respectively pension benefit versus respectively postretirement benefit reflect short duration postretirement liability december respectively health care cost retiree population assume increase trend expect increase year actual cost higher assume likely significant upward pressure company expense retiree health care effect medicare prescription drug improvement modernization act reflect net periodic postretirement benefit cost reduction million accumulate postretirement benefit obligation january reduction million recognition actuarial gain loss sfas require recognition actuarial gain loss component stockholder equity accumulate comprehensive income sfas provide delayed recognition year prior amount arise change estimate plan benefit obligation change assume discount rate difference actual expect return plan asset assumption change net actuarial gain loss determine base marketrelated value plan asset differ fair market value calculate value recognize change fair value systematic rational manner year amortize pension income expense year extent unrecognize net actuarial loss gain exceed great project benefit obligation marketrelated value plan asset begin year net gain loss recognize pension income expense prospectively period approximate average remain service period active employee expect receive benefit plan approximately year extent offset loss gain subsequent year unrecognized net actuarial loss reflect large steady reduction weightedaverage discount rate year offset future unrecognized gain high discount rate higher expect return plan asset amortization unrecognized loss expect increase pension expense million progressively low amount follow year plan funding company fund policy define benefit plan contribute amount provide current service fund past service liability company contribute million million define benefit plan respectively discussion retirement benefit item financial statementsnote pension postretirement benefit plan acquire inprocess research development fair value inprocess research development acquire business combination determine independent appraisal base present value research project project cash flow income approach utilize consistent guidance practice aid issue american institute certify public accountant asset acquire business combination research development activity focus software electronic device pharmaceutical industry future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximating company weight average cost capital acquire inprocess research development expense incurred underlying product receive regulatory approval future alternative use addition cost nonrefundable relate acquisition licensing product receive regulatory approval market alternative future use charge earning incur discussion acquire inprocess research development item financial statementsnote accounting policiesacquire inprocess research development impairment longlive asset accordance sfas accounting impairment disposal longlive asset company periodically evaluate current fact circumstance indicate carry value depreciable asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow company report asset dispose low carrying value estimate net realizable value accordance sfas goodwill intangible asset goodwill tested annually impairment twostep process step identify potential impairment second step measure impairment loss goodwill deem impaired carrying reporting unit goodwill exceed estimate fair value sfas require indefinitelive intangible asset test impairment onestep process consist comparison fair value carry value intangible asset intangible asset deem impaired net book value exceed estimate fair value intangible asset evaluate impairment accordance sfas describe estimate future cash flow base reasonable supportable assumption projection require management judgment change key assumption company business prospect change market condition result impairment charge discussion impairment longlive asset item financial statementsnote accounting policiesimpairment longlive asset goodwill intangible asset equity investment company review equity investment impairment base determination decline market value investment company carry value temporary making determination company consider apb opinion equity method accounting investment common stock relate interpretation set forth factor evaluate determine loss value recognize include company ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity justify carry investment company investment imclone subject accounting discussion company investment imclone item financial statementsnote alliance investment discussion equity investment item financial statementsnote accounting policiesinvestment note alliance investment restructure streamline operation rationalize manufacture facility company periodically record restructuring charge result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place actual result vary estimate adjustment million million million record respectively reflect change estimate restructure action take prior period discussion restructure item financial statementsnote accounting policiesrestructuring note restructure item contingency normal course business company subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability tax matter accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate discussion contingency item financial statementsnote accounting policiesincome taxis contingency note income taxis note legal proceeding contingency income taxis provision income taxis determine asset liability approach accounting income taxis approach defer taxis represent future tax consequence expect occur report amount asset liability recover pay provision income taxis represent income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis company asset liability adjust change tax rate tax law change enact valuation allowance record reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment december company net defer tax asset million million respectively net valuation allowance million million respectively increase net defer tax asset primarily result adoption sfas item financial statementsnote income taxis note pension postretirement benefit plan company record significant defer tax asset relate foreign tax credit carryforward approximately million research tax credit carryforward approximately million expire vary amount begin realization foreign tax credit research tax credit carryforward dependent generate sufficient domestic taxable income prior expiration realization assure management believe likely defer tax asset realize company anticipate increase level domestic profitability time undertaking action increase biologic manufacturing capacity implement tax planning strategy increase domestic profitability likely cause company effective tax rate increase enhance company ability utilize foreign tax credit research tax credit carryforward foreign tax credit research tax credit carryforward consider realizable reduce near term plavix subject renew additional generic competition event occur company need record significant valuation allowance federal defer tax asset discussion plavix relate matter item financial statementsnote legal proceeding contingency company conduct business country world subject tax numerous jurisdiction result business activity company file significant number tax return subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report company require year resolve company establish liability possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know december company approximately billion undistributed earning foreign subsidiary taxis provide company invest expect invest undistributed earning permanently offshore future earning repatriate company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide discussion income taxis item financial statementsnote accounting policiesincome taxis note income taxis stockbase compensation expense company adopt sfas r sharebase payment require measurement recognition compensation expense stockbase payment award employee director base estimate fair value company use modify prospective transition method require application accounting standard january elect alternative method provide fsp r determine company pool excess tax benefit company consolidate financial statement year end december reflect impact sfas r accordance modify prospective transition method company consolidate financial statement prior period restate reflect include impact sfas r stockbase compensation expense recognize sfas r year end december million million net tax share corresponding record additional paidin capital stockholder equity comparatively pro forma basis stockbase compensation expense million million million million net tax respectively recognize year end december respectively apb additionally million relate performance award reclassify liability stockholder equity connection adoption sfas r company estimate fair value stockbase payment award date grant optionprice model value portion award ultimately expect vest recognize expense requisite service period companys consolidate statement earning prior adoption sfas r company account stockbased award employee director intrinsic value method relate stock option accordance apb allow sfas accounting stockbase compensation intrinsic value method stockbase compensation expense recognize company consolidate statement earning exercise price company stock option grant employee director equal fair market value underlie stock date grant stockbase compensation expense recognize period base value portion stockbase payment award ultimately expect vest period stockbase compensation expense recognize company consolidate statement earning year end december include compensation expense stockbase payment award grant prior vested january base grant date fair value estimate accordance pro forma provision sfas r compensation expense stockbase payment award grant subsequent january base grant date fair value estimate accordance provision sfas r conjunction adoption sfas r company change method attribute value stockbase compensation expense accelerate multipleoption approach straightline single option method compensation expense stockbase payment award grant prior continue recognize accelerated multipleoption approach compensation expense stockbase payment award service condition grant subsequent january recognize straightline singleoption method stockbase payment award grant subsequent january service market condition recognize accelerated multipleoption approach require sfas r prior company apply apb opinion recognize compensation expense stock option grant plan exercise price option date grant equal fair market value date grant restrict stock company recognize compensation expense straightline basis period restriction expire fair value option grant estimate common share common share common share respectively date grant blackschole optionprice model follow assumption expect volatility riskfree interest rate dividend yield expect life yrs yrs yrs company determine fair value certain stockbase payment award date grant optionprice model model affect company stock price assumption number highly complex subjective variable variable include limited company expect stock price volatility term award actual project employee stock option exercise behavior respect accounting treatment retirement eligibility provision employee stockbase compensation award company historically follow nominal vest period approach adoption sfas r company follow nonsubstantive vest period approach recognize compensation cost oneyear period award grant retirement eligible employee period grant date date retirement eligibility achieve year vest period impact apply nonsubstantive vest period approach material company consolidate financial statement stockbase compensation expense recognize consolidated statement earning year end december base award ultimately expect vest reduce estimate forfeiture company estimate forfeiture time grant revise necessary subsequent period actual forfeiture differ estimate company pro forma information require sfas period prior company account forfeiture occur special note forwardlooke statement annual report write oral statement company make time time contain certain forwardlooking statement meaning section security act section e securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing company goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year company include important factor cautionary statement include annual report company believe cause actual result differ materially forwardlooke statement company believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date company undertake obligation release publicly revision forwardlooke statement result new information future event item quantitative qualitative disclosure market risk company expose market risk change currency exchange rate interest rate reduce risk company enter certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument manage consolidated basis efficiently net exposure advantage natural offset derivative financial instrument speculative purpose gain loss hedge transaction offset gain loss underlying exposure hedge ineffective portion hedge report earning occur company primary net foreign currency translation exposure euro japanese yen mexican peso chinese renminbi canadian dollar company utilize foreign currency contract hedge anticipate transaction primarily intercompany transaction certain foreign currency designate derivative instrument foreign currency cash flow hedge appropriate table summarize company outstanding foreign exchange forward contract december fair value foreign exchange forward contract base yearend currency rate fair value foreign exchange forward contract view relation fair value underlie hedged transaction overall reduction exposure adverse fluctuation foreign currency exchange rate weight average fair value dollar million currency rate strike price notional assetliability maturity foreign exchange forward australian dollar british pound canadian dollar euro japanese yen mexican peso swedish krona swiss franc total contract december company hold foreign exchange forward contract maturity date december company hold foreign exchange option contract notional amount fair value foreign exchange forward contract maturity date express table dollar million year maturity notional fair value december fair value company foreign exchange forward contract net liability million million record noncurrent asset million record current liability company estimate appreciation depreciation underlie currency hedge level dollar december variable hold constant decrease increase respectively million fair value foreign exchange forward contract hold december company obligate settle foreign exchange forward contract base specify contract rate december balance defer net aftertax loss foreign exchange forward contract include accumulate comprehensive income million net aftertax loss million estimate reclassify earning month december company hold foreign exchange forward contract aggregate notional million fair value foreign exchange forward contract net asset million million record noncurrent asset million record current liability contract primarily relate exposure euro canadian dollar australian dollar company estimate appreciation depreciation underlie currency hedge level dollar december variable hold constant decrease increase respectively million fair value foreign exchange forward contract hold december year end december impact hedge ineffectiveness earning significant additionally year end december impact discontinue hedge loss million gain million gain million respectively furthermore company use foreign exchange forward contract offset exposure certain currency asset liability foreign exchange forward contract designate hedge change fair value derivative recognize earning occur amount recognize earning relate foreign exchange forward contract qualify hedge accounting treatment significant company use foreign exchange forward contract hedge foreign currency denominate monetary asset liability primary objective foreign exchange forward contract protect dollar value foreign currency denominate monetary asset liability effect volatility foreign exchange rate occur prior receipt settlement dollar foreign currency denominate monetary asset liability primarily denominate euro foreign exchange forward contract designate hedge mark market incomeexpense notional fair value amount purchase foreign exchange forward contract million million asset respectively december million million liability respectively december notional fair value amount sell foreign exchange forward contract million million liability respectively december million million asset respectively december addition foreign exchange forward contract note company use non dollar borrowing less extent foreign exchange forward contract hedge foreign currency exposure company net investment certain foreign affiliate non dollar borrowing foreign exchange forward contract designate hedge net investment effective portion foreign exchange gain loss hedge record foreign currency translation component comprehensive income december million tax loss million tax gain respectively record foreign currency translation component accumulate comprehensive income company use derivative instrument interest rate risk management strategy derivative instrument comprise principally fix float rate interest rate swap subject fairvalue hedge accounting treatment november connection funding retirement fix rate debt company execute fix float interest rate swap convert billion billion euro billion company newly issue fix rate debt pay variable rate debt company execute fix float interest rate swap convert million company fix rate debt pay variable rate debt total notional outstanding interest rate swap billion billion euro billion december billion december respectively accordance sfas accounting derivative instrument hedging activity company recognize net increase interest expense million net reduction interest expense million million respectively impact interest rate swap sfas require revaluation fair value swap contract underlie debt hedge swap contract underlie debt revalue result increase noncurrent asset million current liability million reduction longterm debt million december increase noncurrent asset million current liability million reduction longterm debt million december swap contract generally hold maturity intend create appropriate balance fix float rate debt company swap contract qualify fair value hedge terminate prior maturity date report carry value underlie debt amortize earning remain life debt swap contract qualify cash flow hedge terminate report accumulate comprehensive income amortize earning remain life debt follow table summarize interest rate swap outstanding december terminate interest rate swap notional underlie variable rate year fair interest rate contract debt receive transaction maturity value dollar million swap associate note month libor note month libor million eur note month eur euribor million eur note month eur euribor note month libor note month libor terminate swap contract total pretax pretax pretax year notional defer incomeexpense incomeexpense interest rate contract termination underlie debt gainloss recognize recognize dollar million interest rate swap lock associate note interest rate swap lock associate note swap associate note swap associate note swap associate note swap associate note underlying note extinguish respectively december company hold interest rate swap contract notional value billion billion euro billion fair value net liability million estimate increase decrease basis point shortterm longterm interest rate material impact company consolidate financial position result operation cash flow company million million longterm debt outstanding december respectively additional information item financial statementsnote shortterm borrowing longterm debt note financial instrument company maintain cash cash equivalent marketable security financial institution order limit exposure financial institution financial institution headquarter primarily north america europe bristolmyers squibb company consolidate statement earning dollar share million share datum item financial statement supplementary datum year end december earning net sale cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure net litigation charge net gain sale product asset business equity net income affiliate expense net total expense earning continue operation minority interest income taxis provision income taxis minority interest net taxis earning continue operation discontinue operation earningsloss net taxis gain disposal net taxis net earning earning common share basic earning continue operation discontinue operation loss net taxis gain disposal net taxis net earning common share dilute earning continue operation discontinue operation loss net taxis gain disposal net taxis net earning common share average common share outstanding basic dilute dividend declare common share accompany note integral financial statement bristolmyers squibb company consolidate statement comprehensive income retain earning dollar millions year end december comprehensive income net earning comprehensive incomeloss foreign currency translation tax effect net tax liability tax benefit defer gainslosse derivative qualify hedge net tax benefit net tax liability minimum pension liability adjustment net tax liability net tax benefit available sale security net tax liability net tax benefit tax effect total comprehensive incomeloss comprehensive income retain earning retain earning january net earning cash dividend declare retain earning december accompany note integral financial statement bristolmyers squibb company consolidated balance sheet dollar million share datum december asset current asset cash cash equivalent marketable security receivables net allowance inventory net deferred income taxis net valuation allowance prepaid expense total current asset property plant equipment net goodwill intangible asset net deferred income taxis net valuation allowance prepay pension asset total asset liability current liability shortterm borrowing account payable accrue expense accrue rebate return defer income foreign income taxis payable dividend payable accrue litigation liability total current liability pension postretirement liability defer income liability longterm debt total liability commitment contingency note stockholder equity prefer stock convertible series authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million total stockholder equity total liability stockholder equity accompany note integral financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity depreciation amortization defer income tax benefitsexpense litigation settlement expense net recovery stockbase compensation expense provision restructure gain sale product asset business defer income recognize acquire inprocess research development impairment charge asset writeoff loss disposal property plant equipment investment company defer expense extinguishment longterm debt underover distribution earning affiliate unfunded pension expense change operate asset liability receivables inventory prepaid expense asset litigation settlement payment net insurance recovery account payable accrue expense defer income product liability foreign income taxis payable liability net cash provide operating activity cash flow invest activity purchase proceed marketable security net addition property plant equipment capitalize software proceed disposal property plant equipment investment company proceed sale product asset business proceed sale leaseback property upfront milestone payment purchase acordis speciality fibre purchase trademark patent license business investment company divestiture acquisition cost net cash provide byused investing activity cash flow financing activity shortterm borrowingsrepayment longterm debt borrowing longterm debt repayment charge extinguishment longterm debt issuance common stock stock plan excess tax benefit sharebase payment arrangement dividend pay net cash financing activity effect exchange rate cash cash equivalent decreaseincrease cash cash equivalent cash cash equivalent begin period cash cash equivalent end period accompany note integral financial statement note accounting policy basis consolidation consolidated financial statement include account bristolmyer squibb company bms company bristolmyers squibb control majorityowned subsidiary intercompany balance transaction eliminate certain prior year amount reclassify conform current year presentation use estimate preparation financial statement conformity united states generally accept accounting principle gaap require use estimate assumption affect report amount asset liability disclosure contingent asset contingent liability date financial statement report amount revenue expense report period significant assumption employ estimate determine value intangible asset restructuring charge accrual sale rebate return accrual legal contingency tax asset tax liability estimate apply revenue recognition policy accounting stockbase compensation cost retirement postretirement benefit include actuarial assumption actual result differ estimate result revenue recognition company recognize revenue accordance staff accounting bulletin sab revenue recognition financial statement amend sab revenue recognition substantially risk reward ownership transfer customer generally revenue recognize time shipment case certain sale nutritional health care segment certain nonus business pharmaceutical segment revenue recognize date receipt purchaser revenues reduce time recognition reflect expect return estimate base historical experience business trend additionally provision time revenue recognition discount rebate estimate sale allowance base historical experience update change fact circumstance appropriate provision record reduction revenue case sale wholesaler result incentive excess wholesaler ordinary course business inventory level time understand agreement course deal consistent business practice company extend incentive base level excess inventory connection future purchase time incentive cover substantially vary directly wholesaler cost carry inventory excess wholesaler ordinary course business inventory level substantially risk reward ownership transfer shipment accordingly sale account consignment model determination sale wholesaler meet forego criterion involve evaluation variety factor number complex judgment consignment model company recognize revenue shipment product shipment product company invoice wholesaler record defer revenue gross invoice sale price classifie inventory hold wholesaler consignment inventory company cost inventory company recognize revenue consignment inventory long subject incentive arrangement later inventory sell wholesaler customer firstin firstout basis fifo case new product product introduction extension exist line product company determine product similar therapeutic category company determine new product dissimilar characteristic exist product company reliably estimate expect return new product company defer recognition revenue right return long exist company develop sufficient historical experience estimate sale return sale rebate return accrual medicaid rebate accrual million million december respectively woman infant child wic rebate accrual million million december respectively sale return accrual million million december respectively manage health care rebate contractual discount accrual million million december respectively rebate accrual establish period relate revenue recognize result reduction sale establishment liability include accrue liability accrual record base estimate proportion record revenue result rebate return prime vendor chargeback accrual establish similar manner record reduction account receivable million million december respectively note accounting policy continue income taxis provision income taxis determine asset liability approach accounting income taxis approach defer taxis represent future tax consequence expect occur report amount asset liability recover pay provision income taxis represent income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis company asset liability adjust change tax rate tax law change enact valuation allowance record reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment december company net defer tax asset million million respectively net valuation allowance million million respectively company record significant defer tax asset relate foreign tax credit carryforward approximately million research tax credit carryforward approximately million expire vary amount begin realization foreign tax credit research tax credit carryforward dependent generate sufficient domestic taxable income prior expiration realization assure management believe likely defer tax asset realize company anticipate increase level domestic profitability time undertaking action increase biologic manufacturing capacity implement tax planning strategy increase domestic profitability likely cause company effective tax rate increase enhance company ability utilize foreign tax credit research tax credit carryforward foreign tax credit research tax credit carryforward consider realizable reduce near term plavix subject renew additional generic competition event occur company need record significant valuation allowance federal defer tax asset discussion plavix relate matter note legal proceeding contingency december company approximately billion undistributed earning foreign subsidiary taxis provide company invest expect invest undistributed earning permanently offshore future earning repatriate company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide company conduct business country world subject tax numerous jurisdiction result business activity company file significant number tax return subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report company require year resolve company establish liability possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know cash cash equivalent cash equivalent primarily highly liquid investment original maturity month time purchase record cost approximate fair value marketable security company account marketable security accordance statement financial accounting standard sfas account certain investment debt equity security company determine appropriate classification marketable security availableforsale time purchase december company investment marketable security report fair value unrealize gain loss report component accumulate comprehensive income loss stockholder equity company follow investment manager method determine cost basis computing realize gain loss sale availableforsale security average cost method realize gain loss include income expense note accounting policy continue inventory valuation inventory generally state average cost excess market capital asset depreciation expenditure addition renewal improvement capitalize cost depreciation generally compute straightline method base estimate useful life relate asset estimate useful life major class depreciable asset year building year machinery equipment fixture company periodically evaluate current event circumstance indicate carry value depreciable asset recoverable impairment longlive asset company periodically evaluate current fact circumstance indicate carry value depreciable asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow company report asset dispose low carrying value estimate net realizable value capitalize software certain cost obtain internal use software significant system project capitalize amortize estimate useful life software range year cost obtain software project significant expense incur capitalize software net accumulate amortization include intangible asset million million december respectively amortization expense million million million year end december respectively investment company account own company ability exercise significant influence equity method accounting cost method company share net income loss equity investment include equity net income affiliate consolidate statement earning loss recognize income expense decline market value deem temporary company review equity investment impairment base determination decline market value investment company carry value temporary making determination company consider accounting principle board apb opinion equity method accounting investment common stock relate interpretation set forth factor evaluate determine loss value recognize include company ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity justify carry investment goodwill intangible asset goodwill test impairment annually twostep process step identify potential impairment second step measure impairment loss goodwill deem impaired carrying reporting unit goodwill exceed estimate fair value company complete goodwill impairment assessment indicate impairment goodwill intangible asset consist patent trademark technology license capitalize software amortize straightline basis useful life range year indefinitelive intangible asset test impairment onestep process consist comparison fair value carry value intangible asset intangible asset deem impair net carry value exceed estimate fair value intangible asset evaluate impairment describe impairment longlive asset note accounting policy continue restructure streamline operation rationalize manufacture facility company periodically record restructuring charge result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place actual result vary estimate product liability accrual product liability include associate legal cost record undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically assessment effort progress additional information available receivables relate insurance thirdparty recovery product liability record undiscounted basis probable recovery realize classified reduction litigation charge consolidate statement earning contingency normal course business company subject loss contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability tax matter accordance sfas accounting contingency company record accrual loss contingency probable liability incur loss reasonably estimate company accordance sfas recognize gain contingency realize discussion contingency note income taxis note legal proceeding contingency derivative financial instrument derivative financial instrument company principally management interest rate foreign currency exposure company hold issue derivative financial instrument speculative purpose company record derivative instrument balance sheet fair value change derivative fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize consolidated statement earning derivative designate cash flow hedge effective portion change fair value derivative record comprehensive income loss subsequently recognize consolidated statement earning hedge item affect earning cash flow classify consistent underlying hedged item purchase foreign currency option entire change fair value include measurement hedge effectiveness cash flow hedge ineffective portion change fair value cash flow hedge recognize charge credit earning company designate assign derivative hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long expect occur company immediately recognize gain loss designate hedge financial instrument consolidate statement earning shipping handling cost company typically charge customer shipping handling cost ship handling cost include marketing sell administrative expense million million advertising cost advertising cost expense incur advertising expense million million million respectively research development research development cost expense incur company time time enter strategic alliance party company right develop manufacture market andor sell pharmaceutical product right own party result alliance company obligate payment alliance partner connection research development contingent achievement certain predetermine criterion milestone achieve prior regulatory approval product payment expense research development milestone note accounting policy continue payment connection regulatory approval include nonus regulatory approval additional indication capitalize amortize cost product sell remain useful life asset capitalize milestone payment test recoverability periodically event change circumstance indicate carrying amount recoverable acquire inprocess research development fair value inprocess research development acquire business combination determine independent appraisal base present value research project project cash flow income approach utilize consistent guidance practice aid issue american institute certify public accountant asset acquire business combination research development activity focus software electronic device pharmaceutical industry future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximating company weight average cost capital acquire process research development expense incurred underlying product receive regulatory approval future alternative use addition cost nonrefundable relate acquisition licensing product receive regulatory approval market alternative future use charge earning incur earning share basic earning common share compute weightedaverage number share outstanding year dilute earning common share compute weightedaverage number share outstanding year plus incremental share outstanding assume exercise dilutive stock option restrict stock convertible instrument foreign currency translation statement earning company foreign subsidiary translate dollar average exchange rate net asset company foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation adjustment account include accumulate comprehensive income oci recently issue accounting standard company adopt sfas revise sharebased payment sfas r require measurement recognition compensation expense stockbase payment award employee director base estimate fair value sfas r supersede company previous accounting apb accounting stock issue employee period begin january march securities exchange commission sec issue sab sharebased payment relate sfas r company apply provision sab adoption sfas r company adopt sfas r modify prospective transition method require application accounting standard january elect alternative method provide fasb staff position fsp r transition election relate accounting tax effect sharebase payment award determine company pool excess tax benefit company consolidate financial statement year end december reflect impact sfas r accordance modify prospective transition method company consolidate financial statement prior period restate reflect include impact sfas r stockbase compensation expense recognize sfas r year end december million million net tax share corresponding record additional paidin capital stockholder equity additionally million relate performance award reclassify liability stockholder equity connection adoption sfas r february financial accounting standard board fasb issue sfas fair value option financial asset financial liability permit entity measure certain financial asset financial liability fair value objective sfas improve financial reporting allow entity mitigate volatility report earning cause measurement relate asset liability different attribute apply complex hedge accounting provision sfas entity elect fair value option instrument report unrealize gain loss earning subsequent reporting date fair value option election irrevocable new election date occur sfas establishe presentation disclosure requirement help financial statement user understand effect entitys election earning eliminate disclosure requirement accounting standard asset liability measure fair value display face balance sheet statement effective fiscal year begin november company evaluate pronouncement september fasb issue statement sfas employer account define benefit pension postretirement plansan amendment fasb statement r pronouncement require employer recognize overfunde underfunded status define benefit postretirement plan multiemployer plan asset liability statement financial position recognize change fund status year change occur comprehensive income business entity pronouncement require employer measure fund status plan date yearend statement financial position limited exception pronouncement require prior period restate reflect impact sfas company adopt sfas fiscal year end december adoption accounting pronouncement result million reduction accumulate oci stockholder equity million reduction total asset million increase total liability adoption sfas impact company result operation cash flow note accounting policy continue september fasb issue sfas fair value measurement pronouncement define fair value establishe framework measure fair value expand disclosure fair value measurement statement effective fiscal year begin november adoption accounting pronouncement expect material effect company consolidate financial statement september sec issue sab consider effect prior year misstatement quantify misstatement current year financial statement express staff view process quantify financial statement misstatement bulletin effective interim period fiscal year end november sab require company utilize dual approach assess quantitative effect financial statement misstatement dual approach include income statement focus balance sheet focus assessment adoption bulletin effect company consolidate financial statement july fasb issue fasb interpretation number fin accounting uncertainty income taxesan interpretation fasb statement case company effective january fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas accounting income taxis fin require tax position evaluate recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return difference tax position take tax return amount recognize financial statement record adjustment income taxis payable receivable adjustment defer taxis fin require expand disclosure end annual reporting period include tabular reconciliation unrecognized tax benefit accordance fin company report difference net asset liability recognize statement financial position prior application fin cumulative effect adjustment opening balance retain earning adoption account pronouncement expect material effect company consolidate financial statement march fasb issue sfas accounting servicing financial assetsan amendment fasb statement pronouncement relate account separately recognize service asset servicing liability statement effective fiscal year begin september adoption accounting pronouncement expect material effect company consolidate financial statement february fasb issue sfas account certain hybrid financial instrument amendment fasb statement pronouncement primarily resolve certain issue address implementation sfas accounting derivative instrument hedge activity concern beneficial interest securitize financial asset statement effective financial instrument acquire issue subject remeasurement event occur begin fiscal year adoption accounting pronouncement expect material effect company consolidate financial statement fasb issue sfas accounting change error correction replace apb opinion accounting change sfas report accounting change interim financial statement pronouncement apply voluntary change account principle revise requirement accounting reporting change accounting principle sfas require retrospective application prior period financial statement voluntary change accounting principle impracticable pronouncement require change method depreciation amortization depletion longlive nonfinancial asset account change accounting estimate affect change accounting principle sfas effective accounting change correction error fiscal year begin december statement change transition provision exist accounting pronouncement include transition phase effective date sfas adoption account pronouncement material effect company consolidate financial statement march fasb issue fin accounting conditional asset retirement obligation fin clarifie entity record liability conditional asset retirement obligation fair value obligation reasonably estimate asset retirement obligation cover fin entity legal obligation perform asset retirement activity time method settling obligation conditional future event control entity fin clarifie entity sufficient information reasonably estimate fair value asset retirement obligation company adopt provision fin fiscal year end december adoption accounting pronouncement material effect company consolidate financial statement note accounting policy continue december fasb issue fsp application sfas accounting income taxis tax deduction qualified production activity provide american job creation act fsp provide deduction qualified production activity treat special deduction describe sfas accounting income taxis accordingly tax effect deduction report component company tax provision effect defer tax asset liability internal revenue service irs issue final tax regulation ftr respect deduction qualified production activity section internal revenue code final regulation effective taxable year begin june taxable year begin prior effective date final regulation taxpayer apply final regulation provide taxpayer apply provision final regulation subject certain limitation rule provide notice propose regulation issuance ftr adoption fsp material impact company consolidate financial statement december fasb issue sfas exchange nonmonetary asset provision statement effective nonmonetary asset exchange occur fiscal period begin june provision statement apply prospectively eliminate exception fair value measurement nonmonetary exchange similar productive asset paragraph b apb accounting nonmonetary transaction replace exception exchange commercial substance adoption account pronouncement material effect company consolidate financial statement november fasb issue sfas inventory costsan amendment arb chapter standard require abnormal amount idle facility relate expense recognize current period charge require allocation fix production overhead cost conversion base normal capacity production facility sfas effective inventory cost incur fiscal year begin june adoption accounting pronouncement material effect company consolidate financial statement note alliance investment sanofiaventis company agreement sanofiaventis sanofi codevelopment cocommercialization avaproavalide irbesartan angiotensin ii receptor antagonist indicate treatment hypertension diabetic nephropathy plavix clopidogrel platelet aggregation inhibitor worldwide alliance operate framework geographic territory america principally canada puerto rico latin american countries australia europe asia accordingly territory partnership form manage central expense market research development royalty supply finish product individual country general country level agreement copromote partnership form party sell brand comarket party operate sell brand independently place agreement expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patent exclusivity right applicable territory company act operating partner territory cover americas australia own majority control interest territory sanofis ownership interest territory company consolidate country partnership result territory record sanofis share result minority interest net taxis million million million company record sale territory comarkete country outside territory germany italy spain greece million million million cash flow operating activity partnership territory cover americas australia record operating activity company consolidate statement cash flow distribution partnership profit sanofi sanofis fund ongoing partnership operation occur routine basis record operating activity company consolidated statement cash flow sanofi act operating partner territory cover europe asia own majority financial control interest territory company ownership interest partnership territory company account investment partnership entity territory equity method record share result equity net income affiliate consolidate statement earning company share net income partnership entity tax million million million note alliance investment continue company routinely receive distribution profit provide fund ongoing operation partnership territory cover europe asia transactions record operating activity company consolidate statement cash flow company sanofi company form alliance copromotion irbesartan company contribute irbesartan distribution right sanofi pay company total million year end december company account transaction sale interest license defer amortize million income expect useful life license approximately year formation irbesartan copromotion alliance company recognize income million million million respectively unamortize portion defer income record liability section consolidate balance sheet million million december respectively otsuka company worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote otsuka abilify aripiprazole treatment schizophrenia relate psychiatric disorder japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt product currently copromote otsuka united kingdom uk germany france spain germany spain product sell otsuka affiliate distributor company records alliance revenue contractual share otsukas net sale record expense relate product company recognize alliance revenue abilify ship risk reward ownership transfer otsukas customer uk france italy company presently exclusive distributor product company record net sale relate cost product sell expense company exclusive right sell abilify country europe americas number countries asia country company record net sale relate cost product sell term agreement company purchase product otsuka perform finish manufacture sale company customer agreement expire november puerto rico entire european union eu agreement expire june country company exclusive right sell abilify agreement expire later tenth anniversary commercial sale country expiration applicable patent country company record total revenue abilify million million million total milestone payment otsuka agreement december million million expense acquire inprocess research development remain million capitalize intangible asset amortize cost product sell remain life agreement range year company amortize cost product sell million million million unamortized capitalize payment balance million million december respectively imclone company commercialization agreement expire september imclone system incorporate imclone biopharmaceutical company focus develop targeted cancer treatment codevelopment copromotion erbitux food drug administration fda approve biologics license application bla erbitux use combination irinotecan treatment patient epidermal growth factor receptor egfrexpresse metastatic colorectal cancer refractory irinotecanbase chemotherapy use single agent treatment patient egfrexpresse metastatic colorectal cancer intolerant irinotecanbase chemotherapy fda approve imclone chemistry manufacture control supplemental bla licensure bb manufacturing facility march fda approve erbitux use treatment squamous cell carcinoma head neck combination radiation monotherapy company pay million milestone payment imclone fda approval agreement imclone receive distribution fee base flat rate net sale north america addition company coexclusive right commercialize erbitux japan imclone previously grant coexclusive right merck kgaa japan december company japanese affiliate bmkk merck kgaa merck ltd imclone execute joint development agreement erbitux japan erbitux market japan application submit japanese pharmaceutical medical device agency use erbitux treat patient advance colorectal cancer note alliance investment continue company account million approval milestone pay license acquisition capitalize amortize cost product sell remain term agreement end company amortize cost product sell million million million respectively unamortized portion approval payment record intangible asset million million december respectively company account investment imclone equity method record share result equity net income affiliate consolidate statement earning company record investment market value holding imclone common stock million approximately million december respectively million approximately million december respectively company hold million share imclone stock represent approximately imclone share outstanding december share basis carry value imclone investment closing market price imclone share december respectively compare respectively december company determine equity share imclone net income loss eliminate imclone result milestone revenue imclone recognize million preapproval milestone payment company company record million preapproval milestone payment equity investment expense remain million acquire inprocess research development period milestone revenue recognize imclone excess million eliminate company determine equity share imclone result share imclone result operation company record net income million net loss million net income million company record net sale erbitux million million million gilead company gilead sciences inc gilead enter joint venture develop commercialize fixeddose combination company sustiva efavirenz gileads truvada emtricitabine tenofovir disoproxil fumarate canada july fda grant approval atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg treatment human immunodeficiency virus hiv infection adult atripla firstever oncedaily single tablet regimen hiv intend standalone therapy combination antiretroviral gilead record atripla revenue consolidate result joint venture operating result company record revenue bulk efavirenz component atripla sale product gilead joint venture party customer company revenue efavirenz component determine apply percentage atripla revenue approximate revenue sustiva brand company record efavirenz revenue million relate atripla sale company account participation joint venture equity method accounting record share joint venture result equity net income affiliate consolidate statement earning company record equity loss joint venture gilead million million year end december respectively summary financial information follow summarize financial information company equity investment joint venture sanofi europe asia dollar millions revenue gross profit net income current asset current liability note restructure activity company record pretax charge million relate termination benefit relate cost workforce reduction approximately sell operate administrative personnel charge decrease million adjustment reflect change estimate restructure action take prior period follow table present detail charge segment type company expect substantially complete activity termination dollar million benefit exit cost total pharmaceutical nutritional health care subtotal change estimate restructure reflect statement earning activity company record pretax charge million relate termination benefit relate cost workforce reduction streamline worldwide operation charge million relate employee termination benefit relate expense approximately sell administrative personnel include restructure cardiovascularmetabolic primary care sale organization workforce headcount reduction million relate retention bonus million relate asset impairment charge decrease million adjustment reflect change estimate restructure action take prior period follow table present detail charge segment type company substantially complete restructuring activity late termination relocation asset dollar million benefit exit cost retention writedown total pharmaceutical nutritional health care subtotal change estimate restructure reflect statement earning activity company record pretax charge million relate termination benefit relate cost workforce reduction streamline worldwide operation charge million primarily relate employee termination benefit relate expense approximately sell administrative manufacturing personnel million relate primarily asset impairment million relate consolidation certain research facility million retention bonus charge partially offset million adjustment reflect change estimate restructure action take prior period million gain sale research facility previously write restructuring follow table present detail charge segment type company substantially complete restructuring activity termination relocation asset dollar million benefit exit cost retention write down total pharmaceutical health care corporateother subtotal change estimate gain sale research facility restructuring reflect statement earning note restructure continue rollforward restructuring charge spend liability associate prior current action follow employee termination exit cost dollar million liability liability total balance january charge spend change estimate balance december charge spend change estimate balance december charge spend change estimate balance december liability million million december respectively include accrue expense consolidate balance sheet longterm liability million include liability december note acquisition divestiture january company complete sale inventory trademark patent intellectual property right relate dovonex treatment psoriasis warner chilcott company inc million cash addition company receive royalty base net sale dovonex end result transaction company recognize pretax gain million million net tax quarter quarter company complete sale canadian consumer medicine consumer medicine business relate asset novartis ag novartis term agreement novartis acquire trademark patent intellectual property right consumer medicine million cash include impact work capital adjustment million attributable postclose supply arrangement company novartis relate asset include right consumer medicine brand latin america europe middle east africa result operation consumer medicine include company consolidated statement earning date disposal result transaction company record pretax gain million million net tax quarter april company complete acquisition acordis speciality fibre acordis company purchase stock acordis million incur million acquisition cost connection transaction december company accrue million liability base achievement production volume record additional goodwill purchase price acquisition allocate tangible identifiable intangible asset acquire liability assume base estimate fair value acquisition date million million allocate process research development immediately expense million assign identifiable intangible asset predominantly patent excess purchase price estimate fair value net asset acquire record goodwill acquisition account purchase method accordingly result operation include accompany consolidated financial statement date acquisition february company complete divestiture adult nutritional business novartis million include million contingent achievement contractual requirement satisfy million upfront payment supply agreement company record total pretax gain million million net tax include million contingent payment million reduction company goodwill associated mead johnson product line note discontinued operation company complete sale oncology therapeutic network otn equity partner llc cash proceed million include impact preliminary work capital adjustment company record pretax gain million million net tax present gain sale discontinue operation consolidated statement earning otn previously present separate segment follow amount related otn business segregate continue operation report discontinue operation date disposition reflect cost certain service provide otn company cost allocate company otn service include legal counsel insurance external audit fee payroll process certain human resource service information technology system support year end december dollar million net sale lossearning income tax net lossearning discontinue operation consolidated statement cash flow include otn business date disposition company use centralized approach cash management financing operation accordingly debt allocate business cash flow operating activity discontinue operation consist outflow million year end december cash inflow million year end december cash flow investing activity discontinue operation million year end december investing activity year end december note earning share numerator basic earning share net earning available common stockholder numerator diluted earning share net earning available common stockholder interest expense add assume conversion convertible debt common stock denominator basic earning share weight average number common stock outstanding period denominator diluted earning share weight average share outstanding adjusted effect dilutive stock option assume conversion convertible debt common stock computation basic diluted earning common share follow year end december amount million share datum basic earning continue operation discontinue operation loss net taxis gain disposal net taxis net earning basic earning share average common share outstanding earning continue operation discontinue operation loss net taxis gain disposal net taxis net earning common share dilute earning continue operation interest expense conversion convertible debt net taxis discontinue operation loss net taxis gain disposal net taxis net earning dilute earning share average common share outstanding conversion convertible debt incremental share outstanding assume exerciseveste dilutive stock optionsrestricte stock earning continue operation discontinue operation loss net taxis gain disposal net taxis net earning common share weightedaverage share issuable exercise stock option include diluted earning share calculation dilutive million million million respectively million weightedaverage share issuable million interest expense net tax assume conversion convertible debt include diluted earning share calculation dilutive note expense net component expense net year end december dollar million interest expense interest income foreign exchange transaction loss net expense net interest expense increase net interest swap loss million interest expense reduce net interest swap gain million million respectively interest income relate primarily cash cash equivalent investment marketable security net include income thirdparty contract manufacture royalty income expense debt retirement cost certain litigation matter gain loss disposal property plant equipment gain loss sale marketable security defer income recognize change net compare primarily debt retirement cost defer income recognize note income taxis component earning loss continue operation minority interest income taxis year end december dollar million nonus amount categorize base location tax authority provisionbenefit income taxis attributable continue operation consist year end december dollar millions current nonus defer nonus note income taxis continue effective tax rate company provision income taxis different compute apply statutory federal income tax rate earning continue operation minority interest income taxis result follow earning minority interest income taxis dollar million earning continue operation minority interest income tax statutory rate foreign tax effect operation ireland puerto rico switzerland state local taxis net valuation allowance federal foreign contingent tax matter dividend repatriation ajca federal research tax credit federal foreign valuation allowance foreign effective income tax rate earning continue operation minority interest income taxis compared increase effective tax rate compare result elimination tax benefit section internal revenue code treatment provision portion certain litigation reserve nondeductible tax benefit associate settlement irs examination favorable adjustment taxis special dividend american job creation act ajca partially offset favorable tax legislation enact related tax treatment certain intercompany transaction company foreign subsidiary implementation tax planning strategy relate utilization certain charitable contribution decrease effective tax rate primarily charge approximately million taxis special dividend ajca charge relate establishment valuation allowance certain charitable contribution tax benefit discuss partially offset lower estimate foreign tax credit note income taxis continue defer taxis valuation allowance component current noncurrent defer income tax asset liability december dollar millions acquire inprocess research development intercompany profit inventory item federal foreign tax credit carryforward defer income federal research development tax credit carryforward federal charitable contribution carryforward state net operating loss carryforward foreign net operating loss carryforward foreign defer tax asset pension postretirement benefit depreciation share base compensation legal settlement net valuation allowance defer tax asset net recognize deferred income taxescurrent defer income taxesnoncurrent foreign income taxis payable liabilitiesnoncurrent total include impact million increase defer tax benefit adoption sfas note pension postretirement benefit plan valuation allowance million december relate million state defer tax asset million foreign net operating loss tax credit carryforward million state net operating loss tax credit carryforward company currently believe likely realize company record significant defer tax asset relate foreign tax credit carryforward approximately million research tax credit carryforward approximately million expire vary amount begin realization foreign tax credit research tax credit carryforward dependent generate sufficient domestic taxable income prior expiration realization assure management believe likely defer tax asset realize company anticipate increase level domestic profitability time undertaking action increase biologic manufacturing capacity implement tax planning strategy increase domestic profitability likely cause company effective tax rate increase enhance company ability utilize foreign tax credit research tax credit carryforward foreign tax credit research tax credit carryforward consider realizable reduce near term plavix subject renew additional generic competition event occur company need record significant valuation allowance federal defer tax asset discussion plavix relate matter note legal proceeding contingency income taxis pay year million million million respectively current tax benefit realize exercise stock option charge capital excess par value stock amount million million million respectively note income taxis continue december company approximately billion undistributed earning foreign subsidiary taxis provide company invest expect invest undistributed earning permanently offshore future earning repatriate company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide company conduct business country world subject tax numerous jurisdiction result business activity company file significant number tax return subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report company require year resolve company establish liability possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation company recognize income tax benefit approximately million settlement company federal income tax return year companys federal income tax return currently examination irs irs propose significant disallowance certain litigation settlement expense significant reduction foreign tax credit claim follow company previously disclose international restructuring irs position matter affect foreign tax credit claim company year currently examination company believe strong position respect issue intends contest irs position possible predict outcome issue company establish tax contingency reserve reflect good estimate probable tax liability matter company prevail final nonappealable determination matter loss excess establish reserve material adverse effect company result operation company believe determination material adverse effect cash flow note receivables major category receivables follow december dollar million trade receivables miscellaneous receivable allowance receivables net miscellaneous receivables include million net allowance million million net allowance million respectively relate receivables alliance partner additional information company alliance partner note alliance investment note inventory major category inventory follow december dollar million finish good work process raw packaging material inventory net note property plant equipment major category property plant equipment follow december dollar million land building machinery equipment fixture construction progress accumulate depreciation property plant equipment net capitalize interest million million million year end december respectively include category property plant equipment show note goodwill change carry goodwill year end december follow pharmaceutical nutritional health care discontinue dollar million segment segment segment operation total balance january adjustment reduction sale otn reduction sale consumer medicine purchase price allocation adjustment balance december adjustment reduction sale business purchase price allocation adjustment balance december note intangible asset december intangible asset consist follow december dollar million patentstrademark accumulate amortization patentstrademark net license accumulate amortization license net technology accumulate amortization technology net capitalize software accumulate amortization capitalize software net total intangible asset net note intangible asset continue quarter year company record impairment charge license million million respectively result actual estimate future sale decline tequin charge record cost product sell company consolidate statement earning march result fda approval erbitux use treatment head neck cancer company million milestone payment imclone capitalize license quarter company record impairment charge license million result lower expect sale emsam charge record cost product sell company consolidate statement earning amortization expense intangible asset year end december million million million respectively expect amortization expense relate current net carrying intangible asset follow year end december dollar million later year note shortterm borrowing longterm debt shortterm borrowing end million million respectively longterm debt billion december compare billion december fourth quarter company restructure longterm debt retire outstanding billion note cash tender offer subsequent redemption issue million million aggregate principal note million million aggregate principal note billion aggregate principal note result million pretax expense comprise item discuss premium pay debt tender million million respectively addition company recognize earning million unamortized discount debt issuance cost associate debt incur pretax loss million relate termination remain billion notional fixedtofloate interest rate swap agreement recognize earning pretax unamortized portion million aforementione loss incur termination million notional fixedtofloate interest rate swap occur june furthermore november company recognize earning accumulate comprehensive income pretax unamortized portion million loss incur settlement interest rate lock contract manage exposure change interest rate anticipate issuance longterm fix rate debt december company replace prior billion revolve credit facility new billion year revolve credit facility syndicate lender extendable anniversary date consent lender facility contain customary term condition substantially similar prior facility include financial covenant ratio consolidated debt consolidated capital exceed end quarter company compliance covenant inception new facility borrowing outstanding revolve credit facility december company unused shortterm line credit available trade finance facility foreign bank million million december respectively august whollyowne subsidiary company enter billion term facility syndicate bank lender borrowings facility guarantee company subsidiary borrower certain european subsidiary company facility contain fiveyear tranche billion twoyear tranche million fully draw december interest pay periodic basis agree lender annual rate equal applicable london interbank offer rate libor plus company subject substantially covenant include december revolve credit facility company subject restriction include certain financial covenant prior borrowing proceed facility company obtain waiver lender covenant default facility time intercompany distribution december company fully repay twoyear tranche billion outstanding fiveyear tranche compliance covenant note shortterm borrowing longterm debt continue second quarter company retire outstanding billion note incur aggregate pretax expense approximately million connection early redemption note termination relate interest rate swap component longterm debt follow december dollar million note float rate bank term facility note float rate convertible debenture euro note euro note note float rate bank term facility note debenture debenture debenture yen note industrial revenue bond yen note yen note variable rate industrial revenue bond company outstanding billion convertible debenture pay interest quarterly annual rate equal month libor reset quarterly minus yield zero final maturity september debenture callable par time september issuer holder redeem debenture par september fundamental change ownership company occur bond initial conversion price conversion rate share adjustable depend average closing price applicable period maximum conversion rate share company enter fixed float interest rate swap billion longterm debt conjunction new issuance billion note billion euro note billion company execute fix float interest rate swap convert new fix rate debt pay variable rate debt company execute fix float interest rate swap convert million company fix rate debt pay variable rate debt year end december company realize net increase interest expense million result higher float rate obtain swap agreement year end december company recognize net reduction interest expense million reflect benefit low float rate obtain swap agreement november connection early retirement outstanding billion note company terminate remain billion notional fix float interest rate swap agreement incur pretax loss million april connection early redemption billion note company terminate billion notional fixedtofloate interest rate swap agreement incur pretax loss million june company terminate million notional fixedtofloate interest rate swap agreement relate billion note incur pretax loss million loss amortize interest expense million million recognize respectively remain loss million million loss incur unwind billion swap fully recognize september company terminate million notional fixedtofloate interest rate swap agreement relate million debenture gain million gain recognize interest expense remain life debenture approximately million recognize note shortterm borrowing longterm debt continue cash payment interest include payment interest rate swap million million million respectively company cash receipt interest rate swap million million million respectively exclude cash payment interest payment period later dollar million total year longterm debt obligation include shortterm borrowing company consolidated balance sheet december balance approximate outstanding nominal longterm debt value company convertible debenture include payment contain feature describe december company provide total million financial guarantee form standby letter credit performance bond standby letter credit insurance company support thirdparty liability program performance bond issue support range ongoing operating activity include sale company product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority company outstanding financial guarantee expire year expect fund note stockholder equity change common share treasury stock capital excess par value stock restrict stock capital excess common share treasury cost treasury par value restrict dollar share million issue share stock stock stock balance january issue pursuant stock plan option amortization restrict stock lapse forfeiture restrict stock balance december issue pursuant stock plan option amortization restrict stock lapse forfeiture restrict stock balance december issue pursuant stock plan option amortization restrict stock lapse forfeiture restrict stock balance december share company prefer stock convertible share common stock callable company option reduction number issue share prefer stock conversion share common stock dividend declare common share note stockholder equity continue accumulate balance relate component comprehensive incomeloss net taxis follow defer charge minimum pension accumulate foreign defer pension currency incomeloss liability postretirement available comprehensive dollar million translation effective hedge adjustment benefit sale security incomeloss balance january comprehensive incomeloss balance december comprehensive incomeloss balance december comprehensive incomeloss adjustment adoption sfas balance december note employee stock benefit plan employee stock plan companys stock incentive plan executive officer key employee grant option purchase company common stock market price date option grant option generally exercisable installment year fourth anniversary grant date maximum term year generally company issue share stock option exercise treasury stock additionally plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price term stock incentive plan authorize share include outstanding share year number share tender prior year pay purchase price option number share previously utilize satisfy withholding tax obligation exercise share available grant prior year grant year share cancel forfeit expire available future grant stock incentive plan provide grant common stock key employee subject restriction continuous employment restriction generally expire fouryear period date grant compensation expense recognize restrict period december million million share restrict stock restrict stock unit outstanding plan respectively year end december approximately million million million share respectively restrict stock restrict stock unit grant weight average fair value common share respectively stock incentive plan incorporate company longterm performance awards award deliver form target number performance share threeyear cycle award base cumulative earning share cumulative sale ultimate payout modify company total stockholder return versus company proxy peer group threshold target meet performance period payment longterm performance award plan maximum performance measure result maximum payout target december million million performance share outstanding plan respectively million million million performance share grant respectively fair value common share respectively teamshare stock option plan terminate january fulltime employee exclude key executive grant option purchase company common stock market price date option grant company authorize million share issuance plan individual grant generally exercisable evenly fourth fifth anniversary grant date maximum term year option million share exercise plan december note employee stock benefit plan continue company result operation year end december reflect impact sfas r include impact expense stock option company elect alternative method provide fsp r determine company pool excess tax benefit result operation year end december restate reflect impact expense stock option prepare accordance apb follow table summarize stockbase compensation expense net tax relate employee stock option restrict stock longterm performance award year end december year end december dollar million cost product sell marketing sell administrative research development total stockbase compensation expense defer tax benefit stockbase compensation net tax table reflect pro forma net income dilute net income share year end december year end december dollar million share datum net earning report total stockbase employee compensation expense include report net earning net relate tax effect total stockbase employee compensation expense determine fair value base method award net relate tax effect pro forma basic earning share report pro forma diluted earning share report pro forma cost relate stockbase compensation capitalize period summary option activity follow share common stock available issue weightedaverage share million option award plan exercise price share balance january authorize grant exercise lapsed balance december authorize grant exercise lapsed balance december authorize grant exercise lapsed balance december note employee stock benefit plan continue weightedaverage grantdate fair value option grant company month end december respectively total intrinsic value option exercise month period end december million million million respectively month end december company receive million million million cash proceed exercise stock option december million total unrecognized compensation cost relate stock option expect recognize weightedaverage period year follow table summarize information concern company stock compensation plan currently outstanding exercisable option number security remain available future number security issue weightedaverage exercise issuance equity exercise outstanding price outstanding compensation plan exclude option right option right security reflect column share millions b c plan category equity compensation plan approve security holder equity compensation plan approve security holder share plan long issue follow table summarize significant range outstanding exercisable option december share million option outstanding option exercisable weighted weight average weight aggregate average weight aggregate remain average intrinsic remain average intrinsic range number contractual exercise price value number contractual exercise price value exercise price outstanding life year share million exercisable life year share million total aggregate intrinsic value precede table represent total pretax intrinsic value base company average stock price december receive option holder option holder exercise option date total number inthe money option exercisable december million december million outstanding option exercisable weight average exercise price december million share common stock reserve issuance pursuant stock plan option conversion prefer stock stock option valuation fair value employee stock option grant estimate date grant prior january estimate weight average estimate option value grant blackschole option pricing model follow assumption expect volatility riskfree interest rate dividend yield expect life yrs yrs yrs note employee stock benefit plan continue company derive expect volatility assumption require blackschole model calculate year historical volatility weighting equally derive imply volatility consistent sfas r sab prior company historical stock price volatility accordance sfas purpose pro forma information selection blend historical imply volatility approach base company assessment calculation expect volatility representative future stock price trend historical volatility riskfree interest rate assumption base treasury yield curve effect time grant dividend yield assumption base company history expectation dividend payout expect life employee stock option represent weightedaverage period stock option expect remain outstanding derive output latticebinomial model expect life employee stock option impact underlying assumption calibration company model latticebinomial model assume employee exercise behavior function option remain vested life extent option inthemoney latticebinomial model estimate probability exercise function variable base entire history exercise cancellation past option grant company prior company optionprice model indirectly estimate expect life stock option expect life expect volatility stock option base historical economic datum trend future forfeiture employee stock option account incur basis stockbase compensation expense recognize consolidated statement earning month end december base award ultimately expect vest reduce estimate forfeiture sfas r require forfeiture estimate time grant revise necessary subsequent period actual forfeiture differ estimate forfeiture estimate base historical experience company pro forma information require sfas period prior company account forfeiture occur restrict stock fair value nonveste share company common stock determine base average trading price company common stock grant date summary restrict share activity follows weight average grant date share thousand number share fair value nonveste share january grant vested forfeited nonveste share december grant vested forfeited nonveste share december grant vested forfeited nonveste share december december million million respectively total unrecognized compensation cost relate nonveste restrict stock restrict stock unit cost expect recognize weightedaverage period year balance december year balance december total fair value share share unit vest month end december million million million respectively note employee stock benefit plan continue longterm performance award prior adoption sfas r compensation expense relate longterm performance award determine base market price company stock time award apply expect number share contingently issuable amortize threeyear performance cycle adoption sfas r fair value longterm performance award estimate date grant monte carlo simulation model instead grant date market price previously company change valuation technique base clarification provide sfas r fact longterm performance award contain market condition performance condition affect factor vest ie variable number share award reflect grant date fair value award monte carlo simulation model utilize multiple input variable determine probability satisfy market condition stipulate award grant calculate fair market value longterm performance award valuation model follow assumption weightedaverage expect expect dividend risk free grant year grant date volatility yield interest rate weightedaverage expect volatility base year historical volatility level company common stock expect dividend yield base historical dividend payment risk free interest rate reflect yield year zero coupon treasury bond base performance share contractual term fair value longterm performance award amortize performance period award longterm performance share thousand share outstanding performance cycle weightedaverage grant date measurement date grant date fair value december december million million respectively total unrecognized compensation cost relate performance share plan expect recognize weightedaverage period year year respectively accuracy fair value estimate company determination fair value stockbase payment award date grant optionprice model affect company stock price assumption number highly complex subjective variable variable include limited company expect stock price volatility term award actual project employee stock option exercise behavior optionprice model develop use estimate value trade option vest hedge restriction fully transferable company employee stock option certain characteristic significantly different trade option change subjective assumption materially affect estimate value management opinion exist valuation model provide accurate measure fair value company employee stock option fair value employee stock option determine accordance sfas r sab optionprice model value indicative fair value observe willing buyerwilling seller market transaction company adopt sfas r require measurement recognition compensation expense stockbase payment award employee director base estimate fair value sfas r supersede company previous accounting apb period begin january march sec issue sab relate sfas r company apply provision sab adoption sfas r company adopt sfas r modify prospective transition method require application accounting standard january elect alternative method provide fsp r determine company pool excess tax benefit company consolidate financial statement year end december reflect impact sfas r accordance modify prospective transition method note employee stock benefit plan continue company consolidate financial statement prior period restate reflect include impact sfas r stockbase compensation expense recognize sfas r year end december million million net tax share corresponding record additional paidin capital stockholder equity additionally million relate performance award reclassify liability stockholder equity connection adoption sfas r note financial instrument company expose market risk change currency exchange rate interest rate reduce risk company enter certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument manage consolidated basis efficiently net exposure advantage natural offset derivative financial instrument speculative purpose company primary net foreign currency translation exposure euro japanese yen mexican peso chinese renminbi canadian dollar company utilize foreign currency contract hedge anticipate transaction primarily intercompany transaction certain foreign currency designate derivative instrument foreign currency cash flow hedge appropriate notional amount company foreign exchange derivative contract december million million respectively derivative majority qualify hedge future anticipate cash flow effective portion change fair value temporarily defer accumulate oci recognize earning hedge item affect earning company reclassify deferred loss million million million respectively accumulate oci earning majority classify cost product sell december balance defer net aftertax loss foreign exchange forward contract include accumulate oci million net aftertax loss million estimate reclassify earning month sfas require company perform periodic assessment hedge effectiveness assessment determine derivative designate qualifying hedge continue highly effective offset change cash flow hedge item ineffective portion fair value long defer accumulate oci include current period earning year end december impact hedge ineffectiveness earning significant additionally year end december impact discontinue hedge loss million gain million respectively furthermore company use foreign exchange forward contract offset exposure certain currency asset liability foreign exchange forward contract designate hedge change fair value derivative recognize earning occur amount recognize earning relate foreign exchange forward contract qualify hedge accounting treatment significant fair value forward contract net liability million december million record noncurrent asset million record current liability fair value forward contract net asset million december million record noncurrent asset million record current liability fair value foreign exchange contract base yearend currency rate blackschole model case option contract company exposure net foreign currency denominate asset liability approximately billion billion december respectively primarily mexico japan uk china australia canada reduction net exposure primarily issuance billion euro billion note additional information note shortterm borrowing longterm debt addition foreign exchange hedge contract note company utilize forward contract hedge foreign currency denominate monetary asset liability primary objective forward contract protect dollar value foreign currency denominate monetary asset liability effect volatility foreign exchange rate occur prior receipt settlement dollar foreign currency denominate monetary asset liability primarily denominate euro forward contract designate hedge mark market incomeexpense notional fair value purchase foreign exchange forward contract million million asset respectively december million million liability respectively december notional fair value sell foreign exchange forward contract million million liability respectively december million million asset respectively december note financial instrument continue company use non dollar borrowing less extent forward contract hedge foreign currency exposure company net investment certain foreign affiliate non dollar borrowing forward contract designate hedge net investment effective portion foreign exchange gain loss hedge record foreign currency translation component oci december million tax loss million tax gain respectively record foreign currency translation component oci company use derivative instrument interest rate risk management strategy derivative instrument comprise principally fix float rate interest rate swap subject fairvalue hedge accounting treatment november connection funding retirement fix rate debt company execute fix float interest rate swap convert billion billion euro billion company newly issue fix rate debt pay variable rate debt company execute fix float interest rate swap convert million company fix rate debt pay variable rate debt total notional outstanding interest rate swap billion billion euro billion december billion december accordance sfas accounting derivative instrument hedging activity company recognize net increase interest expense million net reduction interest expense million million respectively impact interest rate swap swap contract underlie debt hedge record fair value result increase noncurrent asset million current liability million reduction longterm debt million december increase noncurrent asset million current liability million reduction longterm debt million december swap contract generally hold maturity intend create appropriate balance fix float rate debt company swap contract qualify fair value hedge terminate prior maturity date report carry value underlie debt amortize earning remain life debt swap contract qualify cash flow hedge terminate report accumulate oci amortize earning remain life debt follow table summarize new terminate interest rate swap year notional dollarseuro million transaction underlie debt interest rate contract swap associate eur note swap associate eur note swap associate note terminate swap contract total notional pretax pretax pretax year defer incomeexpense incomeexpense interest rate contract termination underlie debt gainloss recognize recognize dollar million interest rate swap lock associate note interest rate swap lock associate note swap associate note swap associate note swap associate note swap associate note underlying note extinguish respectively carry company financial instrument include cash cash equivalent marketable security account receivable account payable approximate fair value december longterm debt difference fair value carry value material note segment information company organize reportable segmentspharmaceutical nutritional health care pharmaceutical segment comprise global pharmaceutical international consumer medicine business nutritional segment consist mead johnson primarily infant formula business children nutritional business health care segment consist convatec medical imaging consumer medicine business quarter company complete sale consumer medicine business additional information sale consumer medicine note acquisition divestiture company product sell principally wholesale retail trade nationally internationally certain product sell drug manufacturer hospital clinic government agency medical profession wholesaler account approximately respectively company total net sale sale wholesaler account respectively company total net sale wholesaler account approximately respectively company total net sale sale concentrate pharmaceutical segment earning minority net sale interest income taxis yearend asset dollar million pharmaceutical nutritional health care health care group total segment corporateother total corporateother consist principally interest income interest expense certain administrative expense allocation business segment certain corporate program litigation expense debt retirement cost gain sale business product asset defer income recognize collaboration agreement restructuring charge corporateother asset include cash cash equivalent marketable security goodwill asset otn hold available sale december sell certain asset capital expenditure depreciation dollar million pharmaceutical nutritional health care health care group total segment corporateother total note segment information continue geographic area net sale yearend asset dollar millions united states europe middle east africa western hemisphere pacific total change yearend asset primarily decrease cash cash equivalent marketable security result reinvestment foreign dividend receive pursuant repatriation earning ajca note lease minimum rental commitment noncancelable operating lease primarily real estate motor vehicle effect december year end december dollar million later year total minimum payment total minimum sublease rental net minimum rental commitment operate lease rental expense net sublease rental income million million million million million million december company complete sale leaseback administrative facility new jersey million result pretax gain transaction million defer reduce future lease rental cost lease period range year note pension postretirement benefit plan company certain subsidiary define benefit pension plan define contribution plan termination indemnity plan regular time employee principal pension plan bristolmyers squibb retirement income plan funding policy contribute amount provide current service fund past service liability plan benefit base primarily participant year credit service compensation plan asset consist principally equity fixedincome security company provide comprehensive medical group life benefit substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement original retire company life insurance plan noncontributory plan asset consist principally equity fixedincome security similar plan exist employee certain country outside note pension postretirement benefit plan continue company adopt sfas fiscal year end december result million reduction accumulate oci stockholder equity million reduction total asset million increase total liability impact adoption summarize follow sfas adjustment dollar million pre sfas pretax tax net post sfas current asset defer income taxis noncurrent asset defer income taxis prepay pension asset current liability accrue expense foreign income taxis payable noncurrent liability liabilitie stockholders equity accumulate comprehensive loss cost company defer benefit postretirement benefit plan include follow component pension benefit benefitsa dollar million service costbenefit earn year interest cost project benefit obligation expect return plan asset net amortization deferral net periodic benefit cost curtailment settlement total net periodic benefit cost company recognize impact medicare prescription drug improvement modernization act accordance fsp record million million million respectively reduction net periodic benefit cost estimate net actuarial loss prior service cost amortize accumulate oci net periodic benefit cost dollar million pension benefit benefit amortization net actuarial loss amortization prior service cost note pension postretirement benefit plan continue change benefit obligation plan asset fund status amount recognize balance sheet year end december company define benefit postretirement benefit plan pension benefit benefit dollar million benefit obligation begin year service costbenefit earn year interest cost project benefit obligation plan participant contribution curtailment settlement actuarial lossesgain plan amendment retiree drug subsidy receive benefit pay exchange rate gainslosse benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement retiree drug subsidy receive benefit pay exchange rate lossesgain fair value plan asset end year fund status unamortized net obligation adoption unrecognize prior service cost unrecognized net actuarial loss net recognize amount recognize balance sheet consist prepay pension prepay benefit cost asset accrue expenses pension postretirement liability accrue benefit cost accumulate comprehensive loss net recognize amount recognize accumulate comprehensive loss net actuarial loss net obligation adoption prior service cost plan underfunde accrue benefit obligation exceed accrue benefit liability december additional minimum liability establish increase accrue benefit liability value underfunde accrue benefit obligation additional minimum liability total million december prior adoption sfa unfunded benefit equalization plan international plan liability reverse adoption sfas additional minimum liability total million december offset intangible asset million charge accumulate oci include stockholder equity million accumulate benefit obligation define benefit pension plan million million december respectively note pension postretirement benefit plan continue information pension plan accumulate benefit obligation excess plan asset december dollar millions project benefit obligation accumulate benefit obligation fair value plan asset attributable primarily unfunded benefit equalization plan plan international market unfunde benefit equalization plan provide pension benefit employee compensation irs limit fund taxadvantage manner additional information pertaining company pension postretirement plan pension benefit benefit dollar million decreaseincrease minimum liability include impact foreign currency fluctuation include comprehensive income weightedaverage assumption determine benefit obligation december pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit cost year end december pension benefit benefit discount rate expect longterm return plan asset rate compensation increase december company expect longterm rate return pension plan asset target asset allocation public equity international private equity fix income approximate apply expect return public equity private equity fix income target allocation actual historical return relevant annualize return period end december year year year pension plan asset represent approximately total company pension plan asset december disclose total company expect return asset pension plan impact international pension plan typically employ aggressive asset allocation expect return disclose benefit relevant asset invest manner pension plan asset international plan asset assume health care cost trend rate december health care cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate note pension postretirement benefit plan continue assume health care cost trend rate effect amount report health care plan onepercentagepoint change assume health care cost trend rate follow effect percentage percentage dollar million point increase point decrease effect total service interest cost effect postretirement benefit obligation company asset allocation pension postretirement benefit december pension benefit benefit public equity security debt security include cash private equity total company investment strategy emphasize equity order achieve high expect return long run low expense low require cash contribution pension plan target asset allocation public equity international private equity fix income maintain cash flow ie cash contribution benefit payment rebalance target necessary investment diversify major asset category equity passively manage investment actively manage investment strategy international pension plan typically similar asset allocation usually conservative bristolmyer squibb company common stock represent plan asset december asset postretirement benefit commingle pension plan asset investment strategy identical describe pension plan contribution minimum contribution require company cash contribution pension plan million million million respectively company plan cash contribution pension plan contribution pension plan company taxdeductible contribution h account retiree medical benefit equal portion pension normal cost contribution international pension plan million million million respectively contribution international plan expect million estimate future benefit payment follow benefit payment mainly pension plan reflect expect future service appropriate expect pay benefit medicare dollar million pension benefit gross subsidy net year note pension postretirement benefit plan continue saving plan principal define contribution plan bristolmyer squibb saving investment program company contribution base employee contribution level company match company contribution plan million million million termination indemnity plan company operate certain jurisdiction primarily europe require record statutory termination obligation obligation assess accordance emerge issue task force issue determination vested benefit obligation define benefit pension plan total pension liability record obligation million december million december note legal proceeding contingency lawsuit claim proceeding investigation pende involve company certain subsidiary accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate matter involve antitrust security patent infringement pricing sale marketing practice environmental health safety matter consumer fraud product liability insurance coverage significant matter describe assurance increase scope matter future lawsuit claim proceeding investigation material management continue believe previously disclose year aggregate impact current reserve legal matter affect company reasonably likely material company result operation cash flow material financial condition liquidity intellectual property plavix litigation plavix currently company large product rank net sale net sale plavix approximately billion year end december billion year end december billion net sale plavix billion billion billion plavix patent subject number challenge significant market product possible reasonably estimate impact lawsuit company loss market exclusivity plavix sustain generic competition material company sale plavix result operation cash flow material company financial condition liquidity company sanofi company intend vigorously pursue enforcement patent right plavix plavix litigation united states patent infringement litigation company territory partnership alliance sanofi plaintiff pende patent infringement lawsuit institute district court southern district new york entitle sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v apotex inc apotex corp apotex suit file march base patent patent composition matter patent disclose claim thing hydrogen sulfate salt clopidogrel medicine available company plavix plaintiff infringement position base defendant file abbreviate new drug application anda fda seek approval sell generic clopidogrel bisulfate prior expiration composition matter patent defendant respond allege patent invalid andor unenforceable march company announce execute propose settlement agreement march agreement apotex settle patent infringement lawsuit pende party district court southern district new york response concern express federal trade commission state attorney general party modify march agreement modify agreement july company announce modify agreement fail receive require antitrust clearance state attorney general august apotex launch generic version clopidogrel bisulfate august company file motion preliminary injunction august trial court issue preliminary injunction order apotex halt sale generic clopidogrel bisulfate court order apotex recall product customer company require post bond million provide security apotex court conclude end patent litigation injunction wrongly impose september company post million bond satisfy requirement company pledge issuer bond collateral million bond consist shortterm high quality security collateral report marketable security consolidate balance sheet december term pledge agreement company entitle receive income generate marketable security certain investment decision restrict million pledge security purpose time bond cancel note legal proceeding contingency continue september court deny apotexs motion stay preliminary injunction apotex file appeal preliminary injunction court appeal federal circuit september file motion stay injunction pende appeal september federal circuit deny september december federal circuit affirm trial court issuance injunction apotex subsequently file motion reconsideration andor rehearing deny january september apotex file motion supplement answer counterclaim add claim breach contract antitrust counterclaim additional equitable defense trial court permit apotex add additional antitrust counterclaim stay pende outcome trial court permit apotex add breach contract claim trial commence january end february court order posttrial briefing expect rule company territory partnership alliance sanofi plaintiff additional pende patent infringement lawsuit institute district court southern district new york dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt relate patent trial date action dr reddys set patent infringement action teva cobalt stay pende resolution apotex litigation party action agree bind outcome litigation apotex teva cobalt appeal outcome litigation dr reddys teva file anda fda exclusivity period statutory stay periods hatchwaxman act expire exception month stay applie teva expire february accordingly final approval fda provide company authorization distribute generic clopidogrel bisulfate product subject legal remedy company apply include injunctive relief damage company territory partnership alliance sanofi plaintiff pende patent infringement lawsuit institute district court district new jersey entitle sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v watson pharmaceuticals inc watson laboratories inc suit file october base patent disclose claim particular crystalline polymorph form hydrogen sulfate salt clopidogrel market plavix case discovery phase december court permit watson pursue declaratory judgment counterclaim respect patent january court approve party stipulation stay case pende outcome trial apotex matter possible time reasonably assess patent litigation apotex plavix patent litigation timing renew generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical company apotex prevail patent litigation company expect face renew generic competition plavix apotex promptly note loss market exclusivity plavix andor sustain generic competition material company sale plavix result operation cash flow material company financial condition liquidity impact apotexs launch generic clopidogrel bisulfate product company reasonably estimate time depend number factor include generic product sell apotex company prevail underlie patent litigation company prevail pende patent case extent launch apotex permanently adversely impact pricing prescription demand plavix damage seek andor recover company apotexs ability pay damage loss market exclusivity plavix andor sustain generic competition material company sale plavix result operation cash flow material company financial condition liquidity launch generic clopidogrel bisulfate product apotex august significant adverse effect sale company estimate range billion billion particular launch adverse impact sale fourth quarter company estimate range million million quarter million fourth quarter second fourth quarter net sale plavix million million million million respectively sale generic clopidogrel note legal proceeding contingency continue bisulfate expect residual impact plavix sale company certainty estimate impact point time previously disclose antitrust division department justice doj conduct criminal investigation propose settlement company cooperate fully investigation possible time reasonably assess outcome investigation impact company previously disclose company enter deferred prosecution agreement dpa attorney office district new jersey usao june pursuant dpa usao file criminal complaint company allege conspiracy commit security fraud defer prosecution company dismiss complaint year company satisfie requirement dpa term dpa usao discretion prosecute company matter subject criminal complaint file usao company connection dpa usao determination company commit criminal conduct dpa criminal conduct define crime relate company business activity commit executive officer director securities fraud accounting fraud financial fraud business fraud materially affect book record publicly file report company obstruction justice possible time reasonably assess impact pende criminal investigation doj company compliance dpa additional information respect dpa include item management discussion analysissec consent order defer prosecution agreement september board directors board announce company current chief executive officer ceo general counsel leave respective position effective immediately announcement take place board receive consider report company outside counsel issue relate plavix patent litigation apotex preliminary recommendation monitor dpa monitor terminate employment individual monitor recommendation follow investigation initiate usao conduct monitor usao corporate governance issue relate company negotiation propose settlement apotex company advise monitor usao investigation involve matter subject ongoing investigation antitrust division doj plavix settlement agreement time monitor preliminary recommendation monitor usao advise company find violation dpa unlawful conduct company employee investigation include review violation federal security law connection propose settlement apotex term sec consent monitor complete investigation submit report investigation usao monitor report find violation sec consent federal security law connection propose settlement monitor conclude company violate certain paragraph dpa related governance matter violation cite monitor report relate thing communication failure include insufficient communication company ceo general counsel board member senior management failure comply certain internal company policy procedure monitor finding respect company knowingly materially breach dpa recommendation usao advise company believe matter cite monitor report fully remediate accordingly intend action dpa respect monitor report antitrust litigation eighteen lawsuit comprise individual suit purport class action file company district court southern district ohio western division plaintiff include pharmacy chain individually assignee certain wholesaler health welfare benefit plansfund individual resident state announcement march agreement apotex march lawsuit allege thing apotex settlement violate sherman act relate law plaintiff seek thing permanent injunctive relief bar apotex settlement andor monetary damage class action file behalf direct purchaser consolidate caption plavix direct purchaser antitrust litigation class action file behalf indirect purchaser consolidate caption plavix indirect purchaser antitrust litigation amend complaint file consolidated class action individual action july announcement modify agreement fail receive require antitrust clearance state attorney general amend complaint include allegation criminal investigation antitrust division doj november company file motion transfer eighteen lawsuit district court southern district new york apotex matter similar plavixrelate patent infringement case pende motion pende court court consider stay litigation pende outcome patent infringement litigation possible time reasonably assess outcome lawsuit impact company note legal proceeding contingency continue shareholder derivative lawsuit september certain member board current officer company name derivative complaint steven w sampson v peter r dolan et al file new york state supreme court september certain member board current officer company name derivative complaint americo marchese v peter r dolan et al file district court southern district new york complaints allege thing breach fiduciary duty claim contribution indemnification relation negotiation apotex plavix patent litigation thing complaint seek money damage injunctive remedy form equitable relief possible time reasonably assess outcome lawsuit impact company plaintiff marchese voluntarily dismiss prejudice name plaintiff sell bristolmyers squibb stock consumer fraud november company serve purport class action complaint subsequently amend include sanofi entity caption skilstaf inc v bristolmyers squibb company et al cv file district court district new jersey complaint allege defendant misrepresent safety effectiveness plavix combination aspirin thirdparty payor mislead cause pay plavix prescription insured compare low cost alternative plaintiff assert thing violation new jersey consumer fraud act plaintiff seek compensatory punitive damage possible time reasonably assess outcome lawsuit impact company plavix litigationinternational sanofisynthelabo sanofisynthelabo canada inc institute prohibition action federal court canada apotex inc minister health response notice allegation noa apotex inc direct canadian patent patent cover clopidogrel bisulfate apotexs noa indicate file abbreviate new drug submission ands clopidogrel bisulfate tablet seek approval notice compliance and expiration patent schedule august apotexs noa allege patent invalid infringe march canadian federal court ottawa reject apotexs challenge canadian plavix patent hold asserted claim novel obvious infringe grant sanofis application order prohibition minister health apotex inc order prohibition preclude approval apotexs ands patent expire federal court decision reverse appeal apotex file appeal canadian federal court appeal hear december december federal court appeal dismiss apotexs appeal uphold federal court issuance order prohibition february apotex file leave appeal decision supreme court canada sanofi sanofisynthelabo canada institute prohibition action federal court canada cobalt minister health response noa cobalt direct patent canadian patent patent cobalt noa indicate file ands clopidogrel bisulfate tablet seek notice compliance and expiration patent cobalt allege patent invalid patent invalid infringe case stay pende outcome apotex appeal june korean intellectual property tribunal invalidate claim sanofis korean patent include claim direct clopidogrel pharmaceutically acceptable salt clopidogrel bisulfate sanofi appeal sanofi commence infringement action generic pharmaceutical company launch generic clopidogrel bisulfate product korea possible time reasonably assess outcome lawsuit impact company intellectual property litigation tequin injectable form company kyorin pharmaceuticals co ltd kyorin commence patent infringement action march apotex sicor pharmaceuticals inc sicor inc sicor pharmaceuticals sales inc teva teva pharmaceutical industries ltd district court southern district new york relate injectable form antibiotic gatifloxacin kyorin hold composition matter patent company sell tequin action relate apotexs sicor file andas generic version injectable gatifloxacin piv certification composition matter patent expire december grant patent term extension december invalid note legal proceeding contingency continue filing lawsuit place stay approval apotexs sicor generic product julyaugust court decision adverse company kyorin date sicor case consolidated proceeding stipulation approve district court southern district new york august party agree apotex case stay pende resolution teva sicor case party bind outcome litigation august court approve stipulation dismissal jointly submit party stipulation plaintiff claim teva sicor dismiss prejudice teva sicor counterclaim concern claim patent dismiss prejudice teva sicor remain counterclaim dismiss prejudice apotex case remain pende possible time reasonably assess outcome apotex lawsuit result company decision discontinue manufacture distribution sale tequin expect outcome apotex lawsuit material impact company erbitux yeda litigation october yeda research development company ltd yeda file suit imclone aventis pharmaceuticals inc federal court claim individual associate yeda name inventor patent patent cover therapeutic combination egfrspecific monoclonal antibody antineoplastic agent chemotherapeutic agent use treatment cancer september follow trial court issue opinion order hold researcher yeda sole inventor subject matter patent give complete ownership patent yeda imclone appeal imclone file declaratory judgment action district court southern district new york complaint allege yeda researcher remain sole inventor patent patent invalid company party action unable predict outcome proceeding result court decision yeda seek damage infringement respect past erbitux sale royalty future erbitux sale yeda right license patent yeda license patent party result product competition erbitux occur early assess extent competitive impact occur quantify impact yeda announce license patent amgen inc amgen amgen receive fda approval market egfr product compete erbitux commercial agreement imclone company pay royalty imclone sale erbitux impact court decision agreement imclone company include provision pursuant certain financial consequence company result decision responsibility imclone addition company own million share imclone common stock company account equity method accounting carrying value share december closing market price imclone common stock december assurance company able realize fully benefit contractual protection commercial agreement imclone financial consequence company result court decision repligen litigation repligen corporation repligen massachusetts institute technology mit file lawsuit district court district massachusetts imclone claim imclone manufacture sale erbitux infringe patent generally cover process protein production mammalian cell july court grant summary judgment favor repligen mit reject imclone defense relate patent exhaustion trial proceed issue patent infringement company party action possible time reasonably assess outcome lawsuit impact company abbott laboratories litigation february abbott laboratories file suit imclone district court district massachusetts case cvrgs complaint allege imclone manufacture sale erbitux infringe patent seek damage allege infringement company party action possible time reasonably assess outcome lawsuit impact company note legal proceeding contingency continue orencia january repligen regent university michigan file complaint company district court eastern district texas marshall division orencia launch february complaint allege company thenanticipate sale orencia infringe patent repligen amend complaint include ongoing future sale orencia august zymogenetics inc file complaint company district court district delaware complaint allege company manufacture sale orencia infringe patent nos trial schedule commence april possible time reasonably assess outcome lawsuit impact company general commercial litigation clayworth litigation company number pharmaceutical manufacturer name defendant action file california state superior court oakland james clayworth et al v bristolmyers squibb company et al allege defendant conspire fix price pharmaceutical agree charge drug charge outside particularly canada assert claim california cartwright act unfair competition law plaintiff sought treble monetary damage injunctive relief relief december court grant company manufacturer motion summary judgment base passon defense judgment enter favor defendant january notice appeal respect judgment file remain pende possible time reasonably assess outcome lawsuit impact company event plaintiff successful appeal weisz stephenson litigation company name defendant pharmaceutical company action originally bring utility consumer action network consumer advocacy organization focus privacy issue lawsuit entitle utility consumer action network behalf privacy right clearinghouse et al v bristolmyers squibb co et al file california state superior court san diego county july substantially similar lawsuit rowan klein representative action behalf similarly situate person consume public v walgreen et al file february court retail pharmacy company pharmaceutical company complaint seek equitable relief monetary damage attorney fee base allegedly unfair business practice untrue misleading advertising california statute include california confidentiality medical information act base allegation retail store sell consumer confidential medical information company consumer medical information direct marketing design increase sale target drug january company pharmaceutical defendant seek dismiss utility consumer action network case ground californias proposition require plaintiff injure party order stand bring suit utility consumer action network personally injure october court enter stay utility consumer action network klein case pende california supreme courts decision review intermediate appellate decision discuss applicability proposition pende case july california supreme court enter decision appeal hold proposition apply pende case complaint amend add plaintiff standing court grant plaintiff lawsuit leave amend amend complaint contain substantially similar allegation early complaint file behalf new plaintiff purport allege personal injury lawsuit file utility consumer action network behalf privacy right clearinghouse entitle kimberly weisz et al v bristolmyers squibb co et al lawsuit file rowan klein entitle roseanna stephenson behalf similarly situate v bristolmyers squibb co et al case preliminary stage possible time reasonably assess outcome lawsuit impact company rxusa wholesale litigation july complaint file drug wholesaler rxusa wholesale inc district court eastern district new york company drug manufacturer drug wholesaler officer defendant mckesson wholesale distribution industry trade group rxusa wholesale inc v alcon labs inc et al complaint allege violation federal new york antitrust law law plaintiff claim defendant allegedly engage anticompetitive act result exclusion plaintiff relevant market seek million damage trebling relief company manufacturer defendant file motion dismiss case november motion pende court possible time reasonably estimate outcome lawsuit impact company note legal proceeding contingency continue security litigation investigation sec investigation wholesaler inventory accounting matter august company enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter company agree admit deny liability violate certain provision security law company establish million fund distribute certain company shareholder plan distribution establish sec settlement resolve ongoing investigation sec activity certain member company management connection wholesaler inventory issue accounting matter company continue cooperate investigation dk health care resource litigation november class action complaint file district court eastern district missouri company dk health care resources inc dk current dk director officer complaint allege company participate fraudulently inflate value dk stock allegedly engage improper channelstuffing agreement dk june court grant company motion dismiss complaint plaintiff time appeal decision appeal lodge begin run litigation dk officer director finally resolve possible time reasonably assess outcome lawsuit impact company starkman litigation september certain company current officer name purport class action starkman v bristolmyers squibb et al file new york state supreme court allege factual claim similar resolve federal class action southern district new york relate allege violation federal security law regulation connection sale incentive wholesaler inventory level assert common law fraud breach fiduciary duty claim behalf certain company stockholder october company remove case district court southern district new york november plaintiff move remand matter state court matter stay supreme court march enter decision case hold holder class action assert security fraud claim state law like starkman preempt federal law follow oral argument court deny plaintiff motion remand september november company plaintiff submit stipulation dismissal prejudice approve court pricing sale promotional practice litigation investigation company number defendant defendant number private civil matter relate pricing practice addition company number pharmaceutical manufacturer receive subpoenas document request government agency seek record relate pricing sale marketing practice good price reporting investigation company doj office attorney district massachusetts reach agreement principle subject approval doj settle investigation involve company drug pricing sale marketing activity agreement principle provide civil resolution expect payment million agreement principle involve matter actively investigate discuss doj attorney district massachusetts number year include matter relate price certain product sell year ago subsidiary reimburse governmental health care program financial relationship subsidiary note certain customer entitie certain consulting program promotion abilify unapproved indication calculation certain medicaid rebate serzone nefazodone hydrochloride price certain company product reimburse governmental health care program agreement contemplate state choose participate settlement criminal charge company respect matter agreement principle provide company enter corporate integrity agreement office inspector general department health human service settlement contingent party agreement term final settlement agreement include term corporate integrity agreement approval doj assurance settlement finalize state choose participate agreement principle cover matter outline doj attorney district massachusetts states indicate pursue matter outside scope expect settlement event matter result assertion civil andor criminal claim note legal proceeding contingency continue result agreement principle company increase reserve relate investigation million bring aggregate reserve matter million increase reserve record fourth quarter accordance gaap aggregate reserve reflect company estimate expect probable loss respect matter assume settlement finalize settlement finalize andor certain state choose participate reserve reflect eventual loss furthermore open investigation issue conduct federal state agency certain congressional committee company produce document actively cooperate investigation result assertion civil andor criminal claim possible time reasonably assess outcome investigation describe additional matter doj office attorney district massachusetts pursue potential impact company previously disclose company undertake analysis method process calculate price report governmental rebate pricing program relate pharmaceutical business analysis complete early base analysis company identify need revision methodology process calculate report pricing relate rebate amount implement revise methodology process begin report federal government agency primary responsibility rebate price reporting obligation center medicare medicaid services cms quarter addition revise methodology process company recalculate good price average manufacturer price require report company federal medicaid rebate agreement certain state agreement correspond revise rebate liability amount program threeyear period completion analysis early company determine estimate rebate liability program threeyear period actually rebate pay company period accordingly fourth quarter company record reduction rebate liability estimate overpayment company submit propose revision update estimate cms review cms position revision company methodology calculation require company believe base current information recalculation period likely result material rebate liability uncertainty surround recoverability company estimate overpayment arise review process describe company record reserve equal estimate overpayment litigation respect private civil matter company number pharmaceutical manufacturer defendant private class action suit bring attorney general state numerous new york counties city new york pende federal state court action plaintiff allege defendant cause average wholesale price awps product inflate injure government program entity person reimburse prescription drug base awps federal case state attorney general action suit new york counties city new york consolidated pretrial purpose district court district massachusetts awp mdl court awp mdl certify class person entity pay reimburse seven company physicianadministere drug nonjury trial class insurance company health welfare fund massachusetts commence november currently ongoing trial date claim class medicare b beneficiary nationwide set company company defendant putative class action file california allegedly behalf entity entitle discount pricing pursuant section b public health service act require prescription drug manufacturer offer discount qualified medical providersgenerally disproportionately service poor people july order enter dismiss california case prejudice plaintiff appeal dismissal california action possible time reasonably assess outcome litigation matter describe potential impact company note legal proceeding contingency continue product liability litigation company party product liability lawsuit involve thing hormone replacement therapy hrt product company serzone prescription drug addition lawsuit company face unfiled claim involve product company decision obtain insurance coverage dependent market condition include cost availability exist time decision result external factor availability insurance continue restrictive cost increase significantly company evaluate risk determine cost obtain insurance product liability loss outweigh benefit coverage protection loss selfinsure product liability loss effective july company continue evaluate risk benefit determine insurance need future serzone serzone antidepressant launch company canada march december company add black box warn serzone label warn potential risk severe hepatic event include possible liver failure need transplantation risk death month black box warning add package insert serzone number lawsuit include class action file company plaintiff masstort litigation allege thing company know know hepatic risk pose serzone failed adequately warn physician user risk addition case file class action file canada admit wrongdoing liability october company enter settlement agreement respect claim territory serzone november district court conditionally certify temporary settlement class preliminarily approve settlement september court issue opinion grant final approval settlement august company agree proceed settlement exercise backend optout right admit wrongdoing liability september company reach agreement principle respect claim canada serzone pursuant term propose settlement claim dismiss litigation terminate defendant receive release company commit pay million fund class member company announce follow evaluation commercial potential product generic entry marketplace rapidly decline brand sale decide discontinue manufacture sale product effective june hormone replacement therapy plaintiff masstort litigation allege thing hormone therapy product include hormone therapy product manufacture company estrace estradiol delestrogen ovcon cause breast cancer stroke blood clot cardiac injury woman defendant aware risk fail warn consumer december company defendant lawsuit file behalf approximately plaintiff federal state court company expect dismiss case product initial trial hrt litigation involve primary defendant wyeth commence federal court july pennsylvania november initial trial involve breast cancer claim company defendant case company hormone therapy product sell company january august company maintain estrace anda continue manufacture product supply agreement possible time reasonably assess outcome lawsuit company party impact company environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include comprehensive environmental response compensation liability act cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency epa counterpart state agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable note legal proceeding contingency continue reasonably estimable december company estimate share total future cost site approximately million record liability represent sum good estimate simple estimate reasonably estimate minimal probable range cost take account potential recovery party currently expect company pay million exclude legal fee year investigation remediation matter include liability cercla onsite remedial obligation puerto rico air emission civil litigation previously report company defendant include major pharmaceutical company purport class action suit file superior court puerto rico february relate air emission government own operate wastewater treatment facility april company execute individual settlement plaintiff subject certain condition include court decide certify case class action court defer decision class certification pende review expert report facilitys operation court consider expert report hear october facilitate settlement discussion party claim discussion ongoing consequently class certification hearing schedule december postpone passaic river nj remediation natural resource damage claim september new jersey department environmental protection njdep issue administrative enforcement directive notice new jersey spill compensation control act require company approximately company perform assessment natural resource damage implement unspecified interim remedial measure restore condition low passaic river directive allege company liable historically send bulk waste inland chemical company facility newark nj own mckesson corp reprocessing release hazardous substance facility migrate newark bay continue adverse impact low passaic river watershe subsequently epa issue notice letter cercla numerous partiesbut include companyseeke cooperation study condition substantially portion passaic river subject njdep directive group party enter consent agreement epa finance portion study epa determine estimate cost study consent agreement private party group commit pay roughly half million estimate subject revision future negotiation study lead cleanup action direct epa army corps engineer group actively negotiate epa successful negotiation result amend consent agreement anticipation agreement company reach agreement principle mckesson corp share cost anticipate agree portion epa study task company work cooperatively group party receive njdep directive andor epa notice explore potential resolution directive address risk collateral claim company believe caused contribute contamination low passaic river watershe company inform njdep willing discuss njdeps allegation company private party group continue discuss federal agency designate trustee natural resource affect contamination passaic river watershe possibility funding cooperative nrd study presumably dovetail ongoing epa study ideally join njdep coordinate action njdep seek directive late njdep issue supplemental directive file suit site party seek compel implementation interim measure unclear njdep additional action site party andor litigation arise response new claim extent liability company face njdep epa respect future claim federal trustees mckesson corp responsible party determine north brunswick nj board education remediation claim october company contact north brunswick nj board education boe discovery industrial waste material allegedly include material er squibb son expansion project north brunswick township high school number neighbor residential property adjacent public park area january njdep send company information request letter possible waste disposal site company respond march boe township current owner school property park conduct jointly finance soil remediation work work plan approve njdep evaluate need conduct response action remediate contain potentially impact ground water financial constraint late boe ask company contribute fund interim basis assure uninterrupted performance necessary site work company actively monitor cleanup project include cost discuss boe township term cooperative funding agreement allocation process municipal record indicate township operate landfill site company investigate historic use site include activity company responsible date boe township assert claim company note legal proceeding contingency continue njdep air permitnew brunswick nj facility december company njdep enter administrative consent order aco concern allege violation new jersey air pollution control act implement regulation company new brunswick facility pursuant aco company agree submit permit application create facilitywide emission cap pay small administrative fine obligation satisfy early subsequently february aco amend provide company install new cogeneration turbine new brunswick facility december obtain applicable air permit december company obtain required operating permit september purchase new cogeneration turbine cost approximately million instal turbine december compliance aco company fulfil term condition aco february receive notice termination aco njdep conclude matter mead johnson facilitynsps issue october company commence voluntary environmental audit mead johnson facility mt vernon indiana determine compliance epa new source performance standard nsps applicable operation incinerator december company disclose possible violation nsps requirement currently process modify operation fall exemption requirement date epa indiana department environmental management pursue penalty potential violation company potentially subject civil penalty past noncompliance nsp december epa respond selfdisclosure state intend pursue enforcement action issue time possible indiana department environmental management future pursue civil penalty past noncompliance nsp od regulatory compliance epa investigate industrial commercial facility use refrigeration equipment contain ozonedeplete substance od enforce compliance regulation govern prevention service repair leak od requirement company perform voluntary corporatewide audit facility puerto rico use odscontaine refrigeration equipment company submit audit report epa november identify potential violation od requirement facility addition matter cover company audit report letter epa epa previously send company wholly own subsidiary mead johnson request information compliance od requirement facility evansville indiana company respond request june result identify potential violation evansville facility company currently discussion epa resolve potential violation discover audit identify result epa request information evansville facility epa determine evansville facility facility violation applicable od requirement company subject penalty andor require convert replace refrigeration equipment use nonod approve substitute mact compliancepuerto rico facilities barceloneta humacao march company commence voluntary environmental audit barceloneta humacao puerto rico facility determine compliance epa regulation maximum achievable control technology requirement emission hazardous air pollutant pharmaceutical production pharmaceutical mact company submit epa audit report humacao facility june barceloneta facility july disclose potential violation pharmaceutical mact requirement facility company epa currently discussion resolution matter note legal proceeding contingency continue proceeding sec germany investigation october sec notify company conduct informal inquiry activity certain company german pharmaceutical subsidiary employee andor agent october sec inform company inquiry formal secs inquiry encompass matter currently investigation german prosecutor munich germany company understand inquiry investigation concern potential violation foreign corrupt practice act german law respectively company cooperate sec german authority company establish accrual represent minimum expect probable loss respect investigation german prosecutor possible time reasonably assess outcome investigation impact company bari italy investigation previously disclose january company notify prosecutor bari region italy bari prosecutor company investigation result activitie employee region investigation involve company number doctor pharmacist pharmaceutical company sale representative main allegation party engage plan defraud national health service bari prosecutor allege company lack appropriate compliance control andor process procedure control activity sale representative bari prosecutor request suspend operation pharmaceutical company investigation appoint judicial administrator preliminary measure pende february company bari prosecutor reach agreement principle settle matter agreement finalize company pay administrative fine material company note subsequent event january company enter worldwide japan codevelopment cocommercialization agreement astrazeneca plc astrazeneca develop commercialize investigational compound study treatment type diabetes company receive upfront payment million astrazeneca addition company receive milestone payment astrazeneca successful achievement regulatory sale relate stage company agree initial development plan compound majority development cost pay astrazeneca subsequent development cost generally share equally note select quarterly financial datum unaudite second fourth dollar million share datum quarter quarter quarter quarter year net sale gross margin earningsloss continue operation net earningsloss earning common share basic earningsloss continue operation discontinue operation net net earningsloss diluted earningsloss continue operation discontinue operation net net earningsloss dividend declare common share cash cash equivalent marketable security net sale gross margin earning continue operation discontinue operation net net earning earning common share basic earning continue operation discontinue operation net net earning dilute earning continue operation discontinue operation net net earning dividend declare common share cash cash equivalent marketable security include net litigation charge million million fourth quarter respectively net litigation income million million second quarter respectively fourth quarter include litigation insurance recovery million million million respectively second fourth quarter include restructure million million million million respectively fourth quarter include upfront milestone payment million million million respectively quarter include million gain sale product asset second fourth quarter include million million million million respectively accelerate depreciation asset impairment contract termination fourth quarter include debt retirement cost million fourth quarter include million claim damage earning share quarter add amount year period compute discrete basis include litigation charge million million million second fourth quarter respectively second quarter include litigation insurance recovery million million respectively second fourth quarter include restructure item million million million million respectively fourth quarter include upfront payment license agreement million million respectively second quarter include million million respectively gain sale equity investment second quarter include million million million respectively loss sale fix asset second quarter include debt retirement cost million fourth quarter include million defer income net cost result termination collaborative agreement merck muraglitazar quarter include gain sale consumer medicine business million note select quarterly financial datum unaudite continued common equivalent share exclude computation dilute earning share effect antidilutive follow million second fourth quarter quarter quarter quarter year month end december result net loss basic diluted loss share equal million weightedaverage share issuable million interest expense net tax conversion convertible debt include diluted earning share calculation dilutive report independent register public accounting firm board director stockholder bristolmyers squibb company audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income retain earning cash flow year end audit include financial statement schedule list index item financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audit provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position company december result operation cash flow year end conformity accounting principle generally accept united states america opinion financial statement schedule consider relation basic consolidated financial statement take present fairly material respect information set forth discuss note consolidated financial statement company adopt statement financial accounting standard sfas r sharebase payment effective january sfas employer account define benefit pension postretirement plan amendment fasb statement r effective december audit accordance standard public company accounting oversight board united states effectiveness company internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion management assessment effectiveness company internal control financial report unqualified opinion effectiveness company internal control financial reporting deloitte touche llp deloitte touche llp parsippany new jersey february report independent register public accounting firm board director stockholder bristolmyers squibb company opinion consolidated balance sheet december relate consolidated statement earning comprehensive income retain earning cash flow year period end december present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america addition opinion financial statement schedule year period end december present fairly material respect information set forth read conjunction relate consolidated financial statement financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audit conduct audits statement accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion pricewaterhousecooper llp pricewaterhousecooper llp philadelphia pa march item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule e base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report form k issue report management assessment effectiveness company internal control financial reporting december include change internal control financial reporting change companys internal control financial reporting quarter end december materially affect reasonably likely materially affect company internal control financial reporting item b information report independent register public accounting firm board director stockholder bristolmyers squibb company audit management assessment include management report internal control financial reporting appear item bristolmyer squibb company subsidiary company maintain effective internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management assessment opinion effectiveness company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion management assessment company maintain effective internal control financial reporting december fairly state material respect base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission opinion company maintain material respect effective internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement financial statement schedule year end december company report date february express unqualified opinion financial statement financial statement schedule include explanatory paragraph company adoption statement financial accounting standard sfas r sharebase payment effective january sfas employer account define benefit pension postretirement plansan amendment fasb statement r effective december deloitte touche llp deloitte touche llp parsippany new jersey february iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item b information require item respect executive officer registrant include ia reliance general instruction g instruction item b regulation sk item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item iv item